Use of chimeric antigen receptor (CAR) T-cell therapy in combination with inhibitors of inflammation-associated soluble factors

JP2023552773A5Active Publication Date: 2024-12-09CELGENE CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023534128
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-04
Filing Date
2021-12-03
Publication Date
2024-12-09
Estimated Expiration
2041-12-03

AI Technical Summary

Technical Problem

Current cancer treatments, including chimeric antigen receptor (CAR) T cell therapy, lack a reliable method to determine patient responsiveness based on inflammation-related soluble factors, leading to suboptimal treatment outcomes.

Method used

Determine the level of inflammation-related soluble factors such as PGF, CD70, TNFRSF9, and CD83 in a patient's serum, and administer BCMA-directed CAR T cells, such as idecabutagene viculucel, based on these levels to enhance treatment efficacy.

Benefits of technology

Improves the responsiveness of cancer treatment by tailoring CAR T cell therapy to individual patient profiles, enhancing therapeutic effectiveness for conditions like multiple myeloma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Provided herein is the use of chimeric antigen receptors (CARs) to treat cancer (e.g., B-cell related cancers, e.g., multiple myeloma).
Need to check novelty before this filing date? Find Prior Art

Description

Technical field

[0001] Cross-reference to related applications This application claims the benefit of U.S. Application No. 63 / 121,716, filed December 4, 2020. This disclosure is incorporated herein by reference in its entirety.

[0002] References to electronically submitted sequence listings This application incorporates by reference the Sequence Listing filed with this application as an ASCII text file entitled 14247-617-228_SEQ_LISTING.txt, created on November 23, 2021, having a size of 33,941 bytes.

[0003] 1.Field The disclosure presented herein relates to methods for treating cancer (eg, B cell-related cancers, eg, multiple myeloma). More specifically, the present disclosure provides improved methods for treating cancer (e.g., B cell-related cancers, e.g., multiple myeloma) using chimeric antigen receptors (CARs). determining the level of one or more inflammation-related soluble factors; and then, based on said determination, a CAR comprising an antibody or antigen-binding fragment thereof (e.g., an anti-BCMA antibody or antigen-binding fragment thereof). and immune effector cells (eg, T cells) genetically modified to express these CARs. [Background technology]

[0004] 2.Background 2.1. Background Many options are currently available to approach the treatment of cancer, including, for example, traditional chemotherapeutic approaches, as well as immunotherapy, such as chimeric antigen receptor (CAR) T cell therapy. In certain cases, the level of certain factors (eg, proteins or biomarkers) in a patient's serum may be relevant to determining whether to administer CAR-T therapy. Therefore, there is a need for certain factors (eg, proteins or biomarkers) in a patient's serum that may be relevant to the decision whether to administer CAR-T therapy. [Summary of the invention]

[0005] 3. Brief overview The present disclosure generally provides improved methods of treating cancer (e.g., B cell-related cancers, e.g., multiple myeloma) using chimeric antigen receptors (CARs), comprising: further comprising determining the level of an inflammation-related soluble factor and, based on the determination, administering a CAR comprising an antibody or antigen-binding fragment thereof (e.g., an anti-BCMA antibody or antigen-binding fragment thereof). Methods and immune effector cells (eg, T cells) genetically modified to express these CARs are provided.

[0006] In one embodiment, a method of predicting whether a cancer in a human is responsive to chimeric antigen receptor (CAR) T cells, comprising: (i) one or more of the following in serum from a human; determining the level of an inflammation-associated soluble factor of; and then (ii) determining the level of one or more soluble factors of (i) from a patient that is responsive to chimeric antigen receptor (CAR) T cells. Provided herein are methods comprising administering to a human a therapeutically effective dose of a CAR T cell, when the CAR T cell is similar to that in the serum of the human.

[0007] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0008] In certain embodiments, the cancer is multiple myeloma.

[0009] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells. In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0010] In certain embodiments, the level of one or more inflammation-related soluble factors is determined by an O-link IO analyte assay.

[0011] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0012] In certain embodiments, a human in need thereof has a level of one or more inflammation-related soluble factors in serum from a patient that is responsive to chimeric antigen receptor (CAR) T cells. A therapeutically effective dose of the chimera after about 1, 2, 3, 4, 5, 6, or 7 days determined to be similar to the level of one or more inflammation-related soluble factors. Antigen receptor (CAR) T cells are subsequently provided. In certain embodiments, a human in need thereof has a level of one or more inflammation-related soluble factors in serum from a patient that is responsive to chimeric antigen receptor (CAR) T cells. A therapeutically effective dose of chimeric antigen receptor (CAR) T cells is administered at approximately 1, 2, 3, or 4 weeks after the levels of one or more inflammation-related soluble factors are determined to be similar. will continue to be provided. In certain embodiments, a human in need thereof has a level of one or more inflammation-related soluble factors in serum from a patient that is responsive to chimeric antigen receptor (CAR) T cells. a therapeutically effective dose of the chimeric antigen receptor after about 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months determined to be similar to the level of one or more inflammation-related soluble factors. (CAR) T cells are subsequently provided.

[0013] In one embodiment, a method of treating cancer in a human in need thereof, the method comprising: determining the level of one or more inflammation-related soluble factors in a serum sample from the human in need thereof; one or more inflammation-associated soluble factors in a serum sample from a patient in which the level of the one or more inflammation-associated soluble factors is responsive to chimeric antigen receptor (CAR) T cells. Provided herein are methods wherein a human in need thereof is subsequently provided with a therapeutically effective dose of a chimeric antigen receptor (CAR) T cell, when the level of the chimeric antigen receptor (CAR) T cell is similar to that of the human in need thereof.

[0014] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0015] In certain embodiments, the cancer is multiple myeloma.

[0016] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells. In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0017] In certain embodiments, the level of one or more inflammation-related soluble factors is determined by an O-link IO analyte assay.

[0018] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0019] In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. of the therapeutically effective dose after about 1, 2, 3, 4, 5, 6, or 7 days determined to be similar to the level of one or more inflammation-related soluble factors. Chimeric antigen receptor (CAR) T cells are subsequently provided. In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. at a therapeutically effective dose of chimeric antigen receptor (CAR) T cells after about 1 week, 2 weeks, 3 weeks, or 4 weeks determined to be similar to the level of one or more inflammation-related soluble factors. will continue to be provided. In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. After approximately 1, 2, 3, 4, 5, or 6 months, the level of one or more inflammation-related soluble factors determined to be similar to that of a therapeutically effective dose of the chimeric antigen receptor. CAR T cells are subsequently provided.

[0020] In one embodiment, a method of treating cancer in a human in need thereof, comprising: a. the level of one or more inflammation-related soluble factors in a serum sample from a human in need thereof; determining similar levels of one or more inflammation-related soluble factors in a serum sample from a patient responsive to chimeric antigen receptor (CAR) T cells; b. step a. Provided herein are methods comprising the step of subsequently providing a therapeutically effective dose of chimeric antigen receptor (CAR) T cells to a human in need thereof based on the determination in .

[0021] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0022] In certain embodiments, the cancer is multiple myeloma.

[0023] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells. In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0024] In certain embodiments, the level of one or more inflammation-related soluble factors is determined by an O-link IO analyte assay.

[0025] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0026] In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. of the therapeutically effective dose after about 1, 2, 3, 4, 5, 6, or 7 days determined to be similar to the level of one or more inflammation-related soluble factors. Chimeric antigen receptor (CAR) T cells are subsequently provided. In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. at a therapeutically effective dose of chimeric antigen receptor (CAR) T cells after about 1 week, 2 weeks, 3 weeks, or 4 weeks determined to be similar to the level of one or more inflammation-related soluble factors. will continue to be provided. In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. After approximately 1, 2, 3, 4, 5, or 6 months, the level of one or more inflammation-related soluble factors determined to be similar to that of a therapeutically effective dose of the chimeric antigen receptor. CAR T cells are subsequently provided.

[0027] In one embodiment, a method of treating cancer comprising administering to a human patient diagnosed with cancer a therapeutically effective dose of chimeric antigen receptor (CAR) T cells; The level of one or more inflammation-related soluble factors in a serum sample from a human patient before one of the serum samples from the patient is responsive to chimeric antigen receptor (CAR) T cells. Provided herein are methods in which the level of an inflammation-related soluble factor is determined to be similar or greater.

[0028] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0029] In certain embodiments, the cancer is multiple myeloma.

[0030] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells. In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0031] In certain embodiments, the level of one or more inflammation-related soluble factors is determined by an O-link IO analyte assay.

[0032] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0033] In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. of the therapeutically effective dose after about 1, 2, 3, 4, 5, 6, or 7 days determined to be similar to the level of one or more inflammation-related soluble factors. Chimeric antigen receptor (CAR) T cells are subsequently provided. In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. at a therapeutically effective dose of chimeric antigen receptor (CAR) T cells after about 1 week, 2 weeks, 3 weeks, or 4 weeks determined to be similar to the level of one or more inflammation-related soluble factors. will continue to be provided. In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. After approximately 1, 2, 3, 4, 5, or 6 months, the level of one or more inflammation-related soluble factors determined to be similar to that of a therapeutically effective dose of the chimeric antigen receptor. CAR T cells are subsequently provided.

[0034] In one embodiment, a method for determining whether a patient diagnosed with cancer should receive chimeric antigen receptor (CAR) T cells, the method comprising: or determining the level of one or more inflammation-associated soluble factors in the serum sample from the patient, wherein the level of one or more inflammation-associated soluble factors in the serum sample from the patient is Provided herein are methods in which a patient is a candidate for CAR T cells if the level of one or more inflammation-related soluble factors in a serum sample from a patient exhibits a response. be done.

[0035] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0036] In certain embodiments, the cancer is multiple myeloma.

[0037] In certain embodiments, the level of one or more inflammation-related soluble factors is determined by an O-link IO analyte assay.

[0038] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells. In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0039] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0040] In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. of the therapeutically effective dose after about 1, 2, 3, 4, 5, 6, or 7 days determined to be similar to the level of one or more inflammation-related soluble factors. Chimeric antigen receptor (CAR) T cells are subsequently provided. In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. at a therapeutically effective dose of chimeric antigen receptor (CAR) T cells after about 1 week, 2 weeks, 3 weeks, or 4 weeks determined to be similar to the level of one or more inflammation-related soluble factors. will continue to be provided. In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. After approximately 1, 2, 3, 4, 5, or 6 months, the level of one or more inflammation-related soluble factors determined to be similar to that of a therapeutically effective dose of the chimeric antigen receptor. CAR T cells are subsequently provided.

[0041] In one embodiment, a method of treating cancer in a human in need thereof, comprising chimeric antigen receptor (CAR) T cells and PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83. Provided herein is a method comprising administering to a human an antagonist of an inflammation-related soluble factor selected from the group consisting of , IL10, PDCD1, IL12, and NCR1.

[0042] In certain embodiments, the inflammation-related soluble factor is selected from the group consisting of PGF, CD70, TNFRSF9, and CD83.

[0043] In certain embodiments, the antagonist of inflammation-related soluble factors reduces the level of inflammation-related soluble factors in humans to the level of inflammation-related soluble factors in patients who are responsive to chimeric antigen receptor (CAR) T cells. administered to humans in a therapeutically effective amount for.

[0044] In certain embodiments, the cancer is multiple myeloma.

[0045] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells.

[0046] In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0047] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0048] In certain embodiments, an antagonist of an inflammation-related soluble factor is administered prior to said administration of human chimeric antigen receptor (CAR) T cells. In certain embodiments, the inflammation-related soluble factor antagonist is administered about 1, 2, 3, 4, 5, 6, or 7 days prior to said administration of human chimeric antigen receptor (CAR) T cells. administered. In certain embodiments, the inflammation-related soluble factor antagonist is administered about 1 week, 2 weeks, 3 weeks, or 4 weeks prior to said administration of human chimeric antigen receptor (CAR) T cells. In certain embodiments, the inflammation-related soluble factor antagonist is administered about 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months prior to said administration of human chimeric antigen receptor (CAR) T cells. Ru.

[0049] 4. Brief description of the drawing [Brief explanation of the drawing]

[0050]

Figure 1

Figure 2

[0051] 5. Brief explanation of sequence number SEQ ID NOs: 1-3 describe the amino acid sequences of exemplary light chain CDR sequences for BCMA CARs contemplated herein.

[0052] SEQ ID NOs: 4-6 describe the amino acid sequences of exemplary heavy chain CDR sequences for BCMA CARs contemplated herein.

[0053] SEQ ID NO: 7 describes the amino acid sequence of an exemplary light chain sequence for a BCMA CAR contemplated herein.

[0054] SEQ ID NO: 8 describes the amino acid sequence of an exemplary heavy chain sequence for a BCMA CAR contemplated herein.

[0055] SEQ ID NO: 9 describes the amino acid sequence of an exemplary BCMA CAR contemplated herein with a signal peptide (amino acids 1-22). The amino acid sequence of the mature form of BCMA02 is set forth in SEQ ID NO:37.

[0056] SEQ ID NO: 10 describes a polynucleotide sequence encoding an exemplary BCMA CAR contemplated herein.

[0057] SEQ ID NO: 11 describes the amino acid sequence of human BCMA.

[0058] SEQ ID NOS: 12-22 describe the amino acid sequences of various linkers.

[0059] SEQ ID NOS: 23-35 describe the amino acid sequences of the protease cleavage site and the self-cleavable polypeptide cleavage site.

[0060] SEQ ID NO: 36 describes the polynucleotide sequence of a vector encoding an exemplary BCMA CAR. See Table 1.

[0061] SEQ ID NO: 37 describes the amino acid sequence of an exemplary mature BCMA CAR (ie, without a signal sequence) contemplated herein.

[0062] SEQ ID NO: 38 describes the amino acid sequence of BCMA02 scFv.

[0063] Table 1: List of arrays: [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6]

[0064] 6.Detailed explanation 6.1. Methods for treating cancer using chimeric antigen receptor (CAR) T cells The disclosure presented herein generally provides improved methods of treating cancer (e.g., B cell-related cancers, e.g., multiple myeloma) using chimeric antigen receptors (CARs). determining the level of one or more inflammation-related soluble factors; and, based on the determination, producing a CAR comprising an antibody or antigen-binding fragment thereof (e.g., an anti-BCMA antibody or antigen-binding fragment thereof). and immune effector cells (eg, T cells) genetically modified to express these CARs.

[0065] In one embodiment, a method of predicting whether a cancer in a human is responsive to chimeric antigen receptor (CAR) T cells, comprising: (i) one or more of the following in serum from a human; and (ii) the level of one or more soluble factors of (i) is responsive to chimeric antigen receptor (CAR) T cells from a patient. Provided herein are methods comprising administering to a human a therapeutically effective dose of a CAR T cell, when the CAR T cell is similar to that in the serum of the human.

[0066] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0067] In certain embodiments, the cancer is multiple myeloma.

[0068] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells. In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0069] In certain embodiments, the level of one or more inflammation-related soluble factors is determined by an O-link IO analyte assay.

[0070] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0071] In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. of the therapeutically effective dose after about 1, 2, 3, 4, 5, 6, or 7 days determined to be similar to the level of one or more inflammation-related soluble factors. Chimeric antigen receptor (CAR) T cells are subsequently provided. In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. at a therapeutically effective dose of chimeric antigen receptor (CAR) T cells after about 1 week, 2 weeks, 3 weeks, or 4 weeks determined to be similar to the level of one or more inflammation-related soluble factors. will continue to be provided. In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. After approximately 1, 2, 3, 4, 5, or 6 months, the level of one or more inflammation-related soluble factors determined to be similar to that of a therapeutically effective dose of the chimeric antigen receptor. CAR T cells are subsequently provided.

[0072] In certain embodiments of any of the above embodiments, the level of CD83 in the serum sample from the human is about a 3.25 log fold change compared to the control. In certain embodiments of any of the above embodiments, the level of CD83 in the serum sample from the human is about a 3.25 log fold change or less compared to the control. In certain embodiments of any of the above embodiments, the level of TNFRSF9 (sCD137) in the serum sample from the human is about a 6.3 log fold change compared to the control. In certain embodiments of any of the above embodiments, the level of TNFRSF9 (sCD137) in the serum sample from the human is about a 6.3 log fold change or less compared to the control. In certain embodiments of any of the above embodiments, the level of PGF in the serum sample from the human is a log fold change of about 8.6 compared to the control. In certain embodiments of any of the above embodiments, the level of PGF in the serum sample from the human is about a log fold change of about 8.6 or less compared to the control. In certain embodiments of any of the above embodiments, the level of CD70 in the serum sample from the human is a log fold change of about 5.0 compared to the control. In certain embodiments of any of the above embodiments, the level of CD70 in the serum sample from the human is about a 5.0 log fold change or less compared to the control.

[0073] In one embodiment, a method of treating cancer in a human in need thereof, the method comprising: determining the level of one or more inflammation-related soluble factors in a serum sample from the human in need thereof; one or more inflammation-associated soluble factors in a serum sample from a patient in which the level of the one or more inflammation-associated soluble factors is responsive to chimeric antigen receptor (CAR) T cells. Provided herein are methods wherein a human in need thereof is subsequently provided with a therapeutically effective dose of a chimeric antigen receptor (CAR) T cell, when the level of the chimeric antigen receptor (CAR) T cell is similar to that of the human in need thereof.

[0074] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0075] In certain embodiments, the cancer is multiple myeloma.

[0076] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells. In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0077] In certain embodiments, the level of one or more inflammation-related soluble factors is determined by an O-link IO analyte assay.

[0078] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0079] In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. of the therapeutically effective dose after about 1, 2, 3, 4, 5, 6, or 7 days determined to be similar to the level of one or more inflammation-related soluble factors. Chimeric antigen receptor (CAR) T cells are subsequently provided. In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. at a therapeutically effective dose of chimeric antigen receptor (CAR) T cells after about 1 week, 2 weeks, 3 weeks, or 4 weeks determined to be similar to the level of one or more inflammation-related soluble factors. will continue to be provided. In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. After approximately 1, 2, 3, 4, 5, or 6 months, the level of one or more inflammation-related soluble factors determined to be similar to that of a therapeutically effective dose of the chimeric antigen receptor. CAR T cells are subsequently provided.

[0080] In certain embodiments of any of the above embodiments, the level of CD83 in the serum sample from the human is about a 3.25 log fold change compared to the control. In certain embodiments of any of the above embodiments, the level of CD83 in the serum sample from the human is about a 3.25 log fold change or less compared to the control. In certain embodiments of any of the above embodiments, the level of TNFRSF9 (sCD137) in the serum sample from the human is about a 6.3 log fold change compared to the control. In certain embodiments of any of the above embodiments, the level of TNFRSF9 (sCD137) in the serum sample from the human is about a 6.3 log fold change or less compared to the control. In certain embodiments of any of the above embodiments, the level of PGF in the serum sample from the human is a log fold change of about 8.6 compared to the control. In certain embodiments of any of the above embodiments, the level of PGF in the serum sample from the human is about a log fold change of about 8.6 or less compared to the control. In certain embodiments of any of the above embodiments, the level of CD70 in the serum sample from the human is a log fold change of about 5.0 compared to the control. In certain embodiments of any of the above embodiments, the level of CD70 in the serum sample from the human is about a 5.0 log fold change or less compared to the control.

[0081] In one embodiment, a method of treating cancer in a human in need thereof, comprising: a. the level of one or more inflammation-related soluble factors in a serum sample from a human in need thereof; determining similar levels of one or more inflammation-related soluble factors in a serum sample from a patient responsive to chimeric antigen receptor (CAR) T cells; b. step a. Provided herein are methods comprising the step of subsequently providing a therapeutically effective dose of chimeric antigen receptor (CAR) T cells to a human in need thereof based on the determination in .

[0082] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0083] In certain embodiments, the cancer is multiple myeloma.

[0084] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells. In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0085] In certain embodiments, the level of one or more inflammation-related soluble factors is determined by an O-link IO analyte assay.

[0086] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0087] In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. of the therapeutically effective dose after about 1, 2, 3, 4, 5, 6, or 7 days determined to be similar to the level of one or more inflammation-related soluble factors. Chimeric antigen receptor (CAR) T cells are subsequently provided. In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. at a therapeutically effective dose of chimeric antigen receptor (CAR) T cells after about 1 week, 2 weeks, 3 weeks, or 4 weeks determined to be similar to the level of one or more inflammation-related soluble factors. will continue to be provided. In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. After approximately 1, 2, 3, 4, 5, or 6 months, the level of one or more inflammation-related soluble factors determined to be similar to that of a therapeutically effective dose of the chimeric antigen receptor. CAR T cells are subsequently provided.

[0088] In certain embodiments of any of the above embodiments, the level of CD83 in the serum sample from the human is about a 3.25 log fold change compared to the control. In certain embodiments of any of the above embodiments, the level of CD83 in the serum sample from the human is about a 3.25 log fold change or less compared to the control. In certain embodiments of any of the above embodiments, the level of TNFRSF9 (sCD137) in the serum sample from the human is about a 6.3 log fold change compared to the control. In certain embodiments of any of the above embodiments, the level of TNFRSF9 (sCD137) in the serum sample from the human is about a 6.3 log fold change or less compared to the control. In certain embodiments of any of the above embodiments, the level of PGF in the serum sample from the human is a log fold change of about 8.6 compared to the control. In certain embodiments of any of the above embodiments, the level of PGF in the serum sample from the human is about a log fold change of about 8.6 or less compared to the control. In certain embodiments of any of the above embodiments, the level of CD70 in the serum sample from the human is a log fold change of about 5.0 compared to the control. In certain embodiments of any of the above embodiments, the level of CD70 in the serum sample from the human is about a 5.0 log fold change or less compared to the control.

[0089] In one embodiment, a method of treating cancer comprising administering to a human patient diagnosed with cancer a therapeutically effective dose of chimeric antigen receptor (CAR) T cells; The level of one or more inflammation-related soluble factors in a serum sample from a human patient before one of the serum samples from the patient is responsive to chimeric antigen receptor (CAR) T cells. Provided herein are methods in which the level of an inflammation-related soluble factor is determined to be similar or greater.

[0090] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0091] In certain embodiments, the cancer is multiple myeloma.

[0092] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells. In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0093] In certain embodiments, the level of one or more inflammation-related soluble factors is determined by an O-link IO analyte assay.

[0094] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0095] In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. of the therapeutically effective dose after about 1, 2, 3, 4, 5, 6, or 7 days determined to be similar to the level of one or more inflammation-related soluble factors. Chimeric antigen receptor (CAR) T cells are subsequently provided. In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. at a therapeutically effective dose of chimeric antigen receptor (CAR) T cells after about 1 week, 2 weeks, 3 weeks, or 4 weeks determined to be similar to the level of one or more inflammation-related soluble factors. will continue to be provided. In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. After approximately 1, 2, 3, 4, 5, or 6 months, the level of one or more inflammation-related soluble factors determined to be similar to that of a therapeutically effective dose of the chimeric antigen receptor. CAR T cells are subsequently provided.

[0096] In certain embodiments of any of the above embodiments, the level of CD83 in the serum sample from the human patient is about a 3.25 log fold change compared to the control. In certain embodiments of any of the above embodiments, the level of CD83 in the serum sample from the human patient is about a 3.25 log fold change or less compared to the control. In certain embodiments of any of the above embodiments, the level of TNFRSF9 (sCD137) in the serum sample from the human patient is about a 6.3 log fold change compared to the control. In certain embodiments of any of the above embodiments, the level of TNFRSF9 (sCD137) in the serum sample from the human patient is about a 6.3 log fold change or less compared to the control. In certain embodiments of any of the above embodiments, the level of PGF in the serum sample from the human patient is about a log fold change of about 8.6 compared to the control. In certain embodiments of any of the above embodiments, the level of PGF in the serum sample from the human patient is about a log fold change of about 8.6 or less compared to the control. In certain embodiments of any of the above embodiments, the level of CD70 in the serum sample from the human patient is a log fold change of about 5.0 compared to the control. In certain embodiments of any of the above embodiments, the level of CD70 in the serum sample from the human patient is about a 5.0 log fold change or less compared to the control.

[0097] In one embodiment, a method for determining whether a patient diagnosed with cancer should receive chimeric antigen receptor (CAR) T cells, the method comprising: or determining the level of one or more inflammation-associated soluble factors in the serum sample from the patient, wherein the level of one or more inflammation-associated soluble factors in the serum sample from the patient is Provided herein are methods in which a patient is a candidate for CAR T cells if the level of one or more inflammation-related soluble factors in a serum sample from a patient exhibits a response; be done.

[0098] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0099] In certain embodiments, the cancer is multiple myeloma.

[0100] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells. In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0101] In certain embodiments, the level of one or more inflammation-related soluble factors is determined by an O-link IO analyte assay.

[0102] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0103] In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. of the therapeutically effective dose after about 1, 2, 3, 4, 5, 6, or 7 days determined to be similar to the level of one or more inflammation-related soluble factors. Chimeric antigen receptor (CAR) T cells are subsequently provided. In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. at a therapeutically effective dose of chimeric antigen receptor (CAR) T cells after about 1 week, 2 weeks, 3 weeks, or 4 weeks determined to be similar to the level of one or more inflammation-related soluble factors. will continue to be provided. In certain embodiments, a human in need thereof has a serum sample from a patient in which the level of one or more inflammation-related soluble factors is responsive to chimeric antigen receptor (CAR) T cells. After approximately 1, 2, 3, 4, 5, or 6 months, the level of one or more inflammation-related soluble factors determined to be similar to that of a therapeutically effective dose of the chimeric antigen receptor. CAR T cells are subsequently provided.

[0104] In certain embodiments of any of the above embodiments, the level of CD83 in the serum sample from the patient is about a 3.25 log fold change compared to the control. In certain embodiments of any of the above embodiments, the level of CD83 in the serum sample from the patient is about a 3.25 log fold change or less compared to the control. In certain embodiments of any of the above embodiments, the level of TNFRSF9 (sCD137) in the serum sample from the patient is about a 6.3 log fold change compared to the control. In certain embodiments of any of the above embodiments, the level of TNFRSF9 (sCD137) in the serum sample from the patient is about a 6.3 log fold change or less compared to the control. In certain embodiments of any of the above embodiments, the level of PGF in the serum sample from the patient is a log fold change of about 8.6 compared to the control. In certain embodiments of any of the above embodiments, the level of PGF in the serum sample from the patient is about a log fold change of about 8.6 or less compared to the control. In certain embodiments of any of the above embodiments, the level of CD70 in the serum sample from the patient is a log fold change of about 5.0 compared to the control. In certain embodiments of any of the above embodiments, the level of CD70 in the serum sample from the patient is about a 5.0 log fold change or less compared to the control.

[0105] In one embodiment, a method of treating cancer in a human in need thereof, the method comprising: determining the level of one or more inflammation-related soluble factors in a serum sample from the human in need thereof; and the level of the one or more inflammation-associated soluble factors is similar to the level of the one or more inflammation-associated soluble factors in a serum sample from a healthy human. Provided herein are methods in which the human subject is subsequently provided with a therapeutically effective dose of chimeric antigen receptor (CAR) T cells.

[0106] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0107] In certain embodiments, the cancer is multiple myeloma.

[0108] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells. In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0109] In certain embodiments, the level of one or more inflammation-related soluble factors is determined by an O-link IO analyte assay.

[0110] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0111] In certain embodiments, a human in need thereof has a level of one or more inflammation-related soluble factors that is equal to a level of one or more inflammation-related soluble factors in a serum sample from a healthy human. After about 1, 2, 3, 4, 5, 6, or 7 days as determined to be similar, a therapeutically effective dose of chimeric antigen receptor (CAR) T cells is subsequently provided. Ru. In certain embodiments, a human in need thereof has a level of one or more inflammation-related soluble factors that is equal to a level of one or more inflammation-related soluble factors in a serum sample from a healthy human. After about 1 week, 2 weeks, 3 weeks, or 4 weeks as determined to be similar, a therapeutically effective dose of chimeric antigen receptor (CAR) T cells is subsequently provided. In certain embodiments, a human in need thereof has a level of one or more inflammation-related soluble factors that is equal to a level of one or more inflammation-related soluble factors in a serum sample from a healthy human. After about 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months as determined to be similar, a therapeutically effective dose of chimeric antigen receptor (CAR) T cells is subsequently provided.

[0112] In one embodiment, a method of treating cancer in a human in need thereof, comprising: a. the level of one or more inflammation-related soluble factors in a serum sample from a human in need thereof; determining that the level of one or more inflammation-associated soluble factors is similar to that in a serum sample from a healthy human; b. Based on the determination in step a, administering a therapeutically effective dose of the chimeric antigen receptor ( Provided herein are methods comprising the step of subsequently providing CAR) T cells to a human in need thereof.

[0113] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0114] In certain embodiments, the cancer is multiple myeloma.

[0115] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells. In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0116] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0117] In certain embodiments, the level of one or more inflammation-related soluble factors is determined by an O-link IO analyte assay.

[0118] In certain embodiments, the step of subsequently providing a therapeutically effective dose of chimeric antigen receptor (CAR) T cells to a human in need thereof comprises about 1 day, 2 days, 3 days, or 3 days of the determination in step a. Performed after 4, 5, 6, or 7 days.

[0119] In certain embodiments, the step of subsequently providing a therapeutically effective dose of chimeric antigen receptor (CAR) T cells to a human in need thereof comprises about 1 week, 2 weeks, 3 weeks, or about 3 weeks after the determination in step a. or will be carried out after 4 weeks. In certain embodiments, the step of subsequently providing a therapeutically effective dose of chimeric antigen receptor (CAR) T cells to a human in need thereof comprises about 1 month, 2 months, 3 months, Performed after 4, 5, or 6 months.

[0120] In one embodiment, a method of treating cancer comprising administering to a human patient diagnosed with cancer a therapeutically effective dose of chimeric antigen receptor (CAR) T cells; The level of the one or more inflammation-related soluble factors in the serum sample from the previous human patient is similar to the level of the one or more inflammation-related soluble factors in the serum sample from a healthy human. Provided herein are methods for determining that

[0121] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0122] In certain embodiments, the cancer is multiple myeloma.

[0123] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells. In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0124] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0125] In certain embodiments, the level of one or more inflammation-related soluble factors in a serum sample from a human patient is about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days prior, as determined to be similar to the level of one or more inflammation-related soluble factors in a serum sample from a healthy human. In certain embodiments, the level of one or more inflammation-related soluble factors in a serum sample from a human patient is lower than that of a healthy human patient about 1 week, 2 weeks, 3 weeks, or 4 weeks prior to said administration. is determined to be similar to the level of one or more inflammation-related soluble factors in a serum sample from. In certain embodiments, the level of one or more inflammation-related soluble factors in a serum sample from a human patient is about 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months after said administration. The level of one or more inflammation-related soluble factors is determined to be similar to that previously found in serum samples from healthy humans.

[0126] In certain embodiments, the level of one or more inflammation-related soluble factors is determined by an O-link IO analyte assay.

[0127] In one embodiment, a method for determining whether a patient diagnosed with cancer should receive chimeric antigen receptor (CAR) T cells, the method comprising: or determining the level of one or more inflammation-related soluble factors in the serum sample from the patient, wherein the level of the one or more inflammation-related soluble factors in the serum sample from the patient is one or more of the one or more inflammation-related soluble factors in the serum sample from the healthy human. Provided herein are methods in which a patient is a candidate for CAR T cells if the levels of more inflammation-related soluble factors are similar.

[0128] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0129] In certain embodiments, the cancer is multiple myeloma.

[0130] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells. In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0131] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0132] In one embodiment, a method of predicting whether a cancer in a human is responsive to chimeric antigen receptor (CAR) T cells, the method comprising: (i) detecting one or more inflammation in a serum sample; determining the level of the relevant soluble factor; and (ii) administering a therapeutically effective dose of the CAR T cells if the level of the one or more soluble factors of (i) is similar to that in a healthy human. Provided herein are methods comprising administering to a human.

[0133] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0134] In certain embodiments, the cancer is multiple myeloma.

[0135] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells.

[0136] In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0137] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0138] In certain embodiments, the level of one or more inflammation-related soluble factors is determined by an O-link IO analyte assay.

[0139] In one embodiment, a method of treating cancer in a human in need thereof, comprising: chimeric antigen receptor (CAR) T cells and PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83. Provided herein is a method comprising administering to a human an antagonist of an inflammation-associated soluble factor selected from the group consisting of , IL10, PDCD1, IL12, and NCR1.

[0140] In certain embodiments, the inflammation-related soluble factor is selected from the group consisting of PGF, CD70, TNFRSF9, and CD83.

[0141] In certain embodiments, an antagonist of inflammation-related soluble factor is administered to a human in a therapeutically effective amount to reduce the level of inflammation-related soluble factor in the human to the level of inflammation-related soluble factor in a healthy human.

[0142] In certain embodiments, the antagonist of inflammation-related soluble factors reduces the level of inflammation-related soluble factors in humans to the level of inflammation-related soluble factors in patients who are responsive to chimeric antigen receptor (CAR) T cells. administered to humans in a therapeutically effective amount for.

[0143] In certain embodiments, the cancer is multiple myeloma.

[0144] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells.

[0145] In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0146] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0147] In certain embodiments, an antagonist of an inflammation-related soluble factor is administered prior to said administration of human chimeric antigen receptor (CAR) T cells. In certain embodiments, the inflammation-related soluble factor antagonist is administered about 1, 2, 3, 4, 5, 6, or 7 days prior to said administration of human chimeric antigen receptor (CAR) T cells. administered. In certain embodiments, the inflammation-related soluble factor antagonist is administered about 1 week, 2 weeks, 3 weeks, or 4 weeks prior to said administration of human chimeric antigen receptor (CAR) T cells. In certain embodiments, the inflammation-related soluble factor antagonist is administered about 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months prior to said administration of human chimeric antigen receptor (CAR) T cells. Ru.

[0148] In one embodiment, a method of treating cancer in a human in need thereof, comprising chimeric antigen receptor (CAR) T cells and PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83. Provided herein is a method comprising administering to a human an inhibitor of an inflammation-related soluble factor selected from the group consisting of , IL10, PDCD1, IL12, and NCR1.

[0149] In certain embodiments, the inflammation-related soluble factor is selected from the group consisting of PGF, CD70, TNFRSF9, and CD83.

[0150] In certain embodiments, the inhibitor of inflammation-related soluble factors is administered to a human in a therapeutically effective amount to reduce the level of inflammation-related soluble factors in the human to the level of inflammation-related soluble factors in a healthy human.

[0151] In certain embodiments, the cancer is multiple myeloma.

[0152] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells.

[0153] In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0154] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0155] In certain embodiments, the inhibitor of inflammation-related soluble factors is administered prior to said administration of human chimeric antigen receptor (CAR) T cells. In certain embodiments, the inhibitor of inflammation-related soluble factors is administered about 1, 2, 3, 4, 5, 6, or 7 days before said administration of human chimeric antigen receptor (CAR) T cells. administered to In certain embodiments, the inhibitor of inflammation-related soluble factors is administered about 1 week, 2 weeks, 3 weeks, or 4 weeks prior to said administration of human chimeric antigen receptor (CAR) T cells. In certain embodiments, the inhibitor of inflammation-related soluble factors is administered about 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months prior to said administration of human chimeric antigen receptor (CAR) T cells. be done.

[0156] In one embodiment, a method of treating cancer in a human in need thereof, comprising: a. a first of one or more inflammation-related soluble factors in a serum sample from a human in need thereof. determining that the level is greater than the level of one or more inflammation-related soluble factors in a serum sample from a healthy human; b. a therapeutically effective dose of the inflammation-related soluble factor based on the determination in step a; c. determining a second level of one or more inflammation-related soluble factors in a serum sample from a human in need thereof after step b; including; a second level of the one or more inflammation-related soluble factors is similar to the level of the one or more inflammation-related soluble factors in a serum sample from a healthy human; Provided herein are methods wherein a human in need thereof is subsequently provided with a therapeutically effective dose of chimeric antigen receptor (CAR) T cells.

[0157] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0158] In certain embodiments, the cancer is multiple myeloma.

[0159] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells. In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0160] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0161] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0162] In certain embodiments, the human in need thereof has a second level of the one or more inflammation-related soluble factors in a serum sample from a healthy human. Subsequently administering a therapeutically effective dose of chimeric antigen receptor (CAR) T cells after approximately 1, 2, 3, 4, 5, 6, or 7 days determined to be similar to the level of provided. In certain embodiments, the human in need thereof has a second level of the one or more inflammation-related soluble factors in a serum sample from a healthy human. A therapeutically effective dose of chimeric antigen receptor (CAR) T cells is subsequently provided after about 1 week, 2 weeks, 3 weeks, or 4 weeks determined to be similar to the level of chimeric antigen receptor (CAR) T cells. In certain embodiments, the human in need thereof has a second level of the one or more inflammation-related soluble factors in a serum sample from a healthy human. Therapeutically effective doses of chimeric antigen receptor (CAR) T cells are subsequently provided after about 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months, as determined to be similar to the level of Ru.

[0163] In one embodiment, a method of treating cancer in a human in need thereof, comprising: a. the level of one or more inflammation-related soluble factors in a serum sample from a human in need thereof; determining that the level of one or more inflammation-associated soluble factors in a serum sample from a healthy human is greater than the level of the one or more inflammation-associated soluble factors; b. Subsequently providing to a human; c. After step b, the level of one or more inflammation-related soluble factors in a serum sample from a human in need thereof is such that the level of one or more inflammation-related soluble factors in a serum sample from a healthy human is determining that the level of one or more inflammation-related soluble factors is similar; d. Based on the determination in step c, administering a therapeutically effective dose of chimeric antigen receptor (CAR) T cells as required; Provided herein are methods comprising the step of subsequently providing to a human being.

[0164] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0165] In certain embodiments, the cancer is multiple myeloma.

[0166] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells. In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0167] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0168] In certain embodiments, the step of subsequently providing a therapeutically effective dose of chimeric antigen receptor (CAR) T cells to a human in need thereof comprises about 1 week, 2 weeks, 3 weeks, or about 3 weeks after the determination in step c. or will be carried out after 4 weeks. In certain embodiments, the step of subsequently providing a therapeutically effective dose of chimeric antigen receptor (CAR) T cells to a human in need thereof comprises about 1 month, 2 months, 3 months, Performed after 4, 5, or 6 months.

[0169] In one embodiment, a method of treating cancer includes administering a therapeutically effective dose of chimeric antigen receptor (CAR) T cells to a human patient diagnosed with cancer, the method comprising: , a serum sample from a patient who has previously been administered a therapeutically effective dose of an antagonist of an inflammation-related soluble factor and prior to said administration of chimeric antigen receptor (CAR) T cells is compared with serum samples from healthy humans. Provided herein are methods in which the level of one or more inflammation-related soluble factors is determined to be similar.

[0170] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0171] In certain embodiments, the cancer is multiple myeloma.

[0172] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells. In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0173] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0174] In certain embodiments, the level of one or more inflammation-related soluble factors in a serum sample from a human patient is about 1 to 2 days after said administration of a therapeutically effective dose of chimeric antigen receptor (CAR) T cells. The level of the one or more inflammation-related soluble factors in a serum sample from a healthy human is determined to be similar to the level of the one or more inflammation-related soluble factors in a serum sample from a healthy human 1 day, 3 days, 4 days, 5 days, 6 days, or 7 days ago. In certain embodiments, the level of one or more inflammation-related soluble factors in a serum sample from a human patient is about 2 weeks after said administration of a therapeutically effective dose of chimeric antigen receptor (CAR) T cells. The level of one or more inflammation-related soluble factors is determined to be similar to the level of one or more inflammation-related soluble factors in a serum sample from a healthy human at the previous week, three weeks, or four weeks. In certain embodiments, the level of one or more inflammation-related soluble factors in a serum sample from a human patient is about 2 months after said administration of a therapeutically effective dose of chimeric antigen receptor (CAR) T cells. The level of one or more inflammation-related soluble factors is determined to be similar to the level of one or more inflammation-related soluble factors in a serum sample from a healthy human at a previous month, three months, four months, five months, or six months ago.

[0175] In one embodiment, a method for determining whether a patient diagnosed with cancer should receive chimeric antigen receptor (CAR) T cells, the method comprising: or determining the level of one or more inflammation-related soluble factors in the serum sample from the patient, and the patient has previously been administered an antagonist of one or more inflammation-related soluble factors; A patient is a candidate for CAR T cells if the level of one or more inflammation-associated soluble factors is similar to the level of one or more inflammation-associated soluble factors in serum samples from healthy humans. Provided herein is a method.

[0176] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0177] In certain embodiments, the cancer is multiple myeloma.

[0178] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells. In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0179] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0180] In one embodiment, a method of treating cancer in a human in need thereof, comprising: a. a first of one or more inflammation-related soluble factors in a serum sample from a human in need thereof. determining that the level is greater than the level of one or more inflammation-related soluble factors in a serum sample from a healthy human; b. a therapeutically effective dose of the inflammation-related soluble factor based on the determination in step a; c. determining, after step b, a second level of one or more inflammation-related soluble factors in a serum sample from a human in need thereof; the second level of the one or more inflammation-related soluble factors is similar to the level of the one or more inflammation-related soluble factors in a serum sample from a healthy human; Provided herein are methods wherein a human in need of a human is subsequently provided with a therapeutically effective dose of chimeric antigen receptor (CAR) T cells.

[0181] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0182] In certain embodiments, the cancer is multiple myeloma.

[0183] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells. In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0184] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0185] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0186] In certain embodiments, the human in need thereof has a second level of the one or more inflammation-related soluble factors in a serum sample from a healthy human. Subsequently administering a therapeutically effective dose of chimeric antigen receptor (CAR) T cells after approximately 1, 2, 3, 4, 5, 6, or 7 days determined to be similar to the level of provided. In certain embodiments, the human in need thereof has a second level of the one or more inflammation-related soluble factors in a serum sample from a healthy human. A therapeutically effective dose of chimeric antigen receptor (CAR) T cells is subsequently provided after about 1 week, 2 weeks, 3 weeks, or 4 weeks determined to be similar to the level of chimeric antigen receptor (CAR) T cells. In certain embodiments, the human in need thereof has a second level of the one or more inflammation-related soluble factors in a serum sample from a healthy human. Therapeutically effective doses of chimeric antigen receptor (CAR) T cells are subsequently provided after about 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months, as determined to be similar to the level of Ru.

[0187] In one embodiment, a method of treating cancer in a human in need thereof, comprising: a. the level of one or more inflammation-related soluble factors in a serum sample from a human in need thereof; determining that the level of one or more inflammation-associated soluble factors in a serum sample from a healthy human is greater than; b. based on the determination in step a, a therapeutically effective dose of an inhibitor of inflammation-associated soluble factors; c. After step b, the second level of the one or more inflammation-related soluble factors in the serum sample from the human in need thereof is that of a healthy human. determining that the level of one or more inflammation-related soluble factors in the serum sample is similar; d. Based on the determination in step c, administering a therapeutically effective dose of chimeric antigen receptor (CAR) T cells; Provided herein is a method comprising the step of subsequently providing the same to a human in need thereof.

[0188] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0189] In certain embodiments, the cancer is multiple myeloma.

[0190] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells. In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0191] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0192] In certain embodiments, the step of subsequently providing a therapeutically effective dose of chimeric antigen receptor (CAR) T cells to a human in need thereof comprises about 1 week, 2 weeks, 3 weeks, or about 3 weeks after the determination in step c. Or it will be carried out after 4 weeks. In certain embodiments, the step of subsequently providing a therapeutically effective dose of chimeric antigen receptor (CAR) T cells to a human in need thereof comprises about 1 month, 2 months, 3 months, Performed after 4, 5, or 6 months.

[0193] In one embodiment, a method of treating cancer includes administering a therapeutically effective dose of chimeric antigen receptor (CAR) T cells to a human patient diagnosed with cancer, the method comprising: , had previously been administered a therapeutically effective dose of an inhibitor of an inflammation-related soluble factor, and the serum sample from a patient prior to said administration of a therapeutically effective dose of chimeric antigen receptor (CAR) T cells was tested in a healthy human patient. Provided herein are methods in which the level of one or more inflammation-related soluble factors is determined to be similar in a serum sample from a patient.

[0194] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0195] In certain embodiments, the cancer is multiple myeloma.

[0196] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells. In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0197] In certain embodiments, CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0198] In certain embodiments, the level of one or more inflammation-related soluble factors in a serum sample from a human patient is about 1 to 2 days after said administration of a therapeutically effective dose of chimeric antigen receptor (CAR) T cells. The level of the one or more inflammation-related soluble factors in a serum sample from a healthy human is determined to be similar to the level of the one or more inflammation-related soluble factors in a serum sample from a healthy human 1 day, 3 days, 4 days, 5 days, 6 days, or 7 days ago. In certain embodiments, the level of one or more inflammation-related soluble factors in a serum sample from a human patient is about 2 weeks after said administration of a therapeutically effective dose of chimeric antigen receptor (CAR) T cells. The level of one or more inflammation-related soluble factors is determined to be similar to the level of one or more inflammation-related soluble factors in a serum sample from a healthy human at the previous week, three weeks, or four weeks. In certain embodiments, the level of one or more inflammation-related soluble factors in a serum sample from a human patient is about 2 months after said administration of a therapeutically effective dose of chimeric antigen receptor (CAR) T cells. The level of one or more inflammation-related soluble factors is determined to be similar to the level of one or more inflammation-related soluble factors in a serum sample from a healthy human at a previous month, three months, four months, five months, or six months ago.

[0199] In one embodiment, a method for determining whether a patient diagnosed with cancer should receive chimeric antigen receptor (CAR) T cells, the method comprising: or determining the level of one or more inflammation-related soluble factors, and the patient has previously been administered an inhibitor of one or more inflammation-related soluble factors, and Patients are eligible for CAR T cells if the levels of one or more inflammation-associated soluble factors are similar to the levels of one or more inflammation-associated soluble factors in serum samples from healthy humans. Candidate methods are provided herein.

[0200] In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. be done. In certain embodiments, the one or more inflammation-related soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. That's all. In certain embodiments, the one or more inflammation-related soluble factors are one or more of PGF, CD70, TNFRSF9, and CD83.

[0201] In certain embodiments, the cancer is multiple myeloma.

[0202] In certain embodiments, the CAR T cells are BCMA-directed CAR T cells. In certain embodiments, the BCMA-directed CAR T cell is an idecabutagene viculucel cell (ide-cel).

[0203] In certain embodiments, CAR T cells are 150 x 106 cells ~450×10 6 The cells are administered in a range of doses. In certain embodiments, BCMA CAR T cells are 150 x 10 6 cells ~450×10 6 The cells are administered in a range of doses.

[0204] In the methods presented herein, determinations may be made using standard techniques well known to those skilled in the relevant art. Additionally, the determining step includes determining the level of inflammation-related soluble factors (e.g., PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1). standard techniques such as serum or plasma or blood tests. For example, one in a blood sample (e.g. peripheral blood sample) from a patient or healthy human being responsive to chimeric antigen receptor (CAR) T cells (e.g. BCMA CAR T cells, e.g. ide-cel). or higher levels of inflammation-related soluble factors are determined using standard techniques well known to those skilled in the relevant art, such as serum, blood, or plasma tests, such as the assays used in the Examples. may be done. A healthy human may be, for example, a human who has not been diagnosed with a disease (eg, a human who does not have cancer).

[0205] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma.

[0206] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma. , immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.

[0207] In certain embodiments of any of the above embodiments, the cancer is brain cancer, glioblastoma, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, melanoma, lung cancer, uterine cancer, Cancer, ovarian cancer, colorectal cancer, anal cancer, liver cancer, hepatocellular carcinoma, stomach cancer, testicular cancer, endometrial cancer, cervical cancer, Hodgkin's disease, non-Hodgkin's lymphoma, esophageal cancer , bowel cancer, thyroid cancer, adrenal cancer, bladder cancer, kidney cancer, breast cancer, multiple myeloma, sarcoma, anal cancer, or squamous cell cancer.

[0208] In certain embodiments of any of the above embodiments, the inflammation-related soluble factor is placental growth factor (PGF), CD70, tumor necrosis factor receptor superfamily member 4 (TNFRSF4), tumor necrosis factor receptor superfamily member 9 (TNFRSF9 or sCD137 or s4-1BB), decorin (DCN), cluster of differentiation 83 (CD83), interleukin 10 (IL-10), programmed cell death 1 (PDCD1), interleukin 12 (IL-12), and one or more of the natural cytotoxic trigger receptors 1 (NCR1).

[0209] In certain embodiments of any of the above embodiments, the inflammation-related soluble factor inhibitor or antagonist is PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, or is an inhibitor or antagonist of NCR1. In certain embodiments of any of the above embodiments, the inhibitor or antagonist of inflammation-related soluble factors is an inhibitor or antagonist of PGF. In certain embodiments of any of the above embodiments, the inhibitor or antagonist of inflammation-related soluble factors is an inhibitor or antagonist of CD70. In certain embodiments of any of the above embodiments, the inhibitor or antagonist of inflammation-related soluble factors is an inhibitor or antagonist of TNFRSF4. In certain embodiments of any of the above embodiments, the inflammation-related soluble factor inhibitor or antagonist is an inhibitor or antagonist of TNFRSF9 (sCD137 or s4-1BB). In certain embodiments of any of the above embodiments, the inhibitor or antagonist of an inflammation-related soluble factor is an inhibitor or antagonist of DCN. In certain embodiments of any of the above embodiments, the inhibitor or antagonist of inflammation-related soluble factors is an inhibitor or antagonist of CD83. In certain embodiments of any of the above embodiments, the inhibitor or antagonist of inflammation-related soluble factors is an inhibitor or antagonist of IL10. In certain embodiments of any of the above embodiments, the inhibitor or antagonist of an inflammation-related soluble factor is an inhibitor or antagonist of PDCD1. In certain embodiments of any of the above embodiments, the inhibitor or antagonist of inflammation-related soluble factors is an inhibitor or antagonist of IL12. In certain embodiments of any of the above embodiments, the inhibitor or antagonist of an inflammation-related soluble factor is an inhibitor or antagonist of NCR1.

[0210] In certain embodiments of any of the above embodiments, the inhibitor of inflammation-related soluble factors is PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, or NCR1 is an inhibitor of In certain embodiments of any of the above embodiments, the inhibitor of inflammation-related soluble factors includes PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. An inhibitor of inflammation-related soluble factors selected from the group consisting of: In certain embodiments of any of the above embodiments, the inhibitor of inflammation-related soluble factors is an inhibitor of PGF. In certain embodiments of any of the above embodiments, the inhibitor of inflammation-related soluble factors is an inhibitor of CD70. In certain embodiments of any of the above embodiments, the inhibitor of inflammation-related soluble factors is an inhibitor of TNFRSF4. In certain embodiments of any of the above embodiments, the inhibitor of inflammation-related soluble factors is an inhibitor of TNFRSF9 (sCD137 or s4-1BB). In certain embodiments of any of the above embodiments, the inhibitor of inflammation-related soluble factors is an inhibitor of DCN. In certain embodiments of any of the above embodiments, the inhibitor of inflammation-related soluble factors is an inhibitor of CD83. In certain embodiments of any of the above embodiments, the inhibitor of inflammation-related soluble factors is an inhibitor of IL10. In certain embodiments of any of the above embodiments, the inhibitor of inflammation-related soluble factors is an inhibitor of PDCD1. In certain embodiments of any of the above embodiments, the inhibitor of inflammation-related soluble factors is an inhibitor of IL12. In certain embodiments of any of the above embodiments, the inhibitor of inflammation-related soluble factors is an inhibitor of NCR1.

[0211] In certain embodiments of any of the above embodiments, the inflammation-related soluble factor antagonist is PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, or NCR1. is an antagonist. In certain embodiments of any of the above embodiments, the antagonist of inflammation-related soluble factors is from PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. It is an antagonist of inflammation-related soluble factors selected from the group consisting of: In certain embodiments of any of the above embodiments, the inflammation-related soluble factor antagonist is an antagonist of PGF. In certain embodiments of any of the above embodiments, the antagonist of inflammation-related soluble factors is an antagonist of CD70. In certain embodiments of any of the above embodiments, the inflammation-related soluble factor antagonist is an antagonist of TNFRSF4. In certain embodiments of any of the above embodiments, the inflammation-related soluble factor antagonist is an antagonist of TNFRSF9 (sCD137 or s4-1BB). In certain embodiments of any of the above embodiments, the antagonist of an inflammation-related soluble factor is an antagonist of DCN. In certain embodiments of any of the above embodiments, the inflammation-related soluble factor antagonist is an antagonist of CD83. In certain embodiments of any of the above embodiments, the inflammation-related soluble factor antagonist is an IL10 antagonist. In certain embodiments of any of the above embodiments, the inflammation-related soluble factor antagonist is a PDCD1 antagonist. In certain embodiments of any of the above embodiments, the inflammation-related soluble factor antagonist is an IL12 antagonist. In certain embodiments of any of the above embodiments, the inflammation-related soluble factor antagonist is an NCR1 antagonist.

[0212] In certain embodiments of any of the above embodiments, the inhibitor or antagonist of inflammation-related soluble factors is an antibody. In certain embodiments, the inflammation-related soluble factor antagonist is an antibody against PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, or NCR1. In certain embodiments, the antagonist of an inflammation-related soluble factor is an inflammation-related soluble factor selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. It is an antibody against a soluble factor. In certain embodiments, the inflammation-related soluble factor antagonist is an antibody against PGF. In certain embodiments, the inflammation-related soluble factor antagonist is an antibody against CD70. In certain embodiments, the inflammation-related soluble factor antagonist is an antibody against TNFRSF4. In certain embodiments, the inflammation-related soluble factor antagonist is an antibody against TNFRSF9 (sCD137 or s4-1BB). In certain embodiments, the inflammation-related soluble factor antagonist is an antibody against DCN. In certain embodiments, the inflammation-related soluble factor antagonist is an antibody to CD83. In certain embodiments, the inflammation-related soluble factor antagonist is an antibody against IL10. In certain embodiments, the inflammation-related soluble factor antagonist is an antibody against PDCD1. In certain embodiments, the inflammation-related soluble factor antagonist is an antibody against IL12. In certain embodiments, the inflammation-related soluble factor antagonist is an antibody against NCR1.

[0213] In certain embodiments of any of the above embodiments, the antagonist of IL-12 is STELARA® (ustekinumab). In certain embodiments, STELARA® (ustekinumab) is administered subcutaneously to adult humans weighing 100 kg or less at a dose of about 45 mg subcutaneously initially and 4 weeks later, followed by subcutaneously every 12 weeks. Administered at a dose of 45 mg. In certain embodiments, STELARA® (ustekinumab) is administered subcutaneously to adult humans weighing more than 100 kg at a dose of about 90 mg subcutaneously initially and 4 weeks later, followed by subcutaneously every 12 weeks. Administered at a dose of 90 mg. In certain embodiments, STELARA® (ustekinumab) is administered to pediatric human patients weighing less than 60 kg at a dose of about 0.75 mg / kg. In certain embodiments, STELARA® (ustekinumab) is administered to pediatric human patients weighing between 60 kg and 100 kg at a dose of about 45 mg. In certain embodiments, STELARA® (ustekinumab) is administered to pediatric human patients weighing more than 100 kg at a dose of about 90 mg. In certain embodiments, STELARA® (ustekinumab) is administered at a dose of about 260 mg to an adult human weighing up to 55 kg. In certain embodiments, STELARA® (ustekinumab) is administered at a dose of about 390 mg to an adult human weighing between 55 kg and 85 kg. In certain embodiments, STELARA® (ustekinumab) is administered at a dose of about 520 mg to adult humans weighing more than 85 kg.

[0214] An inhibitor or antagonist of a factor (eg, protein) may be a protein trap. Protein traps can be created, for example, by fusing the first three Ig domains of the receptor (ie, the ligand binding elements) to the constant region (Fc) of human IgG1. See Holash et al., Proc Natl Acad Sci U S A. 2002 Aug 20; 99(17):11393-11398. In certain embodiments of any of the above embodiments, the inflammation-associated soluble factor antagonist is a protein trap. In certain embodiments, the protein trap binds an inflammation-associated soluble factor selected from the group consisting of PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1. do. In certain embodiments, the protein trap binds PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, or NCR1. In certain embodiments, the protein trap binds an inflammation-related soluble factor selected from the group consisting of PGF, CD70, TNFRSF9, and CD83. In certain embodiments, the protein trap binds PGF, CD70, TNFRSF9, or CD83.

[0215] may be combined with CAR T therapy, e.g., may be administered prior to CAR T therapy to reduce the level or activity of one or more inflammation-related soluble factors described herein; Exemplary antagonists of soluble factors include: ustekinumab for IL-12 and urelumab and utmilumab for CD137.

[0216] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of CAR T cells prior to administration of CAR T cells to the subject.

[0217] In certain embodiments, CAR T cells are administered by intravenous infusion.

[0218] In certain embodiments of any of the above aspects or embodiments, the subject is a human (eg, a human patient).

[0219] In certain embodiments of any of the above aspects or embodiments, the CAR T cell has the sequence BCMA02, ABECMA (copyright), JCARH125, JNJ-68284528 (LCAR-B38M; SEQ ID NO: 265 of 10,934,363 or WO2018 / 028647 300 with or without a signal peptide) (Janssen / Legend), P-BCMA-101 (Poseida), PBCAR269A (Poseida), P-BCMA-Allo1 (Poseida), Allo-715 (Pfizer / CD19 CAR T therapy, such as Yescarta, Kymriah, Tecartus, Liso-cel , or any other cell surface marker-targeted CAR T therapy.

[0220] In certain embodiments of any of the above aspects or embodiments, the CAR T cell therapy is of BCMA02, ABECMA (copyright), JCARH125, JNJ-68284528 (LCAR-B38M; 300 with or without a signal peptide) (Janssen / Legend), P-BCMA-101 (Poseida), PBCAR269A (Poseida), P-BCMA-Allo1 (Poseida), Allo-715 (Pfizer CD19 CAR T therapies, such as Yescarta, Kymriah, Tecartus, liso-cel ), or any other cell surface marker.

[0221] In certain embodiments, the CAR T cell is a BCMA directed CAR T cell (BCMA CAR T cell). BCMA is a member of the tumor necrosis factor receptor superfamily (e.g. Thompson et al., J. Exp. Medicine, 192(1): 129-135, 2000 and Mackay et al., Annu. Rev. Immunol, 21: 231-264, 2003). BCMA binds B cell activating factor (BAFF) and proliferation-inducing ligand (APRIL) (see, eg, Mackay et al., 2003 and Kalled et al., Immunological Reviews, 204: 43-54, 2005). Among benign cells, BCMA has been reported to be mainly expressed in plasma cells and a subset of mature B cells (e.g. Laabi et al., EMBO J., 77(1 ): 3897-3904, 1992; Laabi et al., Nucleic Acids Res., 22(7): 1147-1154,, 1994;Kalled et al., 2005;O'Connor et al., J. Exp. Medicine, 199(1): 91-97, 2004; and Ng et al., J. Immunol., 73(2): 807-817, 2004). Mice deficient in BCMA are healthy and have normal numbers of B cells, but survival of long-lived plasma cells is impaired (e.g. O'Connor et al., 2004; Xu et al., Mol. Cell. Biol., 21(12): 4067-4074, 2001; and Schiemann et al., Science, 293(5537): 2 111-21 14, 2001). BCMA RNA has been universally detected in multiple myeloma cells and other lymphomas, and BCMA protein has been detected by some researchers on the surface of plasma cells from multiple myeloma patients (e.g. Novak et al. et al., Blood, 103(2): 689-694, 2004;Neri et al., Clinical Cancer Research, 73(19): 5903-5909, 2007;Bellucci et al., Blood, 105(10): 3945 -3950, 2005; and Moreaux et al., Blood, 703(8): 3148-3157, 2004).

[0222] In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises BCMA02 scFv, eg, SEQ ID NO: 38.

[0223] In certain embodiments of any of the above aspects or embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR. In certain embodiments, a BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments of any of the above aspects or embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments of any of the above aspects or embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises SEQ ID NO:37. In certain embodiments of any of the above aspects or embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a BCMA02 scFv, eg, SEQ ID NO: 38. In certain embodiments, the CAR directed to BCMA is encoded by SEQ ID NO:10. In certain embodiments, the BCMA CAR T cell comprises a nucleic acid encoding a BCMA CAR T, e.g., comprising amino acids 22-493 or 1-493 of SEQ ID NO: 9, SEQ ID NO: 37, or SEQ ID NO: 38 A nucleic acid comprising a vector or comprising SEQ ID NO: 10, eg, a vector. In certain embodiments of any of the above aspects or embodiments, the BCMA CAR T cells are idecabutadiene vicleucel cells.

[0224] In certain embodiments of any of the above aspects or embodiments, the CAR T cell therapy (e.g., immune cells expressing BCMA-directed chimeric antigen receptors (CARs) (BCMA CAR T cells), e.g. Decabutagen viculucel (ide-cel cells) is a 10%, 5%, 3%, 2% or 1% senescent population of CAR T cells, e.g. CD4 CAR T cells (CD3+ / CD4+ / CAR+ / CD57+). In certain embodiments of any of the above aspects or embodiments, the tissue sample is blood, plasma or serum. In another particular embodiment of any of the above aspects or embodiments, said disease caused by cells expressing BCMA is multiple myeloma, chronic lymphocytic leukemia or non-Hodgkin's lymphoma (e.g., Burkitt's lymphoma, Chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, and mantle cell lymphoma ). In certain embodiments, the disease is multiple myeloma, such as high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain other embodiments, high-risk multiple myeloma is defined as R-ISS stage III disease and / or disease characterized by early relapse (e.g., the last treatment regimen, e.g., proteasome inhibitors, immunomodulatory agents) and / or progressive disease within 12 months of the date of the last treatment regimen with dexamethasone). In certain embodiments, the multiple myeloma is not R-ISS Stage III disease. In certain embodiments, the disease caused by cells expressing BCMA is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse selected from the group consisting of large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, and mantle cell lymphoma.

[0225] In one embodiment, prior to administration of the T cells expressing a chimeric antigen receptor (CAR) directed against B cell maturation antigen (BCMA) (BCMA CAR T cells), the subject with the tumor is subject to the expression of BCMA by the tumor. has been evaluated for.

[0226] In certain embodiments of any of the above aspects or embodiments, the immune cell is a T cell, such as a CD4+ T cell, a CD8+ T cell or a cytotoxic T lymphocyte (CTL), a T killer cell or a natural They are killer (NK) cells. In another specific embodiment, the immune cells are 150 x 10 6 cells ~450×10 6 Administered in cell doses.

[0227] In certain embodiments of any of the above aspects or embodiments, the immune cells (e.g., CAR T cells, e.g., BCMA CAR T cells) are 6 cells ~450×10 6 Cells, 300×10 6 cells ~600×10 6 cells, 350×10 6 cells ~600×10 6 cells, 350×10 6 cells ~550×10 6 cells, 400×10 6 cells ~600×10 6 cells, 150 x 10 6 cells ~300×10 6 cells or 400×10 6 cells ~500×10 6 The cells are administered in a range of doses. In some embodiments, the immune cells are about 150 x 10 6 cells, approximately 200 x 10 6 cells, approximately 250 x 10 6 Cells, approximately 300 x 10 6 Cells, approximately 350 x 10 6 Cells, approximately 400 x 10 6 Cells, approximately 450 x 10 6 cells, approximately 500 x 10 6 cells or about 550 x 10 6 Administered in cellular doses. In one embodiment, the immune cells are approximately 450 x 10 6 Administered in cellular doses. In some embodiments, the subject is administered a single infusion of immune cells (eg, CAR T cells) expressing chimeric antigen receptors (CARs). In some embodiments, the administration of immune cells expressing the CAR is repeated (eg, a second dose of immune cells is administered to the subject). In some embodiments, the subject is administered a single infusion of immune cells expressing a chimeric antigen receptor (CAR) directed against B cell maturation antigen (BCMA). In some embodiments, administration of immune cells expressing a CAR directed to BCMA is repeated (eg, a second dose of immune cells is administered to the subject).

[0228] In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells (e.g., CAR T cells) are about 150 x 10 6 Cells ~ approx. 300×10 6Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 350 x 10 6 Cells ~ approx. 550×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 400 x 10 6 Cells ~ approx. 500×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 150 x 10 6 Cells ~ approx. 250×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 300 x 10 6 Cells ~ approx. 500×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 350 x 10 6 Cells ~ approx. 450×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 300 x 10 6 Cells ~ approx. 450×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 250 x 10 6 Cells ~ approx. 450×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 300 x 10 6 Cells ~ approx. 600×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 250 x 10 6 Cells ~ approx. 500×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 350 x 10 6 Cells ~ approx. 500×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 400 x 10 6 Cells ~ approx. 600×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 400 x 10 6 Cells ~ approx. 450×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 200 x 10 6 Cells ~ approx. 400×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 200 x 10 6 Cells ~ approx. 350×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 200 x 10 6 Cells ~ approx. 300×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 450 x 10 6 Cells ~ approx. 500×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 250 x 10 6 Cells ~ approx. 400×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 250 x 10 6 Cells ~ approx. 350×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 450 x 10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the immune cell is a T cell (eg, an autologous T cell). In certain embodiments of any of the embodiments described herein, the subject being treated collects autoimmune cells to produce CAR-expressing immune cells prior to their administration to the subject. In order to do so, undergo a leukapheresis procedure. In certain embodiments of any of the embodiments described herein, the immune cells (eg, T cells) are administered by intravenous infusion.

[0229] In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells (e.g., CAR T cells) are about 150 x 10 6 Cells ~ approx. 300×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 350 x 10 6 Cells ~ approx. 550×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 400 x 10 6 Cells ~ approx. 500×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 150 x 10 6 Cells ~ approx. 250×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 300 x 10 6 Cells ~ approx. 500×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 350 x 10 6 Cells ~ approx. 450×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 300 x 10 6 Cells ~ approx. 450×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 250 x 10 6 Cells ~ approx. 450×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 300 x 10 6 Cells ~ approx. 600×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 250 x 10 6 Cells ~ approx. 500×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 350 x 10 6 Cells ~ approx. 500×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 400 x 10 6 Cells ~ approx. 600×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 400 x 10 6 Cells ~ approx. 450×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 200 x 10 6 Cells ~ approx. 400×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 200 x 10 6 Cells ~ approx. 350×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 200 x 10 6 Cells ~ approx. 300×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 450 x 10 6 Cells ~ approx. 500×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 250 x 10 6 Cells ~ approx. 400×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 250 x 10 6 Cells ~ approx. 350×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the CAR-expressing immune cells are about 450 x 10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the immune cell is a T cell (eg, an autologous T cell). In certain embodiments of any of the embodiments described herein, the subject being treated collects autoimmune cells to produce CAR-expressing immune cells prior to their administration to the subject. In order to do so, undergo a leukapheresis procedure. In certain embodiments of any of the embodiments described herein, the immune cells (eg, T cells) are administered by intravenous infusion.

[0230] In certain embodiments of any of the embodiments described herein, the BCMA-directed CAR-expressing immune cells (BCMA CAR T cells) are about 150 x 10 6 Cells ~ approx. 300×10 6Administered in cell doses. In certain embodiments of any of the embodiments described herein, the immune cells expressing the BCMA-directed CAR are about 350 x 10 6 Cells ~ approx. 550×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the immune cells expressing a BCMA-directed CAR are about 400 x 10 6 Cells ~ approx. 500×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the immune cells expressing BCMA-directed CAR are about 150 x 10 6 Cells ~ approx. 250×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the immune cells expressing a BCMA-directed CAR are about 300 x 10 6 Cells ~ approx. 500×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the immune cells expressing the BCMA-directed CAR are about 350 x 10 6 Cells ~ approx. 450×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the immune cells expressing a BCMA-directed CAR are about 300 x 10 6 Cells ~ approx. 450×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the immune cells expressing a BCMA-directed CAR are about 250 x 10 6 Cells ~ approx. 450×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the immune cells expressing a BCMA-directed CAR are about 300 x 10 6 Cells ~ approx. 600×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the immune cells expressing a BCMA-directed CAR are from about 250 x 10 cells to about 500 x 10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the immune cells expressing the BCMA-directed CAR are about 350 x 10 6 Cells ~ approx. 500×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the immune cells expressing a BCMA-directed CAR are about 400 x 10 6 Cells ~ approx. 600×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the immune cells expressing a BCMA-directed CAR are about 400 x 10 6 Cells ~ approx. 450×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the immune cells expressing a BCMA-directed CAR are about 200 x 10 6 Cells ~ approx. 400×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the immune cells expressing a BCMA-directed CAR are about 200 x 10 6 Cells ~ approx. 350×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the immune cells expressing a BCMA-directed CAR are about 200 x 10 6 Cells ~ approx. 300×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the immune cells expressing a BCMA-directed CAR are about 450 x 10 6 Cells ~ approx. 500×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the immune cells expressing a BCMA-directed CAR are from about 250 x 10 cells to about 400 x 10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the immune cells expressing the BCMA-directed CAR are about 250 x 10 6 Cells ~ approx. 350×10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the immune cells expressing a BCMA-directed CAR are about 450 x 10 6 Administered in cell doses. In certain embodiments of any of the embodiments described herein, the immune cell is a T cell (eg, an autologous T cell). In certain embodiments of any of the embodiments described herein, the subject being treated is autologous to produce immune cells expressing a BCMA-directed CAR prior to their administration to the subject. To collect immune cells, undergo a leukapheresis procedure. In certain embodiments of any of the embodiments described herein, the immune cells (eg, T cells) are administered by intravenous infusion.

[0231] In certain embodiments of any of the aspects or embodiments disclosed herein, prior to administration of the CAR-expressing immune cells (e.g., CAR T cells), the subject being treated is lymphocyte depleted. (LD) Chemotherapy is administered. In certain embodiments, the LD chemotherapy comprises fludarabine and / or cyclophosphamide. In certain embodiments, LD chemotherapy comprises fludarabine (e.g., about 30 mg / m2 for intravenous administration) for a period of 1, 2, 3, 4, 5, 6, or 7 days (e.g., 3 days). and cyclophosphamide (eg, about 300 mg / m2 for intravenous administration). In other specific embodiments, the LD chemotherapy includes any of the chemotherapeutic agents described in Section 5.9. In certain embodiments, the subject receives chimeric antigen receptors 1, 2, 3, 4, 5, 6 or 7 days after administration of LD chemotherapy (e.g., 2 or 3 days after administration of LD chemotherapy). (CAR) expressing immune cells are administered. In certain embodiments, the subject undergoes at least 1 week or more, at least 2 weeks or more (at least 14 days or more), at least 3 weeks or more before starting LD chemotherapy. Did not receive any therapy for longer, at least 4 weeks or longer, at least 5 weeks or longer, or at least 6 weeks or longer. In certain embodiments of any of the embodiments disclosed herein, prior to administration of the chimeric antigen receptor (CAR)-expressing immune cells, the subject being treated has received a single prior treatment. He was only receiving the regimen.

[0232] In certain embodiments of any of the aspects or embodiments disclosed herein, prior to administration of the BCMA-directed CAR-expressing immune cells (e.g., BCMA CAR T cells), the subject being treated are administered lymphocyte depletion (LD) chemotherapy. In certain embodiments, the LD chemotherapy comprises fludarabine and / or cyclophosphamide. In certain embodiments, LD chemotherapy comprises fludarabine (e.g., about 30 mg / m2 for intravenous administration) for a period of 1, 2, 3, 4, 5, 6, or 7 days (e.g., 3 days). and cyclophosphamide (eg, about 300 mg / m2 for intravenous administration). In other specific embodiments, the LD chemotherapy includes any of the chemotherapeutic agents described in Section 5.9. In certain embodiments, the subject receives B cell maturation antigen 1, 2, 3, 4, 5, 6 or 7 days after administration of LD chemotherapy (e.g., 2 or 3 days after administration of LD chemotherapy). (BCMA)-directed immune cells expressing chimeric antigen receptors (CARs). In certain embodiments, the subject undergoes at least 1 week or more, at least 2 weeks or more (at least 14 days or more), at least 3 weeks or more before starting LD chemotherapy. Did not receive any therapy for longer, at least 4 weeks or longer, at least 5 weeks or longer, or at least 6 weeks or longer. In certain embodiments of any of the embodiments disclosed herein, prior to administration of the immune cells expressing a chimeric antigen receptor (CAR) directed against B cell maturation antigen (BCMA), the treated subjects had received only a single prior treatment regimen.

[0233] For any of the above embodiments, the subject undergoes apheresis to collect and isolate said immune cells, eg, T cells. In certain embodiments of any of the above embodiments, said subject exhibits at the time of said apheresis: M-protein (serum protein electrophoresis [sPEP] or urine protein electrophoresis [uPEP]): sPEP≧ 0.5 g / dL or uPEP ≥200 mg / 24 hours; serum immunoglobulin free light chain ≥10 mg / dL and light chain with abnormal serum immunoglobulin kappa lambda free light chain ratio without measurable disease in serum or urine multiple myeloma; and / or Eastern Cooperative Oncology Group (ECOG) activity status ≤1. In a more particular embodiment, said subject has, at the time of apheresis, further undergone at least three of said previous treatments, including: a previous treatment with a proteasome inhibitor, an immunomodulator (lenalidomide or pomalidomide) and an anti-CD38 antibody. had received at least 2 consecutive cycles of therapy for each of said at least 3 lines of prior therapy until progressive disease was the best response to that line of therapy; have evidence of progressive disease on or within 60 days of the most recent line; and / or have responded to at least one of the previous lines of therapy (minimal response or better); ) had been reached. In certain embodiments of any of the above embodiments, said subject exhibits at the time of said administration: M-protein (serum protein electrophoresis [sPEP] or urine protein electrophoresis [uPEP]): sPEP≧ 0.5 g / dL or uPEP ≥200 mg / 24 hours; serum immunoglobulin free light chain ≥10 mg / dL and light chain with abnormal serum immunoglobulin kappa lambda free light chain ratio without measurable disease in serum or urine multiple myeloma; and / or East Coast Cancer Trials Group (ECOG) activity status ≤1. In another more specific embodiment, the subject further: has received only one previous anti-myeloma treatment regimen; has the following high-risk factors: R-ISS stage III and (i) the subject progressive disease (PD) less than 12 months from the date of first transplant if the subject has undergone induction and stem cell transplantation; or (ii) at a minimum a proteasome inhibitor if the subject has undergone induction only; , early relapse defined as PD less than 12 months from the date of the last treatment regimen, which must have contained an immunomodulator and dexamethasone.

[0234] In certain embodiments of any of the above aspects or embodiments, the CAR comprises an antibody or antibody fragment that targets BCMA. In a more specific embodiment, said CAR comprises a single chain Fv antibody fragment (scFv). In a more specific embodiment, said CAR comprises BCMA02 scFv, eg SEQ ID NO: 38. In certain embodiments of any of the above aspects or embodiments, the immune cells are idecabutagene viculuucel cells. In one embodiment, the chimeric antigen receptor comprises BCMA, eg, a murine single chain Fv antibody fragment that targets BCMA. In one embodiment, the chimeric antigen receptor is a BCMA polypeptide, e.g., a human BCMA polypeptide comprising a CD8α polypeptide, a CD8α transmembrane domain, a CD137(4-1BB) intracellular costimulatory signaling domain, and a CD3ζ primary signaling domain. Contains a mouse anti-BCMA scFv that binds to a polypeptide hinge domain. In one embodiment, the chimeric antigen receptor comprises a murine scFv that targets BCMA, eg, the scFv is that of the anti-BCMA02 CAR of SEQ ID NO:9. In one embodiment, the chimeric antigen receptor is or comprises SEQ ID NO: 9 or SEQ ID NO: 37. In one embodiment, the chimeric antigen receptor is or comprises SEQ ID NO:9. In one embodiment, the chimeric antigen receptor is or comprises SEQ ID NO: 37. In a more particular embodiment of any embodiment herein, the immune cell is an ide-cel cell. In one embodiment, the immune cell comprises a chimeric antigen receptor comprising BCMA, eg, a murine single chain Fv antibody fragment that targets BCMA. In one embodiment, the immune cell comprises a BCMA polypeptide, e.g., a CD8α polypeptide, a CD8α transmembrane domain, a CD137(4-1BB) intracellular costimulatory signaling domain, and a CD3ζ primary signaling domain, a BCMA hinge domain. contains a chimeric antigen receptor containing a mouse anti-BCMA scFv that binds to. In one embodiment, the immune cell comprises a chimeric antigen receptor that is or comprises SEQ ID NO: 9 or SEQ ID NO: 37. In one embodiment, the immune cell comprises a chimeric antigen receptor that is or comprises SEQ ID NO:9. In one embodiment, the immune cell comprises a chimeric antigen receptor that is or comprises SEQ ID NO: 37.

[0235] In other embodiments, genetically modified immune effector cells contemplated herein are administered to a patient with a B cell-related condition, such as a B cell malignancy.

[0236] The amount of soluble (i.e., non-membrane bound) BCMA (sBCMA) after administration of CAR T cell therapy, e.g. It can be predicted or determined whether a subject should receive a different anti-cancer therapy. A greater reduction in sBCMA levels in tissue samples (e.g., serum, plasma, lymph, or blood) after administration of CAR T-cell therapy is associated with a more clinically beneficial outcome (e.g., very good partial response, complete response, or stringent response). complete response). In one embodiment, for example, determining a first level of soluble BCMA (sBCMA) in a tissue sample obtained from a subject; an immune cell expressing a chimeric antigen receptor (CAR) directed to BCMA (BCMA CAR T cells); administering to the subject a first BCMA-based treatment modality comprising: determining a second level of soluble BCMA (sBCMA) in a tissue sample obtained from the subject; A method of treating a disease caused by cells expressing a B cell maturation agent (BCMA), wherein the second level of sBCMA is greater than about 30% of the first level of sBCMA, the method comprising: is subsequently provided with a second BCMA-based treatment modality for treating said disease, the first BCMA-based treatment modality and the second BCMA-based treatment modality being different BCMA-based treatment modalities. , methods are provided herein. In certain embodiments, the immune cells are idekabutagene viculuucel cells. In certain embodiments, the second BCMA-based treatment modality is not idecabutagene viculuucel cells. In certain embodiments, the second BCMA-based treatment modality does not include idecabutagene viculuucel cells.

[0237] In certain embodiments of any of the above aspects or embodiments, the CAR T cell therapy (e.g., immune cells expressing BCMA-directed chimeric antigen receptors (CARs) (BCMA CAR T cells), e.g. Decabutagen viculucel (ide-cel cells) can be used to generate approximately 10%, 5%, 3%, 2% or 1% activated CAR T cells, such as activated CD8 CAR T cells (CD3+ / CD8+ / CAR+ / CD25+).

[0238] In certain embodiments of any of the above aspects or embodiments, the CAR comprises an antibody or antibody fragment targeted to an antigen of interest. The antigen of interest may be any antigen of interest, eg, an antigen on a tumor cell. Tumor cells may be, for example, cells in a solid tumor or cells of a blood cancer. The antigen may be expressed in cells of any tumor or cancer type, e.g. lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, e.g. malignant melanoma, skin cancer, colorectal cancer. cancer, tendinoma, adhesive small round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, It can be any antigen expressed on cells such as retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, or lipoma. In a more particular embodiment, said lymphoma is chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström's macroglobulinemia, splenic marginal zone. Lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, mediastinum (Thymus) Large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic leukemia, aggressive NK cell leukemia , adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blastic NK cell lymphoma, mycosis fungoides, Sézary syndrome , primary cutaneous anaplastic large cell lymphoma, lymphomatoid papulosis, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, or multiple May be sexual myeloma.

[0239] In certain embodiments, the antigen is a tumor-associated antigen (TAA) or a tumor-specific antigen (TSA). In various specific embodiments, without limitation, the tumor-associated antigen or tumor-specific antigen is Her2, prostate stem cell antigen (PSCA), alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen- 125 (CA-125), CA19-9, calretinin, MUC-1, epithelial membrane protein (EMA), epithelial tumor antigen (ETA), tyrosinase, melanoma-associated antigen (MAGE), CD19, CD20, CD34, CD45, CD99 , CD117, chromogranin, cytokeratin, desmin, glial fibrillary acidic protein (GFAP), gross cystic disease fluid protein (GCDFP-15), HMB-45 antigen, high molecular weight melanoma-associated antigen (HMW-MAA), protein melan -A(MART-1), myo-D1, muscle-specific actin (MSA), neurofilament, neuron-specific enolase (NSE), placental alkaline phosphatase, synaptophysis, thyroglobulin, thyroid transcription factor-1, diminution pyruvate kinase isoenzyme type M2 (tumor M2-PK), abnormal ras protein, or abnormal p53 protein.

[0240] In certain embodiments, the TAA or TSA is a cancer / testis (CT) antigen, e.g., BAGE, CAGE, CTAGE, FATE, GAGE, HCA661, HOM-TES-85, MAGEA, MAGEB, MAGEC, NA88, NY -ESO-1, NY-SAR-35, OY-TES-1, SPANXB1, SPA17, SSX, SYCP1, or TPTE.

[0241] In certain other embodiments, the TAA or TSA is a carbohydrate or ganglioside, e.g., fuc-GM1, GM2 (carcinoembryonic antigen-immunogenic-1; OFA-I-1); GD2 (OFA-I -2), GM3, and GD3.

[0242] In certain other embodiments, the TAA or TSA is alpha-actinin-4, Bage-1, BCR-ABL, Bcr-Abl fusion protein, beta-catenin, CA 125, CA15-3(CA27.29\BCAA ), CA195, CA242, CA-50, CAM43, Casp-8, CDC27, CDK4, CDKN2A, CEA, COA-1, DEK-CAN fusion protein, EBNA, EF2, Epstein-Barr virus antigen, ETV6-AML1 fusion protein, HLA -A2, HLA-A11, hsp70-2, KIAAO205, Mart2, Mum-1, 2, and 3, neo-PAP, myosin class I, OS-9, pml-RARα fusion protein, PTPRK, K-ras, N- ras, triose phosphate isomerase, Gage 3, 4, 5, 6, 7, GnTV, Herv-K-mel, Lage-1, NA-88, NY-Eso-1 / Lage-2, SP17, SSX-2, TRP2 -Int2, gp100(Pmel 17), tyrosinase, TRP-1, TRP-2, MAGE-1, MAGE-3, RAGE, GAGE-1, GAGE-2, p15(58), RAGE, SCP-1, Hom / Mel-40, PRAME, p53, H-Ras, HER-2 / neu, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR, human papillomavirus (HPV) antigens E6 and E7, TSP-180, MAGE- 4, MAGE-5, MAGE-6, p185erbB2, p180erbB-3, c-met, nm-23H1, PSA, TAG-72-4, CA19-9, CA72-4, CAM17.1, NuMa, K-ras, 13-catenin, Mum-1, p16, TAGE, PSMA, CT7, telomerase, 43-9F, 5T4, 791Tgp72, 13HCG, BCA225, BTAA, CD68\KP1, CO-029, FGF-5, G250, Ga733(EpCAM) , HTgp-175, M344, MA-50, MG7-Ag, MOV18, NB\70K, NY-CO-1, RCAS1, SDCCAG16, TA-90, TAAL6, TAG72, TLP, TPS, CD19, CD22, CD27, CD30 , CD70, GD2 (ganglioside G2), EGFRvIII (epidermal growth factor variant III), sperm protein 17 (Sp17), mesothelin, PAP (prostatic acid phosphatase), prostein, TARP (T cell receptor gamma alternative reading frame protein), Trp-p8, STEAP1 (six-transmembrane prostate epithelial antigen 1), abnormal ras protein, or abnormal p53 protein. In another specific embodiment, the tumor-associated or tumor-specific antigen is integrin αvβ3 (CD61), galactin, K-Ras (V-Ki-ras2 Kirsten rat sarcoma virus oncogene), or Ral -B.

[0243] In certain embodiments, the TAA or TSA is CD20, CD123, CLL-1, CD38, CS-1, CD138, ROR1, FAP, MUC1, PSCA, EGFRvIII, EPHA2, or GD2. In further specific embodiments, the TAA or TSA is CD123, CLL-1, CD38, or CS-1. In certain embodiments, the extracellular domain of the CAR binds CS-1. In further specific embodiments, the extracellular domain comprises a single chain version of elotuzumab and / or an antigen binding fragment of elotuzumab. In certain embodiments, the extracellular domain of the CAR binds CD20. In a more specific embodiment, the extracellular domain of the CAR is an scFv or an antigen-binding fragment thereof that binds CD20.

[0244] Other tumor-associated and tumor-specific antigens are known to those skilled in the art.

[0245] Antibodies and scFvs that bind TSA and TAA are known in the art, as are the nucleotide sequences encoding them.

[0246] In certain embodiments, the antigen is not believed to be a TSA or TAA, but is nevertheless an antigen associated with tumor cells or damage caused by a tumor. In certain embodiments, the antigen is a tumor microenvironment associated antigen (TMAA). In certain embodiments, for example, the TMAA is, for example, a growth factor, cytokine, or interleukin, such as a growth factor, cytokine, or interleukin associated with angiogenesis or vasculogenesis. Such growth factors, cytokines, or interleukins include, for example, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), hepatocyte growth factor (HGF), Insulin-like growth factor (IGF), or interleukin-8 (IL-8) can be included. Tumors can also create a local hypoxic environment for the tumor. Thus, in other specific embodiments, the TMAA is a hypoxia-related factor, such as HIF-1α, HIF-1β, HIF-2α, HIF-2β, HIF-3α, or HIF-3β. Tumors can also cause localized damage to normal tissue, triggering the release of molecules known as damage-associated molecular pattern molecules (DAMPs; also known as alarmins). Accordingly, in certain other specific embodiments, the TMAA is a DAMP, e.g., heat shock protein, chromatin-associated protein high mobility group box 1 (HMGB1), S100A8 (MRP8, calgranulin A), S100A9 (MRP14). , calgranulin B), serum amyloid A (SAA), or deoxyribonucleic acid, adenosine triphosphate, uric acid, or heparin sulfate. In certain embodiments, the TMAA is VEGF-A, EGF, PDGF, IGF, or bFGF. In certain embodiments of any of the above aspects or embodiments, the CAR comprises an antibody or antibody fragment targeted to an antigen of interest. In a more specific embodiment, said CAR comprises a single chain Fv antibody fragment (scFv). In one embodiment, the chimeric antigen receptor comprises an antigen of interest, e.g., an scFv that binds to an antigen on tumor cells, a hinge domain comprising a CD8α polypeptide, a CD8α transmembrane domain, a CD137(4-1BB) intracellular costimulatory a signaling domain, and a CD3ζ primary signaling domain. Tumor cells may be, for example, cells in a solid tumor or cells of a blood cancer. The antigen can be any antigen expressed on cells of any tumor or cancer type. In one embodiment, the immune cell comprises a chimeric antigen receptor comprising a single chain Fv antibody fragment targeted to an antigen of interest. In one embodiment, the immune cell comprises an scFv that binds an antigen of interest, a hinge domain comprising a CD8α polypeptide, a CD8α transmembrane domain, a CD137(4-1BB) intracellular costimulatory signaling domain, and a CD3ζ primary signaling domain. including chimeric antigen receptors containing.

[0247] In certain embodiments of any of the above aspects or embodiments, the CAR comprises an antibody or antibody fragment that targets BCMA. In a more specific embodiment, said CAR comprises a single chain Fv antibody fragment (scFv). In a more specific embodiment, said CAR comprises BCMA02 scFv, eg SEQ ID NO: 38. In certain embodiments of any of the above aspects or embodiments, the immune cell is an idekabutagene viculuucel cell. In one embodiment, the chimeric antigen receptor comprises BCMA, eg, a murine single chain Fv antibody fragment that targets BCMA. In one embodiment, the chimeric antigen receptor comprises a BCMA polypeptide, e.g., a murine anti-BCMA scFv that binds to a human BCMA polypeptide, a hinge domain comprising a CD8α polypeptide, a CD8α transmembrane domain, a CD137(4-1BB) intracellular Contains a costimulatory signaling domain, and a CD3ζ primary signaling domain. In one embodiment, the chimeric antigen receptor comprises a murine scFv that targets BCMA, eg, the scFv is that of the anti-BCMA02 CAR of SEQ ID NO: 9 or SEQ ID NO: 37. In one embodiment, the chimeric antigen receptor is or comprises SEQ ID NO:9. In one embodiment, the chimeric antigen receptor is or comprises SEQ ID NO: 37. In a more particular embodiment of any embodiment herein, the immune cell is an ide-cel cell. In one embodiment, the immune cell comprises a chimeric antigen receptor comprising BCMA, eg, a murine single chain Fv antibody fragment that targets BCMA. In one embodiment, the immune cell comprises a BCMA polypeptide, e.g., a murine anti-BCMA scFv that binds to BCMA, a hinge domain comprising a CD8α polypeptide, a CD8α transmembrane domain, a CD137(4-1BB) intracellular costimulatory signaling domain. , and a chimeric antigen receptor containing the CD3ζ primary signaling domain. In one embodiment, the immune cell comprises a chimeric antigen receptor that is or comprises SEQ ID NO:9. In one embodiment, the immune cell comprises a chimeric antigen receptor that is or comprises SEQ ID NO: 37.

[0248] In other embodiments, genetically modified immune effector cells contemplated herein are administered to a patient with a B cell-related condition, such as an autoimmune disease associated with B cells or B cell malignancies.

[0249] The practice of the subject matter presented herein is within the skill of the art in chemistry, biochemistry, organic chemistry, molecular biology, microbiology, recombinant engineering, etc., unless indicated otherwise. Conventional methods of DNA technology, genetics, immunology, and cell biology are used, many of which are described below for purposes of illustration. Such techniques are well explained in the literature. For example, Sambrook, et al., Molecular Cloning: A Laboratory Manual (3rd Edition, 2001);Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Edition, 1989);Maniatis et al., Molecular Cloning: A Laboratory Manual (1982);Ausubel et al., Current Protocols in Molecular Biology (John Wiley and Sons, updated July 2008);Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley- Interscience;Glover, DNA Cloning: A Practical Approach, vol. I & II (IRL Press, Oxford, 1985);Anand, Techniques for the Analysis of Complex Genomes, (Academic Press, New York, 1992);Transcription and Translation (B Hames & S. Higgins, Eds., 1984);Perbal, A Practical Guide to Molecular Cloning (1984);Harlow and Lane, Antibodies, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1998) Current Protocols in Immunology See monographs in journals such as Q. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach and W. Strober, eds., 1991); Annual Review of Immunology; and Advances in Immunology.

[0250] 6.2.Definition Unless otherwise defined, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, preferred embodiments of the compositions, methods, and materials are described herein. For purposes of this disclosure, the following terms are defined below.

[0251] The articles "a," "an," and "the" are used herein to refer to one or more than one (i.e., at least one, or one or more) of the grammatical object of the article. be done. By way of example, "an element" means an element or one or more elements.

[0252] Use of an option (eg, "or") should be understood to mean either one of the options, both, or any combination thereof.

[0253] It is to be understood that the term "and / or" means either one or both of the options.

[0254] As used herein, the term "about" or "approximately" means 15% of a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length; quantity, level, value, number, frequency, percentage, dimension, size, varying by as much as , 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1%; Refers to quantity, weight, or length. In one embodiment, the term "about" or "approximately" refers to ±15%, ±10%, with respect to a referenced quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length; ±9%, ±8%, ±7%, ±6%, ±5%, ±4%, ±3%, ±2%, or ±1% quantity, level, value, number, frequency, percentage, dimension , refers to a range of size, amount, weight, or length.

[0255] Throughout this specification, unless the context requires otherwise, the words "comprise", "comprises" and "comprising" refer to the steps or elements described or the steps or elements described. is understood to be meant to include groups of, but not exclude any other steps or elements or groups of steps or elements. By "consisting of" it is meant to include and be limited to whatever follows the phrase "consisting of". As such, the phrase "consisting of" indicates that the listed element is required or obligatory and that no other element may be present. By "consisting essentially of" we include any element listed after the phrase and are limited to other elements that do not interfere with or contribute to the activity or effect specified in this disclosure for the listed element. That is what is meant. Thus, the phrase "consisting essentially of" means that the listed element is required or obligatory, but that no other element substantially affects the activity or action of the listed element. point to.

[0256] “one embodiment”, “an embodiment”, “a particular embodiment”, “related embodiments”, “a particular embodiment”, “additional embodiment”, or “further embodiment” or References throughout this specification to combinations of embodiments refer to the fact that a particular feature, structure, or characteristic described in connection with that embodiment is included in at least one embodiment of the disclosure presented herein. means. Therefore, the appearances of these phrases in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. It is also understood that a positive description of a feature in one embodiment serves as a basis for excluding that feature in certain embodiments.

[0257] 6.3. Mode of administration In certain embodiments of any of the above aspects or embodiments, antagonists of CAR T cells and inflammation-related soluble factors (e.g., PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, antagonists of PDCD1, IL12, and NCR1) to reduce the levels of inflammation-related soluble factors in the serum of a subject. may be administered to a subject simultaneously (ie, co-administration) and / or sequentially (ie, sequential administration) as appropriate to achieve levels determined to be similar.

[0258] In certain embodiments of any of the above aspects or embodiments, antagonists of CAR T cells and inflammation-related soluble factors (e.g., PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, antagonists of PDCD1, IL12, and NCR1) are administered simultaneously. The term "co-administration" as used herein means that the CAR T cells and the inflammation-associated soluble factor antagonist are separated by a time of no more than about 15 minutes, such as no more than about 10, 5, or 1 minute. means to be administered. When CAR T cells and an inflammation-related soluble factor antagonist are administered simultaneously, the CAR T cells and inflammation-related soluble factor antagonist may be administered in the same composition (e.g., a composition containing both CAR T cells and an inflammation-related soluble factor antagonist). (e.g., the CAR T cell and inflammation-related soluble factor antagonist are contained in separate compositions) or in separate compositions (eg, the CAR T cell and inflammation-related soluble factor antagonist are contained in separate compositions).

[0259] In certain embodiments of any of the above aspects or embodiments, antagonists of CAR T cells and inflammation-related soluble factors (e.g., PGF, CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, antagonists of PDCD1, IL12, and NCR1) are administered sequentially. The term "sequential administration" as used herein means that the CAR T cell and inflammation-related soluble factor antagonist is administered for more than about 15 minutes, such as about 20, 30, 40, 50, 60 minutes or more. means administered with time separations greater than any of minutes. Either CAR T cells and an inflammation-related soluble factor antagonist may be administered first. The CAR T cells and the inflammation-related soluble factor antagonist are contained in separate compositions that may be contained in the same or different packages.

[0260] In certain embodiments of any of the above aspects or embodiments, the administration of the CAR T cells and the antagonist of inflammation-related soluble factors is concurrent, i.e., the period of administration of the CAR T cells and the antagonist of inflammation-related soluble factors. overlap with each other.

[0261] In some embodiments, the antagonist of an inflammation-related soluble factor is administered for at least one cycle (eg, at least one of 2, 3, or 4 cycles) prior to administration of the CAR T cells. In certain embodiments, the period of administration of the CAR T cells is such that subsequent to administration of the antagonist and the level of inflammation-related soluble factors from the patient is responsive to the chimeric antigen receptor (CAR) T cells. Begins approximately 1, 2, 3, 4, 5, 6, or 7 days after the level of inflammation-related soluble factors in serum is determined to be similar. In certain embodiments, the period of administration of the CAR T cells is such that subsequent to administration of the antagonist and the level of inflammation-related soluble factors from the patient is responsive to the chimeric antigen receptor (CAR) T cells. Begins approximately 1 week, 2 weeks, 3 weeks, or 4 weeks after the levels of inflammation-related soluble factors in serum are determined to be similar. In certain embodiments, the period of administration of the CAR T cells is such that subsequent to administration of the antagonist and the level of inflammation-related soluble factors from the patient is responsive to the chimeric antigen receptor (CAR) T cells. Begins approximately 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months after the level of inflammation-related soluble factors in serum is determined to be similar.

[0262] In some embodiments, administration of the CAR T cells and the inflammation-related soluble factor antagonist begins at approximately the same time (e.g., within any one of 1, 2, 3, 4, 5, 6, or 7 days) be done. In some embodiments, the administration of the CAR T cells and the inflammation-related soluble factor antagonist is at approximately the same time (e.g., within any one of 1, 2, 3, 4, 5, 6, or 7 days). be terminated. In some embodiments, administration of the CAR T cells occurs after administration of the inflammation-related soluble factor antagonist (e.g., about 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months). In some embodiments, administration of CAR T cells occurs after the initiation of administration of an antagonist of an inflammation-related soluble factor (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or after any one of 12 months). In some embodiments, administration of the CAR T cells and the inflammation-related soluble factor antagonist begins and ends at approximately the same time. In some embodiments, administration of the CAR T cells and the antagonist of an inflammation-related soluble factor is stopped at approximately the same time, and administration of the CAR T cell is stopped after the initiation of administration of the antagonist of the inflammation-related soluble factor (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months).

[0263] In certain embodiments of any of the above aspects or embodiments, the administration of the CAR T cell and the inflammation-related soluble factor antagonist are non-simultaneous. For example, in some embodiments, administration of the inflammation-related soluble factor antagonist is terminated before the CAR T cells are administered. In some embodiments, administration of CAR T cells is terminated before the antagonist of inflammation-related soluble factors is administered. The period between these two non-concurrent administrations can range from about 2 to 8 weeks, such as about 4 weeks.

[0264] The CAR T cell and inflammation-related soluble factor antagonists described herein can be used, for example, intravenously, intraarterially, intraperitoneally, intrapulmonally, orally, by inhalation, intracapsularly, intramuscularly, intratracheally, subcutaneously, intraocularly, It can be administered to an individual (eg, a human, eg, a human patient) via a variety of routes, including intrathecally, transmucosally, and transdermally. In some embodiments, sustained continuous release formulations of the compositions may be used. In one embodiment, the inflammation-related soluble factor antagonist is administered by any method including, but not limited to, orally, intramuscularly, transdermally, intravenously, through an inhaler or other airborne delivery system. It can be administered by any acceptable route.

[0265] 6.4. Chimeric antigen receptor In various embodiments, genetically engineered receptors are provided that redirect the cytotoxicity of immune effector cells to B cells. These genetically engineered receptors are referred to herein as chimeric antigen receptors (CARs). CARs are molecules that combine antibody-based specificity for a desired antigen (e.g., BCMA) with a T-cell receptor-activating intracellular domain to generate chimeric proteins that exhibit specific anti-BCMA cellular immune activity. It is. As used herein, the term "chimera" describes being composed of different proteins or portions of DNA from different origins.

[0266] The CAR T cell therapy to which embodiments described herein are applied may be any CAR T therapy, e.g. BCMA CAR T cell therapy, e.g. ;10,934,363 SEQ ID NO: 265 or WO2018 / 028647 SEQ ID NO: 300, with or without a signal peptide) (Janssen / Legend), P-BCMA-101 (Poseida), PBCAR269A (Poseida), P-BCMA -Allo1 (Poseida), Allo-715 (Pfizer / Allogene), CT053 (Carsgen), Descartes-08 (Cartesian), PHE885 (Novartis), CTX120 (CRISPR Therapeutics); CD19 CAR T therapy, e.g. Yescarta, Kymriah, Tecartus , lysocabtagen malalleucel (liso-cel), and any other cell surface marker-targeted CAR T therapy.

[0267] The extracellular domain (also referred to as the binding domain or antigen-specific binding domain) of the polypeptide binds the antigen of interest. In certain embodiments, the extracellular domain comprises a receptor, or a portion of a receptor, that binds the antigen. The extracellular domain may be, for example, a receptor, or a portion of a receptor, that binds the antigen. In certain embodiments, the extracellular domain comprises or is an antibody or antigen-binding portion thereof. In certain embodiments, the extracellular domain comprises or is a single chain Fv domain. A single-chain Fv domain can be isolated by a flexible linker, e.g. H V connected to L and the above V L and V H is from an antibody that binds to said antigen.

[0268] The antigen to which the extracellular domain of the polypeptide binds can be any antigen of interest, eg, an antigen on a tumor cell. Tumor cells may be, for example, cells in a solid tumor or cells of a blood cancer. The antigen may be expressed in cells of any tumor or cancer type, e.g. lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, e.g. malignant melanoma, skin cancer, colorectal cancer. cancer, tendinoma, adhesive small round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, It can be any antigen expressed on cells such as retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, or lipoma. In a more particular embodiment, said lymphoma is chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström's macroglobulinemia, splenic marginal zone. Lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, mediastinum (Thymus) Large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic leukemia, aggressive NK cell leukemia , adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blastic NK cell lymphoma, mycosis fungoides, Sézary syndrome , primary cutaneous anaplastic large cell lymphoma, lymphomatoid papulosis, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, or multiple May be sexual myeloma.

[0269] In certain embodiments, the antigen is a tumor-associated antigen (TAA) or a tumor-specific antigen (TSA). In various specific embodiments, without limitation, the tumor-associated antigen or tumor-specific antigen is Her2, prostate stem cell antigen (PSCA), alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen- 125 (CA-125), CA19-9, calretinin, MUC-1, epithelial membrane protein (EMA), epithelial tumor antigen (ETA), tyrosinase, melanoma-associated antigen (MAGE), CD19, CD20, CD34, CD45, CD99 , CD117, chromogranin, cytokeratin, desmin, glial fibrillary acidic protein (GFAP), gross cystic disease fluid protein (GCDFP-15), HMB-45 antigen, high molecular weight melanoma-associated antigen (HMW-MAA), protein melan -A(MART-1), myo-D1, muscle-specific actin (MSA), neurofilament, neuron-specific enolase (NSE), placental alkaline phosphatase, synaptophysis, thyroglobulin, thyroid transcription factor-1, dimeric form of pyruvate kinase isoenzyme type M2 (tumor M2-PK), abnormal ras protein, or abnormal p53 protein.

[0270] In certain embodiments, the TAA or TSA is a cancer / testis (CT) antigen, e.g., BAGE, CAGE, CTAGE, FATE, GAGE, HCA661, HOM-TES-85, MAGEA, MAGEB, MAGEC, NA88, NY -ESO-1, NY-SAR-35, OY-TES-1, SPANXB1, SPA17, SSX, SYCP1, or TPTE.

[0271] In certain other embodiments, the TAA or TSA is a carbohydrate or ganglioside, e.g., fuc-GM1, GM2 (carcinoembryonic antigen-immunogenic-1; OFA-I-1); GD2 (OFA-I -2), GM3, and GD3.

[0272] In certain other embodiments, the TAA or TSA is alpha-actinin-4, Bage-1, BCR-ABL, Bcr-Abl fusion protein, beta-catenin, CA 125, CA 15-3(CA 27.29\BCAA ), CA 195, CA 242, CA-50, CAM43, Casp-8, CDC27, CDK4, CDKN2A, CEA, COA-1, DEK-CAN fusion protein, EBNA, EF2, Epstein-Barr virus antigen, ETV6-AML1 fusion protein , HLA-A2, HLA-A11, hsp70-2, KIAAO205, Mart2, Mum-1, 2, and 3, neo-PAP, myosin class I, OS-9, pml-RARα fusion protein, PTPRK, K-ras, N-ras, triose phosphate isomerase, Gage 3, 4, 5, 6, 7, GnTV, Herv-K-mel, Lage-1, NA-88, NY-Eso-1 / Lage-2, SP17, SSX-2 , TRP2-Int2, gp100(Pmel 17), tyrosinase, TRP-1, TRP-2, MAGE-1, MAGE-3, RAGE, GAGE-1, GAGE-2, p15(58), RAGE, SCP-1, Hom / Mel-40, PRAME, p53, H-Ras, HER-2 / neu, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR, human papillomavirus (HPV) antigens E6 and E7, TSP-180, MAGE-4, MAGE-5, MAGE-6, p185erbB2, p180erbB-3, c-met, nm-23H1, PSA, TAG-72-4, CA 19-9, CA 72-4, CAM 17.1, NuMa, K -ras, 13-catenin, Mum-1, p16, TAGE, PSMA, CT7, telomerase, 43-9F, 5T4, 791Tgp72, 13HCG, BCA225, BTAA, CD68\KP1, CO-029, FGF-5, G250, Ga733 (EpCAM), HTgp-175, M344, MA-50, MG7-Ag, MOV18, NB\70K, NY-CO-1, RCAS1, SDCCAG16, TA-90, TAAL6, TAG72, TLP, TPS, CD19, CD22, CD27, CD30, CD70, GD2 (ganglioside G2), EGFRvIII (epidermal growth factor variant III), sperm protein 17 (Sp17), mesothelin, PAP (prostatic acid phosphatase), prostein, TARP (T cell receptor gamma alternative reading frame) protein), Trp-p8, STEAP1 (six-transmembrane prostate epithelial antigen 1), abnormal ras protein, or abnormal p53 protein. In another specific embodiment, the tumor-associated or tumor-specific antigen is integrin αvβ3 (CD61), galactin, K-Ras (V-Ki-ras2 Kirsten rat sarcoma virus oncogene), or Ral -B.

[0273] In certain embodiments, the TAA or TSA is CD20, CD123, CLL-1, CD38, CS-1, CD138, ROR1, FAP, MUC1, PSCA, EGFRvIII, EPHA2, or GD2. In further specific embodiments, the TAA or TSA is CD123, CLL-1, CD38, or CS-1. In certain embodiments, the extracellular domain of the CAR binds CS-1. In further specific embodiments, the extracellular domain comprises a single chain version of elotuzumab and / or an antigen binding fragment of elotuzumab. In certain embodiments, the extracellular domain of the CAR binds CD20. In a more specific embodiment, the extracellular domain of the CAR is an scFv or an antigen-binding fragment thereof that binds CD20.

[0274] Other tumor-associated and tumor-specific antigens are known to those skilled in the art.

[0275] Antibodies and scFvs that bind TSA and TAA are known in the art, as are the nucleotide sequences encoding them.

[0276] In certain embodiments, the antigen is not believed to be a TSA or TAA, but is nevertheless an antigen associated with tumor cells or damage caused by a tumor. In certain embodiments, the antigen is a tumor microenvironment associated antigen (TMAA). In certain embodiments, for example, the TMAA is, for example, a growth factor, cytokine, or interleukin, such as a growth factor, cytokine, or interleukin associated with angiogenesis or vasculogenesis. Such growth factors, cytokines, or interleukins include, for example, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), hepatocyte growth factor (HGF), Insulin-like growth factor (IGF), or interleukin-8 (IL-8) can be included. Tumors can also create a local hypoxic environment for the tumor. Thus, in other specific embodiments, the TMAA is a hypoxia-related factor, such as HIF-1α, HIF-1β, HIF-2α, HIF-2β, HIF-3α, or HIF-3β. Tumors can also cause localized damage to normal tissue, triggering the release of molecules known as damage-associated molecular pattern molecules (DAMPs; also known as alarmins). Accordingly, in certain other specific embodiments, the TMAA is a DAMP, e.g., heat shock protein, chromatin-associated protein high mobility group box 1 (HMGB1), S100A8 (MRP8, calgranulin A), S100A9 (MRP14). , calgranulin B), serum amyloid A (SAA), or deoxyribonucleic acid, adenosine triphosphate, uric acid, or heparin sulfate. In certain embodiments, the TMAA is VEGF-A, EGF, PDGF, IGF, or bFGF.

[0277] In certain embodiments, the extracellular domain is joined to said transmembrane domain by a linker, spacer or hinge polypeptide sequence, eg, a sequence from CD28.

[0278] In certain embodiments, the CARs contemplated herein include an extracellular domain that binds BCMA, a transmembrane domain, and an intracellular signaling domain. Engagement of the anti-BCMA antigen-binding domain of the CAR with BCMA on the surface of target cells results in clustering of the CAR and delivers activating stimuli to CAR-containing cells. A key feature of CARs is to exploit the cell-specific targeting ability of monoclonal antibodies, soluble ligands or cell-specific co-receptors to redirect immune effector cell specificity, thereby inhibiting proliferation, cytokine production and phagocytosis. It is their ability to trigger the production of molecules that can mediate cell death of target antigen-expressing cells in a cytosis or major histocompatibility (MHC)-independent manner.

[0279] In various embodiments, the CAR has an extracellular binding domain that includes a mouse anti-BCMA (e.g., human BCMA) specific binding domain; a transmembrane domain; one or more intracellular costimulatory signaling domains; and Contains the primary signaling domain.

[0280] In certain embodiments, the CAR comprises an extracellular binding domain comprising a murine anti-BCMA (e.g., human BCMA) antibody or antigen-binding fragment thereof; a transmembrane domain comprising one or more hinge domains or spacer domains; ; one or more intracellular costimulatory signaling domains; and a primary signaling domain.

[0281] 6.4.1. Binding domain In certain embodiments, a CAR contemplated herein comprises an extracellular binding domain comprising a murine anti-BCMA antibody or antigen-binding fragment thereof that specifically binds a human BCMA polypeptide expressed on a B cell. . As used herein, the terms "binding domain", "extracellular domain", "extracellular binding domain", "antigen-specific binding domain" and "extracellular antigen-specific binding domain" are used synonymously. used to provide a CAR that has the ability to specifically bind to a target antigen of interest, eg, BCMA. Binding domains can be derived from either natural, synthetic, semi-synthetic, or recombinant sources.

[0282] The terms "specific binding affinity" or "specifically bind" or "specifically bound" or "specific binding" or "specifically targeted" are used herein describes the binding of an anti-BCMA antibody or antigen-binding fragment thereof (or a CAR comprising it) to BCMA with binding affinity greater than background binding. The binding domain (or CAR containing the binding domain or fusion protein containing the binding domain) may be, for example, about 10 5 M -1 Affinity or K a (i.e., the equilibrium association constant for a particular binding interaction with units of 1 / M) "specifically binds" to BCMA if it binds or associates with BCMA. In certain embodiments, the binding domain (or fusion protein thereof) has about 10 6 M -1 ,Ten 7 M -1 ,Ten 8 M -1 ,Ten 9 M -1 ,Ten 10 M -1 ,Ten 11 M -1 ,Ten 12 M -1 , or 10 13 M -1 more than K a binds to the target. A "high affinity" binding domain (or single chain fusion protein thereof) is one that has at least 10 7 M -1 , at least 10 8 M -1 , at least 10 9 M -1 , at least 10 10 M -1 , at least 10 11 M -1 , at least 10 12 M -1 , at least 10 13 M -1 , or greater K a refers to those binding domains with

[0283] Alternatively, the affinity may be measured in units of M (e.g., 10 -5 M~10 -13 The equilibrium dissociation constant (K d ) can be defined as Affinity of binding domain polypeptides and CAR proteins according to the present disclosure can be determined using conventional techniques, for example, by competitive ELISA (enzyme-linked immunosorbent assay), or by binding association, or by binding labeled ligands. Depending on the displacement assay used, or surface plasmon resonance devices, such as the Biacore T100 available from Biacore, Inc., Piscataway, NJ, or optical biosensor technology, such as available from Corning and Perkin Elmer, respectively. can be readily determined using certain EPIC systems or EnSpire (see, e.g., Scatchard et al. (1949) Ann. N.Y. Acad. Sci. 51:660; and U.S. Pat. No. 5,283,173; ).

[0284] In one embodiment, the specific binding affinity is about 2 times greater than background binding, about 5 times greater than background binding, about 10 times greater than background binding, about 20 times greater than background binding. about 50 times greater than background binding, about 100 times greater than background binding, or about 1000 times greater than background binding, or greater.

[0285] In certain embodiments, the extracellular binding domain of the CAR comprises an antibody or antigen-binding fragment thereof. "Antibody" means at least a light chain or a heavy Refers to a binding agent that is a polypeptide comprising a chain immunoglobulin variable region.

[0286] "Antigen (Ag)" refers to a compound, composition, or substance that can stimulate the production of antibodies or T cell responses in an animal; including). The antigen reacts with the products of specific humoral or cell-mediated immunity, including those induced by foreign antigens, such as the disclosed antigens. In certain embodiments, the target antigen is an epitope of a BCMA polypeptide.

[0287] "Epitope" or "antigenic determinant" refers to the region of an antigen that is bound by a binding agent. Epitopes can be formed from both contiguous amino acids or non-contiguous amino acids juxtaposed by tertiary folding of the protein. Epitopes formed from consecutive amino acids are usually retained upon exposure to denaturing solvents, whereas epitopes formed by tertiary folding are usually lost upon treatment with denaturing solvents. Epitopes usually contain at least 3, more usually at least 5, about 9, or about 8-10 amino acids in a unique spatial conformation.

[0288] Antibodies include antigen-binding fragments thereof, such as camel Ig, Ig NAR, Fab fragment, Fab' fragment, F(ab)' 2 Fragment, F(ab)’ 3 fragment, Fv, single chain Fv protein (“scFv”), bis-scFv, (scFv) 2 , minibodies, diabodies, triabodies, tetrabodies, disulfide-stabilized Fv proteins (“dsFv”) and single domain antibodies (sdAbs, nanobodies) and the portions of full-length antibodies responsible for antigen binding. The term also includes genetically engineered forms, such as chimeric antibodies (eg, humanized murine antibodies), heteroconjugate antibodies (eg, bispecific antibodies), and antigen-binding fragments thereof. Pierce Catalog and Handbook, 1994-1995 (Pierce Chemical Co., Rockford, IL); see also Kuby, J., Immunology, 3rd Ed., W. H. Freeman & Co., New York, 1997.

[0289] As understood by those skilled in the art, and as described elsewhere herein, a complete antibody includes two heavy chains and two light chains. Each heavy chain consists of a variable region and first, second, and third constant regions, while each light chain consists of a variable region and a constant region. Mammalian heavy chains are classified as alpha, delta, epsilon, gamma, and mu. Mammalian light chains are classified as λ or κ. Immunoglobulins containing alpha, delta, epsilon, gamma, and mu heavy chains are classified as immunoglobulin (Ig) A, IgD, IgE, IgG, and IgM. A complete antibody forms a "Y" shape. The stem of the Y consists of the second and third constant regions of the two heavy chains joined together (for IgE and IgM, the fourth constant region), with disulfide bonds (interchain) formed at the hinge. Ru. Heavy chains γ, α, and δ have a constant region composed of three tandem Ig domains and a hinge region for added mobility; heavy chains μ and ε have four immunoglobulin domains. It has a constant region consisting of. The second and third constant regions are called the "CH2 domain" and the "CH3 domain", respectively. Each arm of the Y includes a single heavy chain variable region and a first constant region joined to a single light chain variable and constant region. The variable regions of the light and heavy chains are responsible for antigen binding.

[0290] The light and heavy chain variable regions contain "framework" regions interrupted by three hypervariable regions, also called "complementarity determining regions" or "CDRs." CDR is performed by conventional methods, e.g., Kabat et al (Wu, TT and Kabat, E. A., J Exp Med. 132(2):211-50, (1970); Borden, P. and Kabat E. A., PNAS, 84: 2440-2443 (1987); (see also Kabat et al., Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services, 1991, incorporated herein by reference), or by Chothia et al ( Chothia, C. and Lesk, A.M., J Mol. Biol., 196(4): 901-917 (1987), Chothia, C. et al, Nature, 342: 877 - 883 (1989)) or Can be identified.

[0291] The framework region sequences of different light or heavy chains are relatively conserved within species, eg, humans. The framework regions of antibodies, the combined framework regions of the component light and heavy chains, serve to position and align the CDRs in three-dimensional space. CDRs are primarily responsible for binding to epitopes of antigens. The CDRs of each chain are usually numbered consecutively starting from the N-terminus and are referred to as CDR1, CDR2, and CDR3, and are also usually identified by the strand in which a particular CDR is located. Therefore, CDRs located in the variable domain of the heavy chain of an antibody are referred to as CDRH1, CDRH2, and CDRH3, whereas CDRs located in the variable domain of the light chain of an antibody are referred to as CDRL1, CDRL2, and CDRL3. Antibodies with different specificities (ie, different combined sites for different antigens) have different CDRs. Although the CDRs differ from antibody to antibody, a limited number of amino acid positions within the CDRs are directly involved in antigen binding. These positions within the CDRs are called specificity determining residues (SDRs). Illustrative examples of light chain CDRs suitable for constructing humanized BCMA CARs contemplated herein include, but are not limited to, the CDR sequences set forth in SEQ ID NOs: 1-3. Illustrative examples of heavy chain CDRs suitable for constructing humanized BCMA CARs contemplated herein include, but are not limited to, the CDR sequences set forth in SEQ ID NOs: 4-6.

[0292] "V H ” or “VH” refers to the variable region of an immunoglobulin heavy chain, including that of an antibody, Fv, scFv, dsFv, Fab, or other antibody fragments as disclosed herein. "V L ” or “VL” refers to the variable region of an immunoglobulin light chain, including that of an antibody, Fv, scFv, dsFv, Fab, or other antibody fragments as disclosed herein.

[0293] A "monoclonal antibody" is an antibody produced by a single clone of B lymphocytes or by cells that have been transfected with the light and heavy chain genes of a single antibody. Monoclonal antibodies are produced by methods known to those skilled in the art, for example, by creating hybrid antibody-forming cells from the fusion of myeloma cells with immune spleen cells. Monoclonal antibodies include humanized monoclonal antibodies.

[0294] A "chimeric antibody" has framework residues from one species, eg, a human, and CDRs (generally conferring antigen binding) from another species, eg, a mouse. In certain embodiments, the CARs contemplated herein include an antigen-specific binding domain that is a chimeric antibody or antigen-binding fragment thereof.

[0295] A "humanized" antibody is an immunoglobulin that contains human framework regions and one or more CDRs derived from a non-human (eg, mouse, rat or synthetic) immunoglobulin. The non-human immunoglobulin that provides the CDRs is called the "donor" and the human immunoglobulin that provides the framework is called the "acceptor."

[0296] In certain embodiments, the murine anti-BCMA (e.g., human BCMA) antibody or antigen-binding fragment thereof includes, but is not limited to, camelid Ig (camelid antibody (VHH)), Ig NAR, Fab fragment, Fab' fragment, F(ab)' 2 Fragment, F(ab)’ 3 fragment, Fv, single chain Fv antibody (“scFv”), bis-scFv, (scFv) 2 , minibodies, diabodies, triabodies, tetrabodies, disulfide-stabilized Fv proteins (“dsFv”) and single domain antibodies (sdAbs, nanobodies).

[0297] "Camelid Ig" or "camelid VHH" as used herein refers to the smallest known antigen-binding unit of a heavy chain antibody (Koch-Nolte, et al, FASEB J., 21: 3490 -3498 (2007)). "Heavy chain antibody" or "camelid antibody" refers to an antibody that contains two VH domains and no light chains (Riechmann L. et al, J. Immunol. Methods 231:25 38 (1999); WO94 / 04678; WO94 / 25591; US ​​Patent No. 6,005,079).

[0298] "IgNAR" in "immunoglobulin novel antigen receptor" is a shark immune repertoire-derived homodimer of one variable novel antigen receptor (VNAR) domain and five constant novel antigen receptor (CNAR) domains. Refers to the class of antibodies. IgNAR represents the smallest known immunoglobulin-based protein scaffold, is highly stable, and has efficient binding characteristics. Intrinsic stability is due to (i) the underlying Ig scaffold, which represents a significant number of charged, hydrophilic, surface-exposed residues compared to conventional antibody VH and VL domains found in murine antibodies; and (ii) loops. It may be due to both stabilizing structural features in the complementarity determining region (CDR) loops, including patterns of inter-disulfide bridges and intra-loop hydrogen bonds.

[0299] Papain digestion of antibodies produces two identical antigen-binding fragments, each called a "Fab" fragment, with a single antigen-binding site, and a remaining "Fc" fragment, whose name reflects its ability to readily crystallize. ” brings the fragments. Pepsin treatment yields an F(ab')2 fragment that has two antigen combining sites and is still capable of cross-linking antigen.

[0300] "Fv" is the smallest antibody fragment that contains a complete antigen binding site. In one embodiment, the double-chain Fv species consists of a dimer of one heavy chain variable domain and one light chain variable domain in tight, non-covalent association. In single-chain Fv (scFv) species, one heavy chain variable domain and one light chain variable domain allow the light and heavy chains to associate in a "dimeric" structure similar to that in double-chain Fv species. may be covalently linked by a flexible peptide linker. It is in this configuration that the three hypervariable regions (HVR) of each variable domain interact to define the antigen binding site on the surface of the VH-VL dimer. Collectively, the six HVRs confer antigen-binding specificity to antibodies. However, even a single variable domain (or half of an Fv containing only three antigen-specific HVRs), although with lower affinity than the entire binding site, increases the ability to recognize and bind antigen. have

[0301] The Fab fragment contains the heavy and light chain variable domains and also contains the light chain constant domain and the heavy chain first constant domain (CH1). Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain, including one or more cysteines from the antibody hinge region. Fab'-SH is the name herein for Fab' in which the cysteine ​​residue(s) of the constant domain have a free thiol group. F(ab')2 antibody fragments were originally produced as pairs of Fab' fragments that have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

[0302] The term "diabody" refers to a fragment that has two antigen-binding sites in the same polypeptide chain, including a heavy chain variable domain (VH) connected to a light chain variable domain (VL) (VH-VL). Refers to antibody fragments. By using a linker that is too short to allow pairing between two domains on the same chain, the domains are forced to pair with complementary domains on another chain, creating two antigen-binding sites. do. Diabodies can be bivalent or bispecific. Diabodies are well defined by, for example, EP404,097; WO1993 / 01161; Hudson et al., Nat. Med. 9:129-134 (2003); It is described in. Triabodies and tetrabodies are also described in Hudson et al., Nat. Med. 9:129-134 (2003).

[0303] "Single domain antibody" or "sdAb" or "nanobody" refers to an antibody fragment consisting of the variable region of an antibody heavy chain (VH domain) or the variable region of an antibody light chain (VL domain) (Holt, L., et al, 2003, Trends in Biotechnology, 21(11): 484-490).

[0304] "Single-chain Fv" or "scFv" antibody fragments contain the VH and VL domains of an antibody, which domains are arranged in either orientation (e.g., VL-VH or VH-VL) in a single polypeptide chain. exists in Generally, scFv polypeptides further include a polypeptide linker between the VH and VL domains, which allows the scFv to form the desired structure for antigen binding. For an overview of scFvs, see, for example, Pluckthun, The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., (Springer-Verlag, New York, 1994), pp. 269-315.

[0305] In certain embodiments, the CARs contemplated herein include an antigen-specific binding domain that is a murine scFv. Single chain antibodies can be cloned from the V region genes of hybridomas specific for the desired target. Generation of such hybrid vectors has become routine. Techniques that can be used to clone variable region heavy chains (VH) and variable region light chains (VL) are described, for example, in Orlandi et al., PNAS, 1989; 86: 3833-3837.

[0306] In certain embodiments, the antigen-specific binding domain is a mouse scFv that binds a human BCMA polypeptide. An example of a heavy chain variable chain suitable for constructing the BCMA CARs contemplated herein includes, but is not limited to, the amino acid sequence set forth in SEQ ID NO:8. An example of a light chain variable chain suitable for constructing the BCMA CARs contemplated herein includes, but is not limited to, the amino acid sequence set forth in SEQ ID NO:7.

[0307] The BCMA-specific binding domains provided herein also include 1, 2, 3, 4, 5, or 6 CDRs. Such CDRs may be non-human CDRs or modified non-human CDRs selected from CDRL1, CDRL2 and CDRL3 of the light chain and CDRH1, CDRH2 and CDRH3 of the heavy chain. In certain embodiments, the BCMA-specific binding domain comprises (a) a light chain variable region comprising light chain CDRL1, light chain CDRL2, and light chain CDRL3; and (b) heavy chain CDRH1, heavy chain CDRH2, and heavy chain CDRL3. Contains the heavy chain variable region, including chain CDRH3.

[0308] 6.4.2.Linker In certain embodiments, the CARs contemplated herein may include linker residues between the various domains, eg, added for proper spacing and conformation of the molecule. In certain embodiments, the linker is a variable region joining sequence. A "variable region linking sequence" is a V H and V L It is an amino acid sequence that connects the domains and provides a spacer function compatible with the interaction of the two subbinding domains. CARs contemplated herein may include 1, 2, 3, 4, or 5 linkers. In certain embodiments, the length of the linker is from about 1 to about 25 amino acids, from about 5 to about 20 amino acids, or from about 10 to about 20 amino acids, or any intervening length of amino acids. be. In some embodiments, the linker includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more amino acids in length.

[0309] As an example of a linker, glycine polymer (G) n ;Glycine-serine polymer (G 1~5 S 1~5 ) n (where n is an integer of at least 1, 2, 3, 4, or 5); glycine-alanine polymers; alanine-serine polymers; and other flexible linkers known in the art. Glycine and glycine-serine polymers are relatively amorphous and therefore have the potential to serve as neutral tethers between domains of fusion proteins such as the CARs described herein. Glycine accesses considerably more phi-psi space than even alanine and is much less restricted than residues with longer side chains (see Scheraga, Rev. Computational Chem. 11173-142 (1992)). . Those skilled in the art will appreciate that the design of the CAR may, in certain embodiments, include a fully or partially flexible linker, such that the linker has a flexible linker as well as a less flexible linker to the desired CAR structure. It will be appreciated that the term may contain one or more parts that give no structure.

[0310] Other exemplary linkers include, but are not limited to, the following amino acid sequences: GGG; DGGGS (SEQ ID NO: 12); TGEKP (SEQ ID NO: 13) (e.g., Liu et al., PNAS 5525-5530 (1997 ); GGRR (SEQ ID NO: 14) (Pomerantz et al. 1995, supra); (GGGGS) n (where n=1, 2, 3, 4 or 5, GGGGS is identified as SEQ ID NO: 15 (Kim et al., PNAS 93, 1156-1160 (1996); EGKSSGSGSESKVD (SEQ ID NO: 16) ( Chaudhary et al., 1990, Proc. Natl. Acad. Sci. U.S.A. 87:1066-1070); KESGSVSSEQLAQFRSLD (SEQ ID NO: 17) (Bird et al., 1988, Science 242:423-426), GGRRGGGS (SEQ ID NO: 18) );LRQRDGERP(SEQ ID NO: 19);LRQKDGGGSERP(SEQ ID NO: 20);LRQKd(GGGS) 2 ERP (SEQ ID NO: 21). Alternatively, flexible linkers can be created using computer programs that can model both the DNA binding site and the peptide itself (Desjarlais & Berg, PNAS 90:2256-2260 (1993), PNAS 91:11099-11103 (1994)). or can be rationally designed by phage display methods. In one embodiment, the linker comprises the following amino acid sequence: GSTSGSGKPGSGEGSTKG (SEQ ID NO: 22) (Cooper et al., Blood, 101(4): 1637-1644 (2003 )).

[0311] 6.4.3.Spacer domain In certain embodiments, the binding domain of the CAR is followed by one or more "spacer domains," which keep the antigen-binding domain away from the effector cell surface and allow for proper cell / cell contact, antigen binding, and activity. Refers to the area that makes it possible to (Patel et al., Gene Therapy, 1999; 6: 412-419). Spacer domains can be derived from either natural, synthetic, semi-synthetic, or recombinant sources. In certain embodiments, the spacer domain is a portion of an immunoglobulin that includes, but is not limited to, one or more heavy chain constant regions, such as CH2 and CH3. The spacer domain can include the amino acid sequence of a naturally occurring or modified immunoglobulin hinge region.

[0312] In one embodiment, the spacer domain comprises the CH2 and CH3 domains of IgG1 or IgG4.

[0313] 6.4.4. Hinge domain The binding domain of the CAR is generally followed by one or more "hinge domains," which connect the antigen-binding domain to the effector cell surface to enable proper cell / cell contact, antigen binding, and activation. It plays a role in positioning it away from. CARs generally contain one or more hinge domains between the binding domain and the transmembrane domain (TM). Hinge domains can be derived from either natural, synthetic, semi-synthetic, or recombinant sources. The hinge domain can include the amino acid sequence of a naturally occurring or modified immunoglobulin hinge region.

[0314] "Altered hinge region" means a naturally occurring (b) at least 10 amino acids (e.g., up to 30% amino acid change (e.g., up to 25%, 20%, 15%, 10%, or 5% amino acid substitution or deletion); (c) a portion of the naturally occurring hinge region that is at least 12, 13, 14 or 15 amino acids long), or (c) a portion of the naturally occurring hinge region that includes the core hinge region (4, 5, 6, 7, 8 , 9, 10, 11, 12, 13, 14, or 15, or at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids in length ). In certain embodiments, one or more cysteine ​​residues in a naturally occurring immunoglobulin hinge region are substituted by one or more other amino acid residues (e.g., one or more serine residues). group). An altered immunoglobulin hinge region may alternatively or additionally have the proline residue of the wild-type immunoglobulin hinge region replaced by another amino acid residue (eg, a serine residue).

[0315] Other exemplary hinge domains suitable for use in the CARs described herein include hinge regions derived from the extracellular regions of type 1 membrane proteins, such as CD8α, CD4, CD28 and CD7, which may be the wild type hinge region from these molecules or may be modified. In another embodiment, the hinge domain comprises the CD8α hinge region.

[0316] 6.4.5. Transmembrane domain The transmembrane (TM) domain is the part of the CAR that fuses the extracellular binding portion and the intracellular signaling domain, anchoring the CAR to the plasma membrane of immune effector cells. TM domains may be derived from either natural, synthetic, semi-synthetic, or recombinant sources. TM domains include T cell receptors, CD3ε, CD3ζ, CD4, CD5, CD8α, CD9, CD16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD134, CD137, CD152, CD154, and It may be derived from the alpha, beta or zeta chain of PD-1 (ie, may include at least the transmembrane region thereof). In certain embodiments, the TM domain is synthetic and contains predominantly hydrophobic residues, such as leucine and valine.

[0317] In one embodiment, a CAR contemplated herein comprises a TM domain derived from CD8α. In another embodiment, the CAR contemplated herein has a TM domain derived from CD8α and preferably 1, 2, 3, 4, 5, Contains short oligo- or polypeptide linkers between 6, 7, 8, 9, or 10 amino acids in length. Glycine-serine based linkers provide particularly suitable linkers.

[0318] 6.4.6. Intracellular signaling domain In certain embodiments, the CARs contemplated herein include an intracellular signaling domain. "Intracellular signal transduction domain" refers to the CAR that is triggered by antigen binding to the extracellular CAR domain by transmitting the message of an effective BCMA CAR that binds to human BCMA polypeptide into the interior of immune effector cells. CARs involved in inducing effector cell functions, such as activation, cytokine production, proliferation and cytotoxic activity, including release of cytotoxic factors or other cellular responses to target cells to which they are bound refers to a part of

[0319] The term "effector function" refers to the specialized functions of immune effector cells. Effector functions of T cells can be, for example, cytolytic or helper activities, including secretion of cytokines. Accordingly, the term "intracellular signaling domain" refers to the portion of a protein that transmits effector function signals and directs the cell to perform specialized functions. Typically, all intracellular signaling domains can be used, but in many cases it is not necessary to use all domains. To the extent that truncated portions of intracellular signaling domains are used, such truncated portions may be used in place of the entire domain so long as it transmits the effector function signal. The term intracellular signaling domain is intended to include any truncated portion of an intracellular signaling domain sufficient to transduce an effector function signal.

[0320] It is known that the signal generated by the TCR alone is insufficient for full activation of T cells and that secondary or costimulatory signals are also required. Therefore, T cell activation consists of two distinct classes of intracellular signaling domains: primary signaling domains that initiate antigen-dependent primary activation by the TCR (e.g., the TCR / CD3 complex) and antigen-independent primary activation domains. It is sometimes said to be mediated by costimulatory signaling domains that act to provide a secondary or costimulatory signal. In certain embodiments, the CARs contemplated herein include an intracellular signaling domain, including one or more "co-stimulatory signaling domains" and "primary signaling domains."

[0321] The primary signaling domain regulates the primary activation of the TCR complex in either a stimulatory or inhibitory manner. A primary signaling domain that acts in a stimulatory manner may contain a signaling motif known as an immunoreceptor tyrosine-based activation motif or ITAM.

[0322] Examples of ITAMs containing primary signaling domains of particular use in the subject matter presented herein are those derived from TCRζ, FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b, and CD66d. Things can be mentioned. In certain embodiments, the CAR comprises a CD3ζ primary signaling domain and one or more costimulatory signaling domains. The intracellular primary signaling and costimulatory signaling domains can be linked to the carboxyl terminus of the transmembrane domain in tandem in any order.

[0323] CARs contemplated herein include one or more costimulatory signaling domains that enhance the efficacy and expansion of T cells expressing the CAR receptor. As used herein, the term "co-stimulatory signaling domain" or "co-stimulatory domain" refers to the intracellular signaling domain of a costimulatory molecule. Co-stimulatory molecules are cell surface molecules other than antigen receptors or Fc receptors that, upon binding to antigen, provide a second signal necessary for efficient activation and function of T lymphocytes. Examples of such costimulatory molecules include CARD11, CD2, CD7, CD27, CD28, CD30, CD40, CD54(ICAM), CD83, CD134(OX40), CD137(4-1BB), CD150(SLAMF1), CD152( CTLA4), CD223 (LAG3), CD270 (HVEM), CD273 (PD-L2), CD274 (PD-L1), CD278 (ICOS), DAP10, LAT, NKD2C SLP76, TRIM, and ZAP70. In one embodiment, the CAR comprises one or more costimulatory signaling domains selected from the group consisting of CD28, CD137, and CD134, and a CD3ζ primary signaling domain.

[0324] In another embodiment, the CAR comprises CD28 and CD137 costimulatory signaling domains and a CD3ζ primary signaling domain.

[0325] In yet another embodiment, the CAR comprises CD28 and CD134 costimulatory signaling domains and a CD3ζ primary signaling domain.

[0326] In one embodiment, the CAR comprises CD137 and CD134 costimulatory signaling domains and a CD3ζ primary signaling domain.

[0327] In certain embodiments, a CAR contemplated herein is a BCMA polypeptide expressed on a B cell, e.g., a human anti-BCMA antibody that specifically binds to human BCMA expressed on a human B cell or Contains antigen-binding fragments thereof.

[0328] In certain embodiments, a CAR contemplated herein is a BCMA polypeptide expressed on a B cell, e.g., a murine anti-BCMA antibody that specifically binds to human BCMA expressed on a human B cell or Contains antigen-binding fragments thereof.

[0329] In one embodiment, the CAR is a murine anti-BCMA scFv that binds to a BCMA polypeptide, e.g., a human BCMA polypeptide; , CD33, CD37, CD45, CD64, CD80, CD86, CD134, CD137, CD152, CD154, and the alpha, beta or zeta chain of PD1; and CARD11, CD2. , CD7, CD27, CD28, CD30, CD40, CD54(ICAM), CD83, CD134(OX40), CD137(4-1BB), CD150(SLAMF1), CD152(CTLA4), CD223(LAG3), CD270(HVEM), one or more intracellular co-stimulatory molecules selected from the group consisting of CD273 (PD-L2), CD274 (PD-L1), CD278 (ICOS), DAP10, LAT, NKD2C SLP76, TRIM, and ZAP70; costimulatory signaling domains; and primary signaling domains from TCRζ, FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b, and CD66d.

[0330] In one embodiment, the CAR is a murine anti-BCMA scFv that binds to a BCMA polypeptide, e.g., a human BCMA polypeptide; , CD33, CD37, CD45, CD64, CD80, CD86, CD134, CD137, CD152, CD154, and the alpha, beta or zeta chain of PD1; and CARD11, CD2. , CD7, CD27, CD28, CD30, CD40, CD54(ICAM), CD83, CD134(OX40), CD137(4-1BB), CD150(SLAMF1), CD152(CTLA4), CD223(LAG3), CD270(HVEM), one or more intracellular co-stimulatory molecules selected from the group consisting of CD273 (PD-L2), CD274 (PD-L1), CD278 (ICOS), DAP10, LAT, NKD2C SLP76, TRIM, and ZAP70; a costimulatory signaling domain; and one or more primary signaling domains from a polypeptide selected from the group consisting of TCRζ, FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b, and CD66d. including.

[0331] In one embodiment, the CAR is selected from the group consisting of a mouse anti-BCMA scFv that binds to a BCMA polypeptide, e.g., a human BCMA polypeptide, IgG1 hinge / CH2 / CH3, IgG4 hinge / CH2 / CH3, and CD8α hinge. Hinge domain; T cell receptor, CD3ε, CD3ζ, CD4, CD5, CD8α, CD9, CD16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD 134, CD137, CD152, CD154, and A transmembrane domain derived from a polypeptide selected from the group consisting of the alpha, beta or zeta chains of PD1; and CARD11, CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD134 (OX40) , CD137(4-1BB), CD150(SLAMF1), CD152(CTLA4), CD223(LAG3), CD270(HVEM), CD273(PD-L2), CD274(PD-L1), CD278(ICOS), DAP10, LAT one or more intracellular costimulatory signaling domains from a costimulatory molecule selected from the group consisting of , NKD2C, SLP76, TRIM, and ZAP70; and TCRζ, FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22 , including the primary signaling domain from CD79a, CD79b, and CD66d.

[0332] In one embodiment, the CAR is selected from the group consisting of a mouse anti-BCMA scFv that binds to a BCMA polypeptide, e.g., a human BCMA polypeptide; IgG1 hinge / CH2 / CH3, IgG4 hinge / CH2 / CH3, and CD8α hinge. Hinge domain; T cell receptor, CD3ε, CD3ζ, CD4, CD5, CD8α, CD9, CD16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD134, CD137, CD152, CD154, and PD1 a transmembrane domain derived from a polypeptide selected from the group consisting of the alpha, beta or zeta chains of CD137(4-1BB), CD150(SLAMF1), CD152(CTLA4), CD223(LAG3), CD270(HVEM), CD273(PD-L2), CD274(PD-L1), CD278(ICOS), DAP10, LAT, one or more intracellular costimulatory signaling domains from a costimulatory molecule selected from the group consisting of NKD2C SLP76, TRIM, and ZAP70; and TCRζ, FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, One or more primary signaling domains from a polypeptide selected from the group consisting of CD79a, CD79b, and CD66d.

[0333] In one embodiment, the CAR is selected from the group consisting of a mouse anti-BCMA scFv that binds to a BCMA polypeptide, e.g., a human BCMA polypeptide; IgG1 hinge / CH2 / CH3, IgG4 hinge / CH2 / CH3, and CD8α hinge. Hinge domain; T cell receptor, CD3ε, CD3ζ, CD4, CD5, CD8α, CD9, CD16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD134, CD137, CD152, CD154, and PD1 a transmembrane domain derived from a polypeptide selected from the group consisting of the alpha, beta or zeta chains of; preferably 1, 2, 3, 4, 5, Short oligo- or polypeptide linkers between 6, 7, 8, 9, or 10 amino acids in length; as well as CARD11, CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD134 (OX40) , CD137(4-1BB), CD150(SLAMF1), CD152(CTLA4), CD223(LAG3), CD270(HVEM), CD273(PD-L2), CD274(PD-L1), CD278(ICOS), DAP10, LAT one or more intracellular costimulatory signaling domains from a costimulatory molecule selected from the group consisting of , NKD2C, SLP76, TRIM, and ZAP70; and TCRζ, FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22 , including the primary signaling domain from CD79a, CD79b, and CD66d.

[0334] In one embodiment, the CAR is selected from the group consisting of a mouse anti-BCMA scFv that binds to a BCMA polypeptide, e.g., a human BCMA polypeptide; IgG1 hinge / CH2 / CH3, IgG4 hinge / CH2 / CH3, and CD8α hinge. Hinge domain; T cell receptor, CD3ε, CD3ζ, CD4, CD5, CD8α, CD9, CD16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD134, CD137, CD152, CD154, and PD1 a transmembrane domain derived from a polypeptide selected from the group consisting of the alpha, beta or zeta chains of; preferably 1, 2, 3, 4, 5, Short oligo- or polypeptide linkers between 6, 7, 8, 9, or 10 amino acids in length; as well as CARD11, CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD134 (OX40) , CD137(4-1BB), CD150(SLAMF1), CD152(CTLA4), CD223(LAG3), CD270(HVEM), CD273(PD-L2), CD274(PD-L1), CD278(ICOS), DAP10, LAT one or more intracellular costimulatory signaling domains from a costimulatory molecule selected from the group consisting of , NKD2C, SLP76, TRIM, and ZAP70; and TCRζ, FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22 , CD79a, CD79b, and CD66d.

[0335] In certain embodiments, the CAR comprises a mouse anti-BCMA scFv that binds to a BCMA polypeptide, e.g., a human BCMA polypeptide; a hinge domain comprising an IgG1 hinge / CH2 / CH3 polypeptide and a CD8α polypeptide; from about 3 to about 10 a CD8α transmembrane domain containing a polypeptide linker of amino acids; a CD137 intracellular costimulatory signaling domain; and a CD3ζ primary signaling domain.

[0336] In certain embodiments, the CAR comprises a mouse anti-BCMA scFv that binds to a BCMA polypeptide, e.g., a human BCMA polypeptide; a hinge domain comprising a CD8α polypeptide; a CD8α membrane comprising a polypeptide linker of about 3 to about 10 amino acids. contains a transmembrane domain; a CD134 intracellular costimulatory signaling domain; and a CD3ζ primary signaling domain.

[0337] In certain embodiments, the CAR comprises a mouse anti-BCMA scFv that binds to a BCMA polypeptide, e.g., a human BCMA polypeptide; a hinge domain comprising a CD8α polypeptide; a CD8α membrane comprising a polypeptide linker of about 3 to about 10 amino acids. It contains a transmembrane domain; a CD28 intracellular costimulatory signaling domain; and a CD3ζ primary signaling domain.

[0338] In certain embodiments, the CAR comprises a mouse anti-BCMA scFv that binds to a BCMA polypeptide, e.g., a human BCMA polypeptide; a hinge domain comprising a CD8α polypeptide; a CD8α transmembrane domain; a CD137(4-1BB) intracellular costimulatory signaling domain; and the CD3ζ primary signaling domain.

[0339] Additionally, the CAR designs contemplated herein result in improved expanded proliferation in T cells expressing the CAR compared to unmodified T cells or T cells modified to express other CARs. Long-term persistence and acceptable cytotoxic properties are possible.

[0340] 6.5. Polypeptide This disclosure contemplates, in part, CAR polypeptides and fragments thereof, cells and compositions containing the same, and vectors expressing the polypeptides. In certain embodiments, polypeptides are provided that include one or more CARs as set forth in SEQ ID NO:9.

[0341] "Polypeptide," "polypeptide fragment," "peptide" and "protein" are used interchangeably according to their conventional meaning, ie, as a sequence of amino acids, unless specified to the contrary. Polypeptides are not limited to a particular length; for example, they may contain full-length protein sequences or fragments of full-length proteins, and may include post-translational modifications of the polypeptide, such as glycosylation, acetylation, phosphorylation, etc. and other modifications known in the art, both naturally occurring and non-naturally occurring. In various embodiments, the CAR polypeptides contemplated herein include a signal (or leader) sequence at the N-terminus of the protein, which co-translationally or post-translationally directs movement of the protein. Examples of suitable signal sequences useful in the CARs disclosed herein include, but are not limited to, the IgG1 heavy chain signal sequence and the CD8α signal sequence. Provided herein are proteins that are mature proteins, ie, they do not contain a signal peptide. For example, the CAR may be a mature CAR. Polypeptides can be prepared using any of a variety of well-known recombinant and / or synthetic techniques. Polypeptides contemplated herein are CARs or sequences of the present disclosure having deletions from, additions to, and / or substitutions of one or more amino acids of the CAR as disclosed herein. specifically includes.

[0342] "Isolated peptide" or "isolated polypeptide," etc., as used herein refers to the in vitro isolation of a peptide or polypeptide molecule from the cellular environment and from the context of other components of the cell. and / or refers to purification, ie, no significant association with the in vivo material. Similarly, an "isolated cell" refers to a cell that is obtained from an in vivo tissue or organ and is substantially free of extracellular matrix.

[0343] Polypeptides include "polypeptide variants." A polypeptide variant may differ from a naturally occurring polypeptide by one or more substitutions, deletions, additions and / or insertions. Such variants may occur naturally or may be produced synthetically, eg, by modifying one or more of the polypeptide sequences described above. For example, in certain embodiments, one or more substitutions, deletions, additions and / or insertions are introduced into the binding domain, hinge, TM domain, costimulatory signaling domain or primary signaling domain of the CAR polypeptide. It may be desirable to improve the binding affinity and / or other biological properties of a CAR thereby. In certain embodiments, such polypeptides have at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% amino acid identity thereto. Contains peptides.

[0344] Polypeptides include "polypeptide fragments." Polypeptide fragments are monomeric or multimeric polypeptides that have amino-terminal deletions, carboxyl-terminal deletions, and / or internal deletions or substitutions of naturally occurring or recombinantly produced polypeptides. Refers to peptides. In certain embodiments, a polypeptide fragment can comprise an amino acid chain from at least 5 to about 500 amino acids in length. In certain embodiments, the fragments are at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 pieces, 19 pieces, 20 pieces, 21 pieces, 22 pieces, 23 pieces, 24 pieces, 25 pieces, 26 pieces, 27 pieces, 28 pieces, 29 pieces, 30 pieces, 31 pieces, 32 pieces, 33 pieces, 34 pieces , 35 pieces, 36 pieces, 37 pieces, 38 pieces, 39 pieces, 40 pieces, 41 pieces, 42 pieces, 43 pieces, 44 pieces, 45 pieces, 46 pieces, 47 pieces, 48 ​​pieces, 49 pieces, 50 pieces, 55 pieces, 60 pieces, 65 pieces, 70 pieces, 75 pieces, 80 pieces, 85 pieces, 90 pieces, 95 pieces, 100 pieces, 110 pieces, 150 pieces, 200 pieces, 250 pieces, 300 pieces, 350 pieces, 400 pieces, or 450 amino acids in length. Particularly useful polypeptide fragments include functional domains that include antigen-binding domains or fragments of antibodies. In the case of mouse anti-BCMA (e.g., human BCMA) antibodies, useful fragments include, but are not limited to, the heavy or light chain CDR region, the CDR3 region; the heavy or light chain variable region; the two CDRs. and a portion of an antibody chain or variable region containing the antibody chain.

[0345] The polypeptide may also be attached to a linker or other sequence (e.g., polyHis) to facilitate synthesis, purification or identification of the polypeptide, or to enhance binding of the polypeptide to a solid support. Can be fused or conjugated in frame.

[0346] As noted above, polypeptides of the present disclosure may be altered in a variety of ways, including amino acid substitutions, deletions, truncations, and insertions. Methods for such manipulation are generally known in the art. For example, amino acid sequence variants of a reference polypeptide can be prepared by mutation in the DNA. Methods of mutagenicity and nucleotide sequence alterations are well known in the art. For example, Kunkel (1985, Proc. Natl. Acad. Sci. USA. 82: 488-492), Kunkel et al., (1987, Methods in Enzymol, 154: 367-382), U.S. Patent No. 4,873,192, Watson, See J. D. et al., (Molecular Biology of the Gene, Fourth Edition, Benjamin / Cummings, Menlo Park, Calif., 1987) and references cited therein. Guidance on appropriate amino acid substitutions that do not affect the biological activity of the protein of interest is provided by the model in Dayhoff et al., (1978) Atlas of Protein Sequence and Structure (Natl. Biomed. Res. Found., Washington, D.C.) can be found in

[0347] In certain embodiments, variants contain conservative substitutions. A "conservative substitution" is one in which an amino acid is replaced with another amino acid having similar properties such that one skilled in the art of peptide chemistry would predict that the secondary structure and hydropathic properties of the polypeptide will not be substantially altered. It is something. Modifications can be made in the structure of the polynucleotides and polypeptides of the present disclosure and still result in functional molecules encoding variant or derivative polypeptides with desirable characteristics. If it is desired to change the amino acid sequence of a polypeptide to create an equivalent or even improved variant polypeptide, one skilled in the art can, for example, modify one of the codons encoding the DNA sequence according to Table 2. One or more can be changed.

[0348] Table 2 - Amino acid codons [Table 2]

[0349] Guidance in determining which amino acid residues can be substituted, inserted, or deleted without loss of biological activity can be obtained using computer programs well known in the art, e.g., DNASTAR™ software. can be found. Preferably, amino acid changes in the protein variants disclosed herein are conservative amino acid changes, ie, substitutions of similarly charged or uncharged amino acids. Conservative amino acid changes involve substitutions of members of a family of amino acids that are related in their side chains. Naturally occurring amino acids are generally divided into four families: acidic (aspartic acid, glutamic acid), basic (lysine, arginine, histidine), and nonpolar (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine). , tryptophan), and uncharged polar (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine) amino acids. Phenylalanine, tryptophan and tyrosine are sometimes classified together as aromatic amino acids. In peptides or proteins, suitable conservative substitutions of amino acids are known to those skilled in the art and can generally be made without altering the biological activity of the resulting molecule. Those skilled in the art will recognize that single amino acid substitutions in non-essential regions of polypeptides generally do not substantially alter biological activity (e.g., Watson et al. the Gene, 4th Edition, 1987, The Benjamin / Cummings Pub. Co., p.224). Exemplary conservative substitutions are described in US Provisional Patent Application No. 61 / 241,647, the disclosure of which is incorporated herein by reference.

[0350] In making such changes, the hydropathic index of amino acids can be considered. The importance of hydropathic amino acid index in conferring interactive biological functions to proteins is generally understood in the art (Kyte and Doolittle, 1982, incorporated herein by reference). Each amino acid is assigned a hydropathic index based on its hydrophobicity and charge characteristics (Kyte and Doolittle, 1982). These values ​​are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine / cysteine ​​(+2.5); methionine (+1.9); alanine (+ 1.8); Glycine (-0.4); Threonine (-0.7); Serine (-0.8); Tryptophan (-0.9); Tyrosine (-1.3); Proline (-1.6); Histidine (-3.2); Glutamic acid (-3.5) ; glutamine (-3.5); aspartic acid (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

[0351] Certain amino acids may be substituted by other amino acids with a similar hydropathic index or score and still result in a protein with similar biological activity, i.e., a biologically functionally equivalent protein. This is known in the art. In making such changes, substitutions of amino acids whose hydropathic indices are within ±2 are preferred, those within ±1 are particularly preferred, and those within ±0.5 are even more particularly preferred. It is also understood in the art that similar amino acid substitutions can be effectively made on the basis of hydrophilicity.

[0352] As detailed in U.S. Patent No. 4,554,101, the following hydrophilicity values ​​have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartic acid (+3.0±1); glutamic acid (+3.0±1); Serine (+0.3); Asparagine (+0.2); Glutamine (+0.2); Glycine (0); Threonine (-0.4); Proline (-0.5±1); Alanine (-0.5); Histidine (-0.5); Cysteine ​​(-1.0); Methionine (-1.3); Valine (-1.5); Leucine (-1.8); Isoleucine (-1.8); Tyrosine (-2.3); Phenylalanine (-2.5); Tryptophan ( -3.4). It is understood that an amino acid may be substituted with another having a similar hydrophilicity value and a biologically equivalent, especially immunologically equivalent, protein will still be obtained. In such changes, substitutions of amino acids whose hydrophilicity values ​​are within ±2 are preferred, those within ±1 are particularly preferred, and those within ±0.5 are even more particularly preferred.

[0353] As outlined above, amino acid substitutions may be based on the relative similarity of amino acid side chain substituents, eg, their hydrophobicity, hydrophilicity, charge, size, etc.

[0354] Polypeptide variants further include glycosylated forms, aggregate conjugates with other molecules, and covalent conjugates with unrelated chemical moieties (eg, pegylated molecules). As is known in the art, covalent variants can be prepared by linking functional groups to groups found in the amino acid chain or at the N- or C-terminal residues. Variants also include allelic variants, species variants and muteins. Terminations or deletions of regions that do not affect the functional activity of the protein are also variants.

[0355] In one embodiment where expression of two or more polypeptides is desired, the polynucleotide sequences encoding them can be separated by an IRES sequence, as discussed elsewhere herein. In another embodiment, two or more polypeptides can be expressed as a fusion protein that includes one or more self-cleavable polypeptide sequences.

[0356] Polypeptides disclosed herein include fusion polypeptides. In certain embodiments, fusion polypeptides and polynucleotides encoding the fusion polypeptides, such as CARs, are provided. Fusion polypeptides and fusion proteins refer to polypeptides having at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more polypeptide segments. Fusion polypeptides are typically linked C-terminus to N-terminus, but may be linked C-terminus to C-terminus, N-terminus to N-terminus, or N-terminus to C-terminus. The polypeptides of the fusion protein can be in any order or in any particular order. Fusion polypeptides or fusion proteins may also include conservatively modified variants, polymorphic variants, alleles, mutants, subsequences, and interspecies homologs, so long as the desired transcriptional activity of the fusion polypeptide is preserved. It can also include the body. Fusion polypeptides may be produced by chemical synthesis methods or by chemical linkage between two moieties, or generally prepared using other standard techniques. As discussed elsewhere herein, the ligated DNA sequence comprising the fusion polypeptide is operably linked to suitable transcriptional or translational control elements.

[0357] In one embodiment, the fusion partner contains sequences (expression enhancers) that aid in the expression of the protein at higher yields than the native recombinant protein. Other fusion partners are selected to increase the solubility of the protein, or to allow the protein to be targeted to the desired intracellular compartment, or to facilitate transport of the fusion protein across the cell membrane. can be done.

[0358] The fusion polypeptide can further include a polypeptide cleavage signal between each of the polypeptide domains described herein. Additionally, polypeptide moieties can be placed in any linker peptide sequence. Exemplary polypeptide cleavage signals include polypeptide cleavage recognition sites, such as protease cleavage sites, nuclease cleavage sites (e.g., rare restriction enzyme recognition sites, self-cleavable ribozyme recognition sites), and self-cleavable viral oligopeptides ( (see deFelipe and Ryan, 2004. Traffic, 5(8); 616-26).

[0359] Suitable protease cleavage sites and self-cleavable peptides are known to those skilled in the art (eg Ryan et al., 1997. J. Gener. Virol. 78, 699-722; Scimczak et al. (2004) Nature Biotech. 5, 589-594). Example protease cleavage sites include, but are not limited to, potyvirus NIa protease (e.g., tobacco etch virus protease), potyvirus HC protease, potyvirus P1 (P35) protease, byovirus NIa protease, biovirus protease encoded by RNA-2, aphthovirus L protease, enterovirus 2A protease, rhinovirus 2A protease, picorna 3C protease, comovirus 24K protease, nepovirus 24K protease, RTSV (rice tungro spherical virus) 3C-like protease , PYVF (parsnip macular virus) 3C-like protease, heparin, thrombin, factor X and enterokinase cleavage sites. The TEV (tobacco etch virus) protease cleavage site is preferred because of its high cleavage stringency. In one embodiment, e.g. EXXYXQ(G / S) (SEQ ID NO: 23), e.g. The cleavage occurs between Q and G or Q and S).

[0360] In certain embodiments, the self-cleaving peptides include polypeptides obtained from potyvirus and cardiovirus 2A peptides, FMDV (foot-and-mouth disease virus), equine rhinitis A virus, Thosea asigna virus, and porcine teschovirus. Contains peptide sequences.

[0361] In certain embodiments, the self-cleavable polypeptide site comprises a 2A or 2A-like site, sequence or domain (Donnelly et al., 2001. J. Gen. Virol. 82:1027-1041).

[0362] Table 3: Exemplary 2A sites include the following sequences: [Table 3]

[0363] In certain embodiments, polypeptides contemplated herein include CAR polypeptides.

[0364] 6.6. Polynucleotide In certain embodiments, polynucleotides encoding one or more CAR polypeptides, eg, SEQ ID NO: 10, are provided. As used herein, the term "polynucleotide" or "nucleic acid" refers to messenger RNA (mRNA), RNA, genomic RNA (gRNA), positive-strand RNA (RNA(+)), negative-strand RNA (RNA (-)), refers to genomic DNA (gDNA), complementary DNA (cDNA) or recombinant DNA. Polynucleotides include single-stranded and double-stranded polynucleotides. Preferably, the polynucleotides disclosed herein are at least about 50%, 55%, 60%, 65% relative to any of the reference sequences described herein (e.g., see the Sequence Listing). , 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity, typically A variant retains at least one biological activity of the reference sequence. In various illustrative embodiments, this disclosure contemplates, in part, polynucleotides, including expression vectors, viral vectors, and transfer plasmids, and compositions and cells containing the same.

[0365] In certain embodiments, at least about 5, 10, 25, 50, 100, 150, 200, 250, 300, 350, 400, 500, 1000, 1250, 1500, 1750, or 2000 or more polypeptides. In addition to contiguous amino acid residues, polynucleotides encoding contiguous amino acid residues of all intermediate lengths are provided by the present disclosure. "Intermediate length" in this context means any length between the stated values, such as 6, 7, 8, 9, etc., 101, 102, 103, etc.; 151, 152, 153, etc.; 201, It is easily understood that it means 202, 203, etc.

[0366] As used herein, terms such as "polynucleotide variant" and "variant" refer to a reference polynucleotide sequence or a polynucleotide that hybridizes to the reference sequence under stringent conditions as defined below. Refers to polynucleotides that exhibit significant sequence identity. These terms include polynucleotides in which one or more nucleotides have been added or deleted, or have been replaced with a different nucleotide, compared to a reference polynucleotide. In this regard, certain changes, including mutations, additions, deletions and substitutions, are made to a reference polynucleotide such that the modified polynucleotide retains the biological function or activity of the reference polynucleotide. It is well understood in the art that this can be done.

[0367] "Sequence identity" or, as used herein, a statement that includes, for example, "a sequence 50% identical to" means that the sequences are compared on a nucleotide-by-nucleotide or amino acid-by-amino acid basis. It refers to the extent to which the window is the same. Therefore, "percentage sequence identity" compares two best-aligned sequences over a window of comparison and determines whether they have identical nucleobases (e.g., A, T, C, G, I) or identical amino acid residues. (e.g. Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys and Met) present in both sequences Determine the number of positions to match to get the number of matched positions, divide the number of matched positions by the total number of positions in the window of comparison (i.e., window size), and multiply the result by 100 to calculate the sequence identity. It may be calculated by obtaining a percentage. at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96% relative to any of the reference sequences described herein; Nucleotides and polypeptides having 97%, 98%, 99% or 100% sequence identity are included, and typically polypeptide variants retain at least one biological activity of the reference polypeptide.

[0368] Terms used to describe the sequence relationship between two or more polynucleotides or polypeptides include "reference sequence," "comparison window," "sequence identity," "percentage sequence identity." ”, and “substantial identity”. A "reference sequence" is a monomeric unit in length, containing at least 12, but frequently 15-18 and often at least 25, nucleotides and amino acid residues. Since two polynucleotides can each contain (1) sequences that are similar between the two polynucleotides (i.e., only portions of the complete polynucleotide sequence), and (2) sequences that are different between the two polynucleotides, , sequence comparisons between two (or more) polynucleotides typically involve comparing the sequences of the two polynucleotides over a "comparison window" to identify and compare local regions of sequence similarity. It is carried out by A "comparison window" is a conceptual segment of at least 6, usually about 50 to about 100, more usually about 100 to about 150 contiguous positions, in which the sequences have the same number of Refers to a reference sequence at consecutive positions and those that are compared after the two sequences have been optimally aligned. The comparison window may include about 20% or less additions or deletions (ie, gaps) compared to the reference sequence (containing no additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning comparison windows is determined by computer implementations of algorithms (GAP, BESTFIT, FASTA, and TFASTA) or by any of a variety of methods examined and selected (i.e., the one that yields the highest percentage of homology over the comparison window). Reference may also be made to the BLAST family of programs as disclosed, for example, by Altschul et al., 1997, Nucl. Acids Res. 25:3389. A detailed discussion of sequence analysis can be found in Unit 19.3 of Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons Inc, 1994-1998, Chapter 15.

[0369] As used herein, an "isolated polynucleotide" refers to a polynucleotide that has been purified from the sequences that flank it in its naturally occurring state, e.g., a DNA fragment that has been removed from the sequences that normally flank it. refers to the fragment. "Isolated polynucleotide" also refers to complementary DNA (cDNA), recombinant DNA, or other polynucleotides that do not occur in nature and are made by human hands.

[0370] Terms describing the orientation of polynucleotides include 5' (usually the end of a polynucleotide with a free phosphate group) and 3' (usually the end of a polynucleotide with a free hydroxyl (OH) group). Polynucleotide sequences can be annotated in a 5' to 3' orientation or a 3' to 5' orientation. For DNA and mRNA, the 5' to 3' strand is referred to as the "sense," "plus," or "coding" strand because its sequence is similar to that of the pre-messenger (premRNA). This is because they are the same [except that uracil (U) is used in RNA instead of thymine (T) in DNA]. For DNA and mRNA, the complementary 3' to 5' strand, which is the strand transcribed by RNA polymerase, is the "template," "antisense," "minus" (negative), or "noncoding" strand. It is called. As used herein, the term "reverse orientation" refers to a 5' to 3' sequence written in a 3' to 5' orientation or a 5' to 3' orientation. Refers to the 3' to 5' sequence written in .

[0371] The terms "complementary" and "complementarity" refer to polynucleotides (ie, sequences of nucleotides) that are related by the base pairing rules. For example, the complementary strand of the DNA sequence 5' A G T C A T G 3' is 3' T C A G T A C 5'. The latter sequence is often written as the reverse complement, 5' C A T G A C T 3', with the 5' end on the left and the 3' end on the right. A sequence that is equivalent to its reverse complement is said to be a palindromic sequence. Complementarity can be "partial," in which only some of the bases of the nucleic acids are matched according to the base pairing rules. Alternatively, there can be "perfect" or "total" complementarity between the nucleic acids.

[0372] Additionally, it will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, there are many nucleotide sequences that encode the polypeptides described herein, or fragments or variants thereof. Some of these polynucleotides have minimal homology to the nucleotide sequence of any native gene. Nevertheless, polynucleotides that vary due to differences in codon usage are specifically contemplated by the present disclosure, such as polynucleotides optimized for human and / or primate codon selection. Additionally, alleles of genes that include the polynucleotide sequences provided herein may also be used. An allele is an endogenous gene that has been altered as a result of one or more mutations, such as nucleotide deletions, additions and / or substitutions.

[0373] The term "nucleic acid cassette" as used herein refers to a genetic sequence within a vector that is capable of expressing RNA and subsequently protein. The nucleic acid cassette contains the gene of interest, eg, a CAR. The nucleic acid cassette is such that the nucleic acid in the cassette is transcribed into RNA and, if necessary, translated into a protein or polypeptide and subjected to appropriate post-translational modifications required for activity in the transformed cell; Positionally and sequence-directed within the vector such that it can be moved to the appropriate compartment for biological activity by targeting to the appropriate intracellular compartment or secretion to the extracellular compartment. Preferably, the cassette has its 3' and 5' ends adapted for ready insertion into a vector, eg, has restriction endonuclease sites at each end. In one embodiment, the nucleic acid cassette contains the sequence of a chimeric antigen receptor used to treat tumors or cancer. In one embodiment, the nucleic acid cassette contains the sequence of a chimeric antigen receptor used to treat B cell malignancies. The cassette can be removed and inserted into a plasmid or viral vector as a single unit.

[0374] In certain embodiments, the polynucleotide comprises at least one polynucleotide of interest. As used herein, the term "polynucleotide of interest" refers to a polynucleotide encoding a polypeptide (ie, a polypeptide of interest) that is inserted into an expression vector for which expression is desired. The vector may contain 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 polynucleotides of interest. In certain embodiments, a polynucleotide of interest encodes a polypeptide that provides therapeutic benefit in the treatment or prevention of a disease or disorder. Polynucleotides of interest, and polypeptides encoded thereby, include both polynucleotides encoding wild-type polypeptides as well as polynucleotides encoding functional variants and fragments thereof. In certain embodiments, a functional variant has at least 80%, at least 90%, at least 95%, or at least 99% identity to a corresponding wild-type reference polynucleotide or polypeptide sequence. In certain embodiments, a functional variant or fragment has at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the biological activity of the corresponding wild-type polypeptide.

[0375] In one embodiment, the polynucleotide of interest does not encode a polypeptide, but serves as a template for transcribing miRNA, siRNA, or shRNA, ribozyme, or other inhibitory RNA. In various other embodiments, the polynucleotides have one or more additional purposes, including, but not limited to, a CAR and inhibitory nucleic acid sequences, including, but not limited to, siRNAs, miRNAs, shRNAs, and ribozymes. a polynucleotide of interest encoding a polynucleotide of interest.

[0376] As used herein, the term "siRNA" or "short interfering RNA" refers to the process of sequence-specific post-transcriptional gene silencing, translation inhibition, transcription inhibition, or epigenetic RNAi in animals. (Zamore et al., 2000, Cell, 101, 25-33; Fire et al., 1998, Nature, 391, 806; Hamilton et al., 1999, Science, 286, 950-951 ;Lin et al., 1999, Nature, 402, 128-129;Sharp, 1999, Genes & Dev., 13, 139-141; and Strauss, 1999, Science, 286, 886). In certain embodiments, the siRNA comprises a first strand and a second strand having the same number of nucleosides; however, the first and second strands have two nucleosides on the first and second strands. The terminal nucleoside is offset from pairing with residues on the complementary strand. In certain cases, the two unpaired nucleosides are thymidine residues. The siRNA should contain sufficient regions of homology to the target gene and should be of sufficient length in terms of nucleotides so that the siRNA, or a fragment thereof, is capable of down-regulating the target gene. can be mediated. As such, siRNA includes a region that is at least partially complementary to the target RNA. Although it is not necessary that there be perfect complementarity between siRNA and target, the correspondence is such that the siRNA, or its cleavage product, directs sequence-specific silencing, e.g., by RNAi cleavage of the target RNA. There must be enough to make it possible. Complementarity, or the degree of homology with the target strand, is most essential in the antisense strand. Although perfect complementarity is often desired, especially in the antisense strand, some embodiments provide one or more, preferably 10, 8, 6, 5, Contains 4, 3, 2, or fewer mismatches. Mismatches are most tolerated in the terminal regions and, if present, are preferably in one or more terminal regions, eg, within 6, 5, 4, or 3 nucleotides of the 5' and / or 3' ends. The sense strand need only be sufficiently complementary to the antisense strand to maintain the overall double-stranded character of the molecule.

[0377] Additionally, siRNAs may be modified or include nucleoside analogs. The single-stranded region of siRNA may be modified or contain nucleoside analogs, e.g., one or more unpaired regions of a hairpin structure, e.g., two complementary The region connecting the regions can have modifications or nucleoside analogs. Modifications are also useful, for example, to stabilize one or more of the 3' or 5' ends of the siRNA against exonucleases, or to facilitate entry of antisense siRNA agents into RISC. Modifications include C3 (or C6, C7, C12) amino linkers, thiol linkers, carboxyl linkers, non-nucleotide spacers (C3, C6, C9, C12, abasic, triethylene glycol, hexaethylene glycol), phosphoramidites, and special biotin or fluorescein reagents with another DMT-protected hydroxyl group to allow multiple couplings during RNA synthesis. Each strand of the siRNA can be equal to or less than 30, 25, 24, 23, 22, 21, or 20 nucleotides in length. The strand is preferably at least 19 nucleotides long. For example, each strand can be 21-25 nucleotides long. Preferred siRNAs have a duplex region of 17, 18, 19, 29, 21, 22, 23, 24, or 25 nucleotide pairs and one or more overhangs of 2-3 nucleotides, preferably 2 with one or two 3' overhangs of ~3 nucleotides.

[0378] As used herein, the term "miRNA" or "microRNA" refers to a 20 to 22 Refers to non-coding RNA with small nucleotides. miRNAs negatively regulate their targets in one of two ways depending on the degree of complementarity between the miRNA and the target. First, miRNAs that bind with perfect or near-perfect complementarity to protein-coding mRNA sequences induce RNA-mediated interference (RNAi) pathways. miRNAs that exert their regulatory effects by binding to imperfectly complementary sites within the 3' untranslated region (UTR) of their mRNA targets are similar to, or in some cases similar to, those used for the RNAi pathway. Through the same RISC complex, it suppresses target gene expression post-transcriptionally, apparently at the level of translation. Consistent with translational control, miRNAs using this mechanism reduce the protein levels of their target genes, whereas the mRNA levels of these genes are only minimally affected. miRNA encompasses both naturally occurring miRNAs as well as artificially designed miRNAs that can specifically target any mRNA sequence. For example, in one embodiment, one of skill in the art can design short hairpin RNA constructs that are expressed as human miRNA (eg, miR-30 or miR-21) primary transcripts. This design adds a Drosha processing site to the hairpin construct and has been shown to greatly increase knockdown efficiency (Pusch et al., 2004). The hairpin stem consists of a 22-nt dsRNA (eg, antisense has perfect complementarity to the desired target) and a 15-19-nt loop from the human miR. Addition of miR loops and miR30 flanking sequences on either or both sides of the hairpin results in greater than 10-fold increase in Drosha and Dicer processing of the expressed hairpin when compared to conventional shRNA designs without microRNAs . Increased Drosha and Dicer processing translates into higher siRNA / miRNA production and higher potency for expressed hairpins.

[0379] As used herein, the term "shRNA" or "short hairpin RNA" refers to a double-stranded structure formed by a single, self-complementary RNA strand. shRNA constructs containing nucleotide sequences identical to portions of the target gene, either coding or non-coding sequences, are preferred for inhibition. RNA sequences with insertions, deletions, and single point mutations relative to the target sequence have also been found to be effective for inhibition. Greater than 90% sequence identity, or even 100% sequence identity between the inhibitory RNA and part of the target gene is preferred. In certain preferred embodiments, the duplex-forming portion of the shRNA is at least 20, 21, or 22 nucleotides in length, e.g., corresponding to the size of the RNA product produced by Dicer-dependent cleavage. do. In certain embodiments, shRNA constructs are at least 25, 50, 100, 200, 300 or 400 bases in length. In certain embodiments, shRNA constructs are 400-800 bases in length. shRNA constructs are highly tolerant of variations in loop sequences and loop sizes.

[0380] As used herein, the term "ribozyme" refers to a catalytically active RNA molecule capable of site-specific cleavage of target mRNA. Several subtypes have been described, including hammerhead and hairpin ribozymes. The catalytic activity and stability of ribozymes can be improved by replacing ribonucleotides at non-catalytic bases with deoxyribonucleotides. Although ribozymes that cleave mRNA at site-specific recognition sequences can be used to destroy specific mRNAs, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNA at positions designated by flanking regions that form complementary base pairs with the target mRNA. The only requirement is that the target mRNA has the following sequence of two bases: 5'-UG-3'. Construction and manufacture of hammerhead ribozymes is well known in the art.

[0381] In certain embodiments, the soluble factor antagonist is an siRNA, miRNA, shRNA, or ribozyme.

[0382] In certain embodiments, methods of delivery of polynucleotides of interest, including siRNAs, miRNAs, shRNAs, or ribozymes, include one or more regulatory sequences, as described elsewhere herein; Examples include strong constitutive pol III promoters, such as the human U6 snRNA promoter, mouse U6 snRNA promoter, human and mouse H1 RNA promoters and human tRNA-val promoter, or strong constitutive pol II promoters.

[0383] The polynucleotides disclosed herein, regardless of the length of the coding sequence itself, may include other DNA sequences, as disclosed elsewhere herein or as known in the art. For example, promoters and / or enhancers, untranslated regions (UTRs), signal sequences, Kozak sequences, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, internal ribosome entry sites (IRES), recombinase recognition sites (e.g., LoxP, FRT, and Att sites), stop codons, transcription termination signals, and self-cleavable polypeptides, as well as polynucleotides encoding epitope tags, so that their overall length may vary considerably. good. Thus, it is contemplated that polynucleotide fragments of nearly any length may be used, with overall length preferably limited by ease of preparation and use in the intended recombinant DNA protocol.

[0384] Polynucleotides may be prepared, manipulated and / or expressed using any of a variety of well-established techniques known and available in the art. In order to express the desired polypeptide, the nucleotide sequence encoding the polypeptide can be inserted into an appropriate vector. Examples of vectors are plasmids, autonomously replicating sequences, and transposable elements. Additional exemplary vectors include, without limitation, plasmids, phagemids, cosmids, artificial chromosomes such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), or P1-derived artificial chromosomes (PACs), bacteriophages such as lambda Includes phage or M13 phage, and animal viruses. Examples of categories of animal viruses useful as vectors include, without limitation, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (e.g., herpes simplex virus), poxviruses, baculoviruses, papillomaviruses. , and papovaviruses (eg, SV40). Examples of expression vectors are the pClneo vector (Promega) for expression in mammalian cells; pLenti4 / V5-DEST™, pLenti6 / V5-DEST(TM) for lentivirus-mediated gene transfer and expression in mammalian cells. Trademark), and pLenti6.2 / V5-GW / lacZ (Invitrogen). In certain embodiments, the coding sequences for chimeric proteins disclosed herein can be ligated into such expression vectors for expression of the chimeric proteins in mammalian cells.

[0385] In one embodiment, a vector encoding a CAR contemplated herein comprises the polynucleotide sequence set forth in SEQ ID NO:36.

[0386] In certain embodiments, the vector is an episomal vector or an extrachromosomally maintained vector. As used herein, the term "episome" refers to a vector capable of replication without integration into the host's chromosomal DNA and without gradual loss from dividing host cells; Also meant to be replicated extrachromosomally or episomally. The vector can be a lymphotropic herpesvirus or gammaherpesvirus, adenovirus, SV40, bovine papillomavirus, or a DNA origin of replication or "ori" from yeast, in particular a lymphotropic herpesvirus or gammacorresponding to the oriP of EBV. Engineered to harbor sequences encoding a herpesvirus origin of replication. In certain embodiments, the lymphotropic herpesvirus may be Epstein-Barr virus (EBV), Kaposi's sarcoma herpesvirus (KSHV), herpesvirus saimiri (HS), or Marek's disease virus (MDV). Epstein-Barr virus (EBV) and Kaposi's sarcoma herpesvirus (KSHV) are also examples of gammaherpesviruses. Typically, the host cell contains a viral replication transactivator protein that activates replication.

[0387] "Control elements" or "regulatory sequences" present in expression vectors are the untranslated regions of the vector (origins of replication, selection cassettes, promoters, enhancers, translation initiation signals ( Shine Dalgarno or Kozak sequences), introns, polyadenylation sequences, 5' and 3' untranslated regions). Such elements can vary in strength and specificity. Any number of suitable transcription and translation elements may be used, including ubiquitous and inducible promoters, depending on the vector system and host utilized.

[0388] In certain embodiments, vectors for use herein include, but are not limited to, expression vectors and viral vectors that contain exogenous, endogenous, or heterologous control sequences, such as promoters and / or enhancers. include. "Endogenous" control sequences are those control sequences that are naturally associated with a given gene in the genome. "Exogenous" control sequences are placed adjacent to a gene by means of genetic engineering (i.e., molecular biology techniques) so that transcription of that gene is directed by the linked enhancer / promoter. This is a control sequence like this. A "heterologous" control sequence is an exogenous sequence from a different species than the cell being genetically engineered.

[0389] The term "promoter" as used herein refers to a recognition site on a polynucleotide (DNA or RNA) to which RNA polymerase binds. RNA polymerase initiates and transcribes a polynucleotide operably linked to a promoter. In certain embodiments, a promoter operable in mammalian cells is found in an AT-rich region located approximately 25-30 bases upstream from the site where transcription is initiated and / or 70-80 bases upstream from the start of transcription. CNCAAT region (where N can be any nucleotide).

[0390] The term "enhancer" refers to a segment of DNA containing sequences that have the ability to provide enhanced transcription, and in some cases function independently of their orientation relative to another control sequence. be able to. Enhancers can function cooperatively or additionally with promoters and / or other enhancer elements. The term "promoter / enhancer" refers to a segment of DNA that contains sequences that have the ability to provide both promoter and enhancer functions.

[0391] The term "operably linked" refers to a juxtaposition in which the described components are in a relationship permitting them to function in their intended manner. In one embodiment, the term refers to a functional linkage between a nucleic acid expression control sequence (e.g., a promoter, and / or an enhancer) and a second polynucleotide sequence, e.g., a polynucleotide of interest, which Refers to a sequence that directs the transcription of a nucleic acid corresponding to a second sequence.

[0392] As used herein, the term "constitutive expression control sequence" refers to a promoter, enhancer, or promoter / enhancer that allows constant or continuous transcription of operably linked sequences. Constitutive expression control sequences can be either "ubiquitous" promoters, enhancers, or promoter / enhancers that allow expression in a variety of cell and tissue types, or "ubiquitous" promoters, enhancers, or promoters / enhancers that allow expression in each of a restricted number of cell and tissue types. It may be a "cell-specific," "cell type-specific," "cell lineage-specific," or "tissue-specific" promoter, enhancer, or promoter / enhancer.

[0393] Illustrative ubiquitous expression control sequences suitable for use in certain embodiments presented herein include the cytomegalovirus (CMV) immediate early promoter, the virus simian virus 40 (SV40) (e.g., early or late), Moloney murine leukemia virus (MoMLV) LTR promoter, Rous sarcoma virus (RSV) LTR, herpes simplex virus (HSV) (thymidine kinase) promoter, H5, P7.5, and P11 promoters from vaccinia virus, extension factor 1-alpha (EF1a) promoter, early growth response 1 (EGR1), ferritin H (FerH), ferritin L (FerL), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), eukaryotic translation initiation factor 4A1 (EIF4A1), heat shock 70kDa protein 5 (HSPA5), heat shock protein 90kDa beta, member 1 (HSP90B1), heat shock protein 70kDa (HSP70), β-kinesin (β-KIN), human ROSA 26 locus (Irions et al., Nature Biotechnology 25, 1477 - 1482 (2007)), ubiquitin C promoter (UBC), phosphoglycerate kinase-1 (PGK) promoter, cytomegalovirus enhancer / chicken β-actin (CAG) promoter, β- The actin promoter and myeloproliferative sarcoma virus enhancer, including a negative regulatory region deletion and the dl587rev primer binding site replacement (MND) promoter (Challita et al., J Virol. 69(2):748-55 (1995)) , but not limited to.

[0394] In one embodiment, vectors of the present disclosure include the MND promoter.

[0395] In one embodiment, a vector of the present disclosure comprises an EF1a promoter that includes the first intron of the human EF1a gene.

[0396] In one embodiment, a vector of the present disclosure comprises an EF1a promoter lacking the first intron of the human EF1a gene.

[0397] In certain embodiments, it may be desirable to express a polynucleotide containing a CAR from a T cell-specific promoter.

[0398] As used herein, "conditional expression" includes inducible expression; suppressive expression; expression in cells or tissues with a particular physiological, biological, or disease state, etc. , can refer to any type of conditional expression, including but not limited to. This definition is not intended to exclude cell type or tissue specific expression. Certain embodiments provide for conditional expression of a polynucleotide of interest, e.g., expression causes the polynucleotide to be expressed or induces expression of a polynucleotide encoded by the polynucleotide of interest. control by subjecting cells, tissues, organisms, etc. to treatments or conditions that cause an increase or decrease in

[0399] Examples of inducible promoters / systems include steroid-inducible promoters, such as promoters for genes encoding glucocorticoids or estrogen receptors (inducible by treatment with the corresponding hormones), metallothionine promoters (inducible by treatment with the corresponding hormones), the MX-1 promoter (inducible by interferon), the “GeneSwitch” mifepristone regulatable system (Sirin et al., 2003, Gene, 323:67), the cumate-inducible gene switch (interferon-inducible 2002 / 088346 pamphlet), tetracycline-dependent regulatory systems, and the like.

[0400] Conditional expression can also be achieved by using site-specific DNA recombinases. According to certain embodiments, the vector contains at least one (typically two) site for recombination mediated by a site-specific recombinase. As used herein, the term "recombinase" or "site-specific recombinase" refers to one or more recombination sites (e.g., 2, 3, 4, 5, 7, 10, 12, 15 , 20, 30, 50, etc.), including excision or integration proteins, enzymes, cofactors, or associated proteins involved in recombination reactions involving wild-type proteins (Landy, Current Opinion in Biotechnology 3:699-707 (1993)), or mutants, derivatives (eg, fusion proteins containing recombinant protein sequences or fragments thereof), fragments, and variants thereof. Examples of recombinases suitable for use herein include Cre, Int, IHF, Xis, Flp, Fis, Hin, Gin, ΦC31, Cin, Tn3 resolvase, TndX, XerC, XerD, TnpX, Hjc, Gin, including, but not limited to, SpCCE1, and ParA.

[0401] The vector may contain one or more recombination sites for any of a variety of site-specific recombinases. It should be understood that target sites for site-specific recombinases are in addition to any sites required for integration of a vector, such as a retroviral or lentiviral vector. As used herein, the term "recombination sequence," "recombination site," or "site-specific recombination site" refers to a specific nucleic acid sequence that a recombinase recognizes and binds to.

[0402] For example, one recombination site for Cre recombinase is loxP, which contains a 34-base pair inverted repeat (which serves as a recombinase binding site) flanking an 8-base pair core sequence. (See FIG. 1 of Sauer, B., Current Opinion in Biotechnology 5:521-527 (1994)). Other exemplary loxP sites are lox511 (Hoess et al., 1996; Bethke and Sauer, 1997), lox5171 (Lee and Saito, 1998), lox2272 (Lee and Saito, 1998), m2 (Langer et al., 2002), lox71 (Albert et al., 1995), and lox66 (Albert et al., 1995).

[0403] Preferred recognition sites for FLP recombinase are FRT (McLeod, et al., 1996), F 1 ,F 2 ,F 3 (Schlake and Bode, 1994), F 4 ,F 5 (Schlake and Bode, 1994), FRT(LE) (Senecoff et al., 1988), FRT(RE) (Senecoff et al., 1988).

[0404] Other examples of recognition sequences are attB, attP, attL, and attR sequences, which are recognized by the recombinase enzyme lambda integrase, such as phi-c31. The φC31 SSR mediates recombination only between the heterotypic sites attB (34 bp long) and attP (39 bp long) (Groth et al., 2000). Both attB and attP, named for the attachment sites for phage integrases on bacterial and phage genomes, respectively, contain incomplete inverted repeats that are likely bound by φC31 homodimers (Groth et al. ., 2000). The production sites, attL and attR, are effectively inert to further φC31-mediated recombination (Belteki et al., 2003), rendering the reaction irreversible. To catalyze insertion, attB-bearing DNA has been found to insert into genomic attP sites more easily than attP sites insert into genomic attB sites (Thyagarajan et al., 2001; Belteki et al. al., 2003). Therefore, a typical strategy is to place an attP-bearing "docking site" by homologous recombination at a defined locus, which site then partners with an incoming attB-bearing sequence for insertion.

[0405] As used herein, an "internal ribosome entry site" or "IRES" facilitates direct internal ribosome entry into the start codon of a cistron (protein coding region), e.g. ATG, thereby capping the gene. Refers to elements that lead to independent translation. See, eg, Jackson et al., 1990. Trends Biochem Sci 15(12):477-83) and Jackson and Kaminski. 1995. RNA 1(10):985-1000. In certain embodiments, vectors contemplated herein include one or more polynucleotides of interest encoding one or more polypeptides. In certain embodiments, the polynucleotide sequences are separated by one or more IRES sequences or polynucleotide sequences encoding self-cleavable polypeptides to achieve efficient translation of each of the plurality of polypeptides. can be done.

[0406] As used herein, the term "Kozak sequence" refers to a short nucleotide sequence that greatly facilitates the initial binding of mRNA to the small subunit of the ribosome, increasing translation. The consensus Kozak sequence is (GCC)RCCATGG, where R is a purine (A or G) (Kozak, 1986. Cell. 44(2):283-92, and Kozak, 1987. Nucleic Acids Res. 15( 20):8125-48). In certain embodiments, vectors contemplated herein include a polynucleotide that has a consensus Kozak sequence and encodes a desired polypeptide, eg, a CAR.

[0407] In some embodiments, the polynucleotide or cell harboring the polynucleotide utilizes a suicide gene, including an inducible suicide gene to reduce the risk of direct toxicity and / or uncontrolled proliferation. In certain embodiments, the suicide gene is not immunogenic to the host harboring the polynucleotide or cell. Certain examples of suicide genes that can be used are caspase-9 or caspase-8 or cytosine deaminase. Caspase-9 can be activated using specific chemical inducers of dimerization (CID).

[0408] In certain embodiments, vectors include gene segments that cause immune effector cells of the disclosure, such as T cells, to become susceptible to negative selection in vivo. By "negative selection" it is meant that the injected cells can be eliminated as a result of changes in the in vivo conditions of the individual. A negatively selectable phenotype may result from the insertion of a gene that confers sensitivity to an administered agent, eg, a compound. Negatively selectable genes are known in the art, in particular: the herpes simplex virus type I thymidine kinase (HSV-I TK) gene, which confers ganciclovir susceptibility (Wigler et al., Cell 11:223, 1977); including the cellular hypoxanthine phosphoribosyltransferase (HPRT) gene, the cellular adenine phosphoribosyltransferase (APRT) gene, and the bacterial cytosine deaminase (Mullen et al., Proc. Natl. Acad. Sci. USA. 89:33 (1992)). .

[0409] In some embodiments, the genetically modified immune effector cell, such as a T cell, comprises a polynucleotide that further comprises a positive marker that allows selection of cells of a negatively selectable phenotype in vitro. A positive selectable marker may be a gene that, when introduced into a host cell, expresses a dominant phenotype, allowing positive selection of cells carrying that gene. Genes of this type are known in the art, in particular the hygromycin-B phosphotransferase gene (hph), which confers resistance to hygromycin B, the aminoglycoside phosphotransferase gene from Tn5, which encodes resistance to the antibiotic G418 ( neo or aph), dihydrofolate reductase (DHFR) gene, adenosine deaminase gene (ADA), and multidrug resistance (MDR) gene.

[0410] Preferably, the positive selectable marker and the negative selectable element are linked such that loss of the negative selectable element entails also loss of the positive selectable marker. Even more preferably, the positive and negative selectable markers are fused such that loss of one obligatorily leads to loss of the other. An example of a fused polynucleotide that provides as an expression product a polypeptide that confers both the desired positive and negative selection characteristics described above is the hygromycin phosphotransferase thymidine kinase fusion gene (HyTK). Expression of this gene results in a polypeptide that confers hygromycin B resistance for positive selection in vitro and ganciclovir sensitivity for negative selection in vivo. See Lupton S. D., et al, Mol. and Cell. Biology 1 1:3374- 3378, 1991. Additionally, in certain embodiments, the polynucleotide encoding the chimeric receptor comprises a fused gene, particularly hygromycin B resistance for positive selection in vitro, and for negative selection in vivo. Retroviral vectors containing fused genes conferring ganciclovir sensitivity, such as in the HyTK retroviral vectors described in Lupton, S. D. et al. (1991), supra. Publication of PCT US91 / 08442 and PCT / US94 / 05601 by S.D. Lupton describing the use of bifunctional selectable fusion genes derived from fusing a dominant positive selectable marker with a negative selectable marker See also Bulletin.

[0411] Positive selectable markers can be derived from, for example, genes selected from the group consisting of hph, nco, and gpt, and negative selectable markers can be derived from, for example, cytosine deaminase, HSV-I TK, VZV TK. , HPRT, APRT and gpt. In certain embodiments, the marker is a bifunctional selectable fusion gene, where the positive selectable marker is derived from hph or neo and the negative selectable marker is derived from the cytosine deaminase or TK gene or selectable It is derived from a marker.

[0412] virus vector In certain embodiments, cells (eg, immune effector cells) are transduced with a retroviral vector, eg, a lentiviral vector, encoding a CAR. For example, the immune effector cell may contain a murine anti-BCMA antibody or its A vector encoding the CAR containing the antigen-binding fragment is transduced. Alternatively, the immune effector cell may contain an extracellular antigen, such as an antibody that binds to a tumor antigen, or its antigen-binding properties, along with an intracellular signaling domain of CD3ζ, CD28, 4-1BB, Ox40, or any combination thereof. A vector encoding the CAR containing the fragment is transduced. These transduced cells are therefore capable of eliciting CAR-mediated cytotoxic responses.

[0413] Retroviruses are common tools for gene delivery (Miller, 2000, Nature. 357: 455-460). In certain embodiments, retroviruses are used to deliver polynucleotides encoding chimeric antigen receptors (CARs) to cells. As used herein, the term "retrovirus" refers to an RNA virus that reverse transcribes its genomic RNA into linear double-stranded DNA copies and subsequently covalently integrates its genomic DNA into the host genome. Point. Once a virus integrates into the host genome, it is referred to as a "provirus." The provirus serves as a template for RNA polymerase II, directing the expression of RNA molecules encoding the structural proteins and enzymes needed to manufacture new virus particles.

[0414] Illustrative retroviruses suitable for use in certain embodiments include Moloney Murine Leukemia Virus (MMuLV), Moloney Murine Sarcoma Virus (MoMSV), Harvey Murine Sarcoma Virus (HaMuSV), Murine Mammary Tumor Virus (MuMTV), Including, but not limited to, gibbon leukemia virus (GaLV), feline leukemia virus (FLV), Spuma virus, Friend murine leukemia virus, murine stem cell virus (MSCV) and Rous sarcoma virus (RSV) and lentiviruses.

[0415] As used herein, the term "lentivirus" refers to a group (or genus) of complex retroviruses. Illustrative lentiviruses include HIV (human immunodeficiency virus; including HIV type 1, and HIV type 2); Visna-Maedi virus (VMV) virus; Caprine arthritis-encephalitis virus (CAEV); Equine infectious anemia virus (EIAV); feline immunodeficiency virus (FIV); bovine immunodeficiency virus (BIV); and simian immunodeficiency virus (SIV). In one embodiment, an HIV-based vector backbone (ie, HIV cis-acting sequence elements) is utilized. In certain embodiments, lentiviruses are used to deliver polynucleotides containing CARs to cells.

[0416] Retroviral vectors, and more particularly lentiviral vectors, may be used in the practice of certain embodiments disclosed herein. Thus, the terms "retrovirus" or "retroviral vector" as used herein are meant to include "lentivirus" and "lentiviral vector," respectively.

[0417] The term "vector" is used herein to refer to a nucleic acid molecule that has the ability to import or transport another nucleic acid molecule. The transferred nucleic acid is generally linked to, eg, inserted into, a vector nucleic acid molecule. The vector may contain sequences that direct autonomous replication in the cell or may contain sufficient sequences to allow integration into the host cell DNA. Useful vectors include, for example, plasmids (eg, DNA or RNA plasmids), transposons, cosmids, bacterial artificial chromosomes, and viral vectors. Useful viral vectors include, for example, replication-defective retroviruses and lentiviruses.

[0418] As will be appreciated by those skilled in the art, the term "viral vector" typically refers to a nucleic acid molecule (e.g., a transfer plasmid) or nucleic acid molecule containing a virus-derived nucleic acid element that facilitates the transfer or integration of the nucleic acid molecule into the genome of a cell. widely used to refer to any viral particle that mediates Viral particles typically include host cell components in addition to various viral components and optionally nucleic acids.

[0419] The term viral vector can refer to either a virus or a viral particle that has the ability to transfer a nucleic acid into a cell or the transferred nucleic acid itself. Viral vectors and transfer plasmids contain structural and / or functional genetic elements that are primarily derived from viruses. The term "retroviral vector" refers to a viral vector or plasmid containing structural and functional genetic elements, or portions thereof, derived primarily from retroviruses. The term "lentiviral vector" refers to a viral vector or plasmid containing structural and functional genetic elements, or portions thereof, including LTRs primarily derived from lentiviruses. The term "hybrid vector" refers to a vector, LTR, or other nucleic acid that contains both retroviral, eg, lentiviral, and non-lentiviral viral sequences. In one embodiment, a hybrid vector refers to a vector or transfer plasmid containing retroviral, eg, lentiviral, sequences for reverse transcription, replication, integration and / or packaging.

[0420] In certain embodiments, the terms "lentiviral vector" and "lentiviral expression vector" may be used to refer to lentiviral transfer plasmids and / or infectious lentiviral particles. When references are made herein to elements, such as cloning sites, promoters, regulatory elements, heterologous nucleic acids, etc., the sequences of these elements are present in RNA form in the lentiviral particles of the present disclosure and are present in the lentiviral particles of the present disclosure. It should be understood that DNA is present in DNA form in plasmids.

[0421] At each end of the provirus there is a structure called a "long terminal repeat" or "LTR." The term "long terminal repeat (LTR)" refers to the base pairs located at the ends of retroviral DNA that, in the context of their natural sequence, are direct repeats and contain the U3, R and U5 regions. Refers to the domain. LTRs generally provide functions fundamental to retroviral gene expression (eg, promotion, initiation, and polyadenylation of gene transcripts) and viral replication. The LTR contains numerous regulatory signals, including transcriptional control elements, polyadenylation signals, and sequences required for viral genome replication and integration. The viral LTR is divided into three regions called U3, R and U5. The U3 region contains enhancer and promoter elements. The U5 region is a sequence between the primer binding site and the R region and contains a polyadenylation sequence. The R (repeat) region is adjacent to the U3 and U5 regions. The LTR is composed of the U3, R and U5 regions and is present at both the 5' and 3' ends of the viral genome. Adjacent to the 5' LTR are sequences necessary for reverse transcription of the genome (tRNA primer binding site) and for efficient packaging of viral RNA into particles (psi site). .

[0422] As used herein, the term "packaging signal" or "packaging sequence" refers to a sequence located within the retroviral genome that is required for insertion of viral RNA into a viral capsid or particle. . See, eg, Clever et al., 1995. J. of Virology, Vol. 69, No. 4; pp. 2101-2109. Some retroviral vectors use a minimal packaging signal (also referred to as the psi [Ψ] sequence) required for encapsidation of the viral genome. Therefore, as used herein, the terms "packaging sequence," "packaging signal," "psi" and the symbol "Ψ" refer to the capsid encapsulation of retroviral RNA strands during virion formation. used in references to non-coding sequences required for

[0423] In various embodiments, the vector includes a modified 5' LTR and / or 3' LTR. Either or both of the LTRs may contain one or more modifications, including, but not limited to, one or more deletions, insertions, or substitutions. Modifications to the 3' LTR are often made to improve the safety of lentiviral or retroviral systems by rendering the virus replication-defective. As used herein, the term "replication-defective" refers to a virus that does not have the capacity for complete, efficient replication and, as a result, no infectious virions are produced (e.g., replication-defective (progeny of lentivirus). The term "replication-competent" refers to wild-type or mutant viruses (e.g., replication-competent (progeny of lentivirus).

[0424] A "self-inactivating" (SIN) vector is one in which the right (3') LTR enhancer-promoter region, known as the U3 region, prevents viral transcription beyond the first round of viral replication. refers to a replication-defective vector, such as a retroviral or lentiviral vector, that has been modified (eg, by deletion or substitution) to This is because the right (3') LTR U3 region is used as a template for the left (5') LTR U3 region during viral replication, and therefore no viral transcripts can be made without the U3 enhancer-promoter. It is. In a further embodiment, the 3' LTR is modified such that the U5 region is replaced with, for example, an ideal poly(A) sequence. It should be noted that modifications to the LTR, such as modifications to the 3' LTR, 5' LTR, or both 3' LTR and 5' LTR, are also included herein.

[0425] An additional safety enhancement is provided by replacing the U3 region of the 5' LTR with a heterologous promoter to drive transcription of the viral genome during production of viral particles. Examples of heterologous promoters that may be used include, for example, viruses simian virus 40 (SV40) (e.g., early or late), cytomegalovirus (CMV) (e.g., immediate early), Moloney murine leukemia virus (MoMLV), Rous sarcoma virus. (RSV), and herpes simplex virus (HSV) (thymidine kinase) promoter. Typical promoters are capable of driving high levels of transcription in a Tat-independent manner. This substitution reduces the likelihood that recombination will generate replication-competent virus, since there is no complete U3 sequence in the virus production system. In certain embodiments, a heterologous promoter has the added advantage of controlling how the viral genome is transcribed. For example, a heterologous promoter can be inducible so that transcription of all or part of the viral genome occurs only in the presence of the inducing factor. Inducers include, but are not limited to, one or more chemical compounds or physiological conditions, such as the temperature or pH at which the host cells are cultured.

[0426] In some embodiments, the viral vector includes a TAR element. The term "TAR" refers to the "transactivation response" genetic element located in the R region of the lentiviral (eg, HIV) LTR. This element interacts with the lentiviral transactivator (tat) genetic element to enhance viral replication. However, this element is not required in embodiments where the U3 region of the 5' LTR is replaced by a heterologous promoter.

[0427] "R region" refers to the region within the retroviral LTR that begins at the start of the capping group (ie, start of transcription) and ends just before the start of the polyA tract. The R region is also defined as being adjacent to the U3 and U5 regions. The R region plays a role in allowing movement of nascent DNA from one end of the genome to the other during reverse transcription.

[0428] As used herein, the term "FLAP element" refers to a nucleic acid whose sequence comprises the central polypurine tract and central termination sequences (cPPT and CTS) of a retrovirus, e.g., HIV-1 or HIV-2. Point. Suitable FLAP elements are described in US Pat. No. 6,682,907 and Zennou, et al., 2000, Cell, 101:173. During HIV-1 reverse transcription, central initiation of positive-strand DNA at the central polypurine tract (cPPT) and central termination at the central termination sequence (CTS) lead to the formation of a three-stranded DNA structure: the HIV-1 central DNA flap. . Without wishing to be bound by any theory, the DNA flap may act as a cis-active determinant of lentiviral genome nuclear export and / or increase viral titer. In certain embodiments, the retroviral or lentiviral vector backbone includes one or more FLAP elements upstream or downstream of the heterologous gene of interest in the vector. For example, in certain embodiments, the transfer plasmid includes a FLAP element. In one embodiment, the vector comprises a FLAP element isolated from HIV-1.

[0429] In one embodiment, the retroviral or lentiviral transfer vector contains one or more export elements. The term "export element" refers to a cis-acting post-transcriptional regulatory element that regulates the transport of RNA transcripts from the nucleus to the cytoplasm of a cell. An example of an RNA export element is the human immunodeficiency virus (HIV) rev response element (RRE) (e.g., Cullen et al., 1991. J. Virol. 65: 1053; and Cullen et al., 1991. Cell 58: 423 ), and the hepatitis B virus post-transcriptional regulatory element (HPRE). Generally, RNA export elements are placed within the 3'UTR of a gene and can be inserted in one or more copies.

[0430] In certain embodiments, expression of heterologous sequences in viral vectors is increased by incorporating into the vector post-transcriptional regulatory elements, efficient polyadenylation sites, and, optionally, transcription termination signals. Various post-transcriptional regulatory elements can increase the expression of heterologous nucleic acids in proteins, for example, woodchuck hepatitis virus post-transcriptional regulatory element (WPRE; Zufferey et al., 1999, J. Virol., 73:2886). ; post-transcriptional regulatory element (HPRE) present in hepatitis B virus (Huang et al., Mol. Cell. Biol., 5:3864); etc. (Liu et al., 1995, Genes Dev., 9:1766 ). In certain embodiments, the vector can include post-transcriptional regulatory elements, such as WPRE or HPRE.

[0431] In certain embodiments, the vector lacks or does not contain post-transcriptional regulatory elements (PTEs), such as WPREs or HPREs, because in some cases these elements pose a risk of cell transformation. and / or substantially or significantly increase the amount of mRNA transcripts, nor do they increase mRNA stability. Thus, in some embodiments, the vector lacks or does not contain a PTE. In other embodiments, the vector lacks or does not include WPRE or HPRE as an additional safety measure.

[0432] Elements that direct efficient termination and polyadenylation of heterologous nucleic acid transcripts increase heterologous gene expression. Transcription termination signals are commonly found downstream of polyadenylation signals. In certain embodiments, the vector includes a polyadenylation sequence 3' to the polynucleotide encoding the polypeptide to be expressed. The term "poly A site" or "poly A sequence" as used herein refers to a DNA sequence that directs both termination and polyadenylation of a nascent RNA transcript by RNA polymerase II. Polyadenylation sequences can promote mRNA stability by adding a polyA tail to the 3' end of the coding sequence, and therefore can contribute to increased translation efficiency. Efficient polyadenylation of recombinant transcripts is desirable because transcripts lacking polyA tails are unstable and rapidly degraded. Examples of polyA signals that can be used in vectors herein include ideal polyA sequences (e.g., AATAAA, ATTAAA, AGTAAA), bovine growth hormone polyA sequence (BGHpA), rabbit β-globin polyA sequence (rβgpA ), or another suitable heterologous or endogenous polyA sequence known in the art.

[0433] In certain embodiments, the retroviral or lentiviral vector further comprises one or more insulator elements. Insulator elements are mediated by cis-acting elements present in the genomic DNA, which can lead to unregulated expression of the imported sequence. Proc. Natl. Acad. Sci., USA, 99:16433; and Zhan et al., 2001, Hum. Genet., 109:471). can contribute to In some embodiments, the transfer vector includes one or more insulator elements in the 3' LTR, and upon integration of the provirus into the host genome, the provirus has 5 Contains one or more insulators in both the ' LTR or the 3' LTR. Suitable insulators for use herein include, but are not limited to, chicken β-globin insulators (Chung et al., 1993. Cell 74:505; Chung et al., 1997. PNAS 94:575 ; and Bell et al., 1999. Cell 98:387; incorporated herein by reference). Examples of insulator elements include, but are not limited to, insulators from the β-globin locus, such as chicken HS4.

[0434] According to certain embodiments, most or all of the viral vector backbone sequences are derived from a lentivirus, eg, HIV-1. However, many different sources of retroviral and / or lentiviral sequences can be used or combined, and numerous substitutions and changes in a given lentiviral sequence will perform the functions described herein. It should be understood that adaptations may be made without compromising the capabilities of the transfer vector. Additionally, a variety of lentiviral vectors are known in the art. See Naldini et al., (1996a, 1996b, and 1998); Zufferey et al., (1997); Dull et al., 1998, US Pat. No. 6,013,516; and US Pat. No. 5,994,136. Many of these may be adapted to produce the viral vectors or transfer plasmids of this disclosure.

[0435] In various embodiments, the vectors described herein can include a promoter operably linked to a polynucleotide encoding a CAR polypeptide. A vector may have one or more LTRs, and any LTR may include one or more modifications, such as one or more nucleotide substitutions, additions, or deletions. good. The vector may contain one or more accessory elements to increase transduction efficiency (e.g., cPPT / FLAP), viral packaging (e.g., psi (Ψ) packaging signal, RRE), and / or a therapeutic gene. It may further contain other elements that increase expression (eg, poly(A) sequences), and may optionally contain WPRE or HPRE.

[0436] In certain embodiments, the transfer vector encodes a left (5') retroviral LTR; a central polypurine tract / DNA flap (cPPT / FLAP); a retroviral export element; a CAR polypeptide as contemplated herein. a promoter active in T cells; and a right (3') retroviral LTR; and, optionally, a WPRE or HPRE, operably linked to the polynucleotide.

[0437] In certain embodiments, the transfer vector is operably linked to a left (5') retroviral LTR; a retroviral export element; a polynucleotide encoding a CAR polypeptide contemplated herein; the right (3') retroviral LTR; and poly(A) sequences; and WPRE or HPRE as appropriate. In another specific embodiment, provided herein is a left (5') LTR; cPPT / FLAP; RRE; A lentiviral vector containing a promoter active in T cells; a right (3') LTR; and a polyadenylation sequence; and WPRE or HPRE, as appropriate.

[0438] In certain embodiments, provided herein are: left (5') HIV-1 LTR; psi (Ψ) packaging signal; cPPT / FLAP; RRE; CAR polypeptides contemplated herein. a promoter active in T cells operably linked to a polynucleotide encoding the peptide; a right (3') self-inactivating (SIN) HIV-1 LTR; and a rabbit β-globin polyadenylation sequence; and optionally WPRE or A lentiviral vector containing HPRE.

[0439] In another embodiment, provided herein are at least one LTR; a central polypurine tract / DNA flap (cPPT / FLAP); a retroviral export element; and a CAR polypeptide contemplated herein. a promoter active in T cells, operably linked to a polynucleotide encoding the vector; and a WPRE or HPRE, as appropriate.

[0440] In certain embodiments, provided herein are at least one LTR; cPPT / FLAP; RRE; T operably linked to a polynucleotide encoding a CAR polypeptide contemplated herein; A vector containing a promoter active in the cell; and a polyadenylation sequence; and, as appropriate, WPRE or HPRE.

[0441] In certain embodiments, provided herein is at least one SIN HIV-1 LTR; psi (Ψ) packaging signal; cPPT / FLAP; RRE; CAR polypeptides contemplated herein. and a rabbit β-globin polyadenylation sequence; and, as appropriate, a WPRE or HPRE.

[0442] In various embodiments, the vector is an integrated viral vector.

[0443] In various other embodiments, the vector is an episomal or non-integrating viral vector.

[0444] In various embodiments, vectors contemplated herein include non-integrating or integrating defective retroviruses. In one embodiment, an "integration-defective" retrovirus or lentivirus refers to a retrovirus or lentivirus that has an integrase that lacks the ability to integrate the viral genome into the host cell's genome. In various embodiments, an integrase protein is mutated to specifically decrease its integrase activity. Integrating incompetent lentiviral vectors are obtained by modifying the pol gene encoding an integrase protein to obtain a mutant pol gene encoding an integrating defective integrase. Such integrated incompetent viral vectors are described in patent application WO 2006 / 010834, which is incorporated herein by reference in its entirety.

[0445] Illustrative mutations in the HIV-1 pol gene suitable for reducing integrase activity are H12N, H12C, H16C, H16V, S81R, D41A, K42A, H51A, Q53C, D55V, D64E, D64V, E69A, K71A , E85A, E87A, D116N, D1161, D116A, N120G, N1201, N120E, E152G, E152A, D35E, K156E, K156A, E157A, K159E, K159A, K160A, R166A, D167A, E170A, H171A , K173A, K186Q, K186T, K188T , including but not limited to: .

[0446] Illustrative mutations in the HIV-1 pol gene suitable for reducing integrase activity are D64E, D64V, E92K, D116N, D1161, D116A, N120G, N1201, N120E, E152G, E152A, D35E, K156E, K156A , E157A, K159E, K159A, W235F, and W235E.

[0447] In certain embodiments, the integrase comprises a mutation at one or more of amino acids D64, D116 or E152. In one embodiment, the integrase contains mutations at amino acids D64, D116 and E152. In certain embodiments, the defective HIV-1 integrase comprises the D64V mutation.

[0448] A "host cell" includes a cell that has been electroporated, transfected, infected, or transduced in vivo, ex vivo, or in vitro with a recombinant vector or polynucleotide disclosed herein. Host cells may include packaging cells, producer cells, and cells infected with viral vectors. In certain embodiments, host cells infected with viral vectors disclosed herein are administered to a subject in need of treatment. In certain embodiments, the term "target cell" is used interchangeably with host cell and refers to a cell that has been transfected, infected, or transduced with the desired cell type. In certain embodiments, the target cell is a T cell.

[0449] Large scale virus particle production is often necessary to achieve reasonable virus titers. Viral particles are transferred into packaging cell lines containing viral structural and / or accessory genes, such as gag, pol, env, tat, rev, vif, vpr, vpu, vpx, or nef genes or other retroviral genes. produced by transfecting.

[0450] As used herein, the term "packaging vector" refers to a vector that lacks packaging signals and that encodes one, two, three, four or more viral structures and / or accessory genes. Refers to expression vectors or viral vectors containing nucleotides. Typically, the packaging vector is contained within a packaging cell and introduced into the cell via transfection, transduction or infection. Methods of transfection, transduction or infection are well known to those skilled in the art. The retroviral / lentiviral transfer vectors disclosed herein can be introduced into packaging cell lines via transfection, transduction or infection to generate producer cells or cell lines. The packaging vectors disclosed herein can be introduced into human cells or cell lines by standard methods, including, for example, calcium phosphate transfection, lipofection or electroporation. In some embodiments, the packaging vector is introduced into the cell with a dominant selectable marker, such as neomycin, hygromycin, puromycin, blasticidin, zeocin, thymidine kinase, DHFR, Gln synthetase or ADA, followed by Selection and isolation of clones in the presence of appropriate drugs is performed. A selectable marker gene can be physically linked to the gene encoded by the packaging vector, for example, by an IRES or a self-cleaving viral peptide.

[0451] The viral envelope protein (env) determines the range of host cells that can ultimately be infected and transformed by a recombinant retrovirus produced from a cell line. For lentiviruses such as HIV-1, HIV-2, SIV, FIV and EIV, env proteins include gp41 and gp120. Preferably, the viral env protein expressed by the packaging cells disclosed herein is encoded on a separate vector from the viral gag and pol genes, as previously described.

[0452] Examples of retrovirus-derived env genes that may be used herein include MLV envelope, 10A1 envelope, BAEV, FeLV-B, RD114, SSAV, Ebola, Sendai, FPV (fowl plague virus), and influenza virus envelope. , but not limited to. Similarly, RNA viruses (e.g., Picornaviridae, Caliciviridae, Astroviridae, Togaviridae, Flaviviridae, Coronaviridae, Paramyxoviridae, Rhabdoviridae, Filoviridae, Orthomyxoviridae) , Bunyaviridae, Arenaviridae, Reoviridae, Birnaviridae, and Retroviridae RNA virus families), as well as DNA viruses (Hepadnaviridae, Circoviridae, Parvoviridae, Papovaviridae, and Adenoviruses). Envelope-encoding genes from the families Herpesviridae, Poxviridae, and Iridoviridae) may be utilized. Typical examples are FeLV, VEE, HFVW, WDSV, SFV, Rabies, ALV, BIV, BLV, EBV, CAEV, SNV, ChTLV, STLV, MPMV, SMRV, RAV, FuSV, MH2, AEV, AMV, CT10, and EIAV.

[0453] In other embodiments, envelope proteins for pseudotyping viruses in connection with the present disclosure include the following viruses: influenza A, e.g. H1N1, H1N2, H3N2 and H5N1 (avian influenza), influenza B, influenza C viruses. , hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, rotavirus, any virus of the Norwalk virus group, enteric adenovirus, parvovirus, dengue virus, sarpox, Mononegavirales, Lyssaviruses such as rabies virus, Lagos bat virus, Mokola virus, Duvenhage virus, European bat virus 1 & 2 and Australian bat virus, ephemerovirus, vesiculovirus, vesicular stomatitis virus (VSV), herpes virus , such as herpes simplex virus types 1 and 2, varicella zoster, cytomegalovirus, Epstein-Barr virus (EBV), human herpesvirus (HHV), human herpesvirus types 6 and 8, human immunodeficiency virus (HIV), papilloma Viruses, murine gammaherpesvirus, arenaviruses such as Argentine hemorrhagic fever virus, Bolivian hemorrhagic fever virus, Sabia-associated hemorrhagic fever virus, Venezuelan hemorrhagic fever virus, Lassa fever virus, Machupo virus, lymphocytic choriomeningitis virus (LCMV) ), Bunyaviridae, including Crimean-Congo hemorrhagic fever virus, hantavirus, viruses causing hemorrhagic fever with renal syndrome, Rift Valley fever virus, Ebola hemorrhagic fever and Marburg hemorrhagic fever, Filoviridae (Filovirus), Kyasanul Forest Flaviviridae, including disease viruses, Omsk hemorrhagic fever virus, tick-borne encephalitis-causing viruses, and Paramyxoviridae, such as Hendra virus and Nipah virus, variola major and variola minor (smallpox), alphaviruses, such as Venezuelan equine encephalitis virus. , Eastern Equine Encephalitis Virus, Western Equine Encephalitis Virus, SARS-related Coronavirus (SARS-CoV), West Nile Virus, and any of the encephalitis-causing viruses.

[0454] In one embodiment, provided herein is a packaging cell that produces a recombinant retrovirus, such as a lentivirus, pseudotyped with a VSV-G glycoprotein.

[0455] The term "pseudotype" or "pseudotype" as used herein refers to a virus whose viral envelope protein has been replaced with the viral envelope protein of another virus that has favorable characteristics. For example, HIV can be pseudotyped with the vesicular stomatitis virus G-protein (VSV-G) envelope protein, which allows HIV to infect a wider range of cells and why This is because the HIV envelope protein (encoded by the env gene) normally targets the virus to CD4+ presenting cells. In one embodiment, the lentiviral envelope protein is pseudotyped with VSV-G. In one embodiment, provided herein is a packaging cell that produces a recombinant retrovirus, such as a lentivirus, pseudotyped with a VSV-G envelope glycoprotein.

[0456] As used herein, the term "packaging cell line" refers to viral structural proteins and replication enzymes (e.g., gag, used in connection with cell lines that stably or transiently express pol and env). Any suitable cell line may be used to prepare packaging cells in connection with this disclosure. Generally, the cell is a mammalian cell. In certain embodiments, the cells used to produce the packaging cell line are human cells. Suitable cell lines that can be used are, for example, CHO cells, BHK cells, MDCK cells, C3H 10T1 / 2 cells, FLY cells, Psi-2 cells, BOSC 23 cells, PA317 cells, WEHI cells, COS cells, BSC 1 cells. , BSC 40 cells, BMT 10 cells, VERO cells, W138 cells, MRC5 cells, A549 cells, HT1080 cells, 293 cells, 293T cells, B-50 cells, 3T3 cells, NIH3T3 cells, HepG2 cells, Saos-2 cells, Huh7 cells, including HeLa cells, W163 cells, 211 cells, and 211A cells. In certain embodiments, the packaging cells are 293 cells, 293T cells, or A549 cells. In another specific embodiment, the cells are A549 cells.

[0457] As used herein, the term "producer cell line" refers to a cell line that has the ability to produce recombinant retroviral particles, including a packaging cell line and a transfer vector construct that includes a packaging signal. Production of infectious virus particles and virus stock solutions may be performed using conventional techniques. Methods for preparing virus stock solutions are known in the art, eg, Soneoka et al. (1995) Nucl. Acids Res. 23:628-633, and N. R. Landau et al. (1992) J. Virol. 66. :5110-5113. Infectious virus particles may be collected from packaging cells using conventional techniques. For example, infectious particles can be collected by cell lysis or collection of cell culture supernatants, as known in the art. Optionally, the collected virus particles may be purified if desired. Suitable purification techniques are well known to those skilled in the art.

[0458] The delivery of genes or other polynucleotide sequences using retroviral or lentiviral vectors by means of viral infection rather than transfection is referred to as "transduction." In one embodiment, retroviral vectors are transduced into cells through infection and proviral integration. In certain embodiments, a target cell, e.g., a T cell, is "transduced" if it contains a gene or other polynucleotide sequence that is delivered to the cell by infection using a viral or retroviral vector. . In certain embodiments, the transduced cell contains in its cell genome one or more genes or other polynucleotide sequences delivered by a retroviral or lentiviral vector.

[0459] In certain embodiments, host cells transduced with a viral vector disclosed herein that express one or more polypeptides are used to treat and / or prevent B cell malignancies. administered to the subject. Other methods for the use of viral vectors in gene therapy that may be utilized in accordance with certain embodiments herein include, for example, Kay, M. A. (1997) Chest 111(6 Supp.):138S-142S; Ferry, N and Heard, J. M. (1998) Hum. Gene Ther. 9:1975-81;Shiratory, Y. et al. (1999) Liver 19:265-74;Oka, K. et al. (2000) Curr. Opin. Lipidol. 11:179-86;Thule, P. M. and Liu, J. M. (2000) Gene Ther. 7:1744-52;Yang, N. S. (1992) Crit. Rev. Biotechnol. 12:335-56;Alt, M. ( 1995) J. Hepatol. 23:746-58;Brody, S. L. and Crystal, R. G. (1994) Ann. N.Y. Acad. Sci. 716:90-101;Strayer, D. S. (1999) Expert Opin. Investig. Drugs 8:2159 -2172; Smith-Arica, J. R. and Bartlett, J. S. (2001) Curr. Cardiol. Rep. 3:43-49; and Lee, H. C. et al. (2000) Nature 408:483-8.

[0460] 6.7. Genetically modified cells In certain embodiments, disclosed herein are cells genetically modified to express a CAR contemplated herein for use in tumor or cancer treatment. In certain embodiments, disclosed herein are cells that are genetically modified to express CARs contemplated herein for use in treating B cell-related conditions. As used herein, the terms "genetically engineered" or "genetically modified" refer to the addition of additional genetic material in the form of DNA or RNA to the total genetic material in a cell. The terms "genetically modified cells," "modified cells," and "redirected cells" are used interchangeably. As used herein, the term "gene therapy" refers to the use of cells in cells for the purpose of restoring, correcting, or modifying the expression of genes or expressing therapeutic polypeptides, e.g., CARs. Refers to the introduction of additional genetic material in the form of DNA or RNA to the total genetic material within.

[0461] In certain embodiments, a CAR contemplated herein is introduced into and expressed in an immune effector cell so as to redirect the specificity of the cell to a target antigen of interest, e.g., a BCMA polypeptide. be done. An "immune effector cell" is any cell of the immune system that has one or more effector functions (eg, cytotoxic cell killing activity, secretion of cytokines, induction of ADCC and / or CDC).

[0462] The immune effector cells of the present disclosure can be autologous / autologous (“autologous”) or non-autologous (“non-self”, eg, allogeneic, syngeneic or xenogeneic).

[0463] "Autologous" as used herein refers to cells from the same subject.

[0464] "Allogeneic" as used herein refers to cells of the same species that are genetically distinct from the cells being compared.

[0465] "Syngeneic" as used herein refers to cells of a different subject that are genetically identical to the cells being compared.

[0466] "Heterologous" as used herein refers to a cell of a different species than the cell being compared. In certain embodiments, the cells of the present disclosure are allogeneic.

[0467] Exemplary immune effector cells for use with the CARs contemplated herein include T lymphocytes. The terms "T cell" or "T lymphocyte" are art-recognized and can include thymocytes, immature T lymphocytes, mature T lymphocytes, resting T lymphocytes, or activated T lymphocytes. intended. The T cell can be a helper T (Th) cell, such as a helper T1 (Th1) or a helper T2 (Th2) cell. T cells are helper T cells (HTL; CD4 + T cells)CD4 + T cells, cytotoxic T cells (CTL; ​​CD8 + T cells), CD4 + CD8 + T cells, CD4 - CD8 - It can be a T cell, or any other subset of T cells. Other exemplary T cell populations suitable for use in certain embodiments include naive T cells and memory T cells.

[0468] As will be understood by those skilled in the art, other cells may also be used as immune effector cells with the CARs described herein. In particular, immune effector cells also include NK cells, NKT cells, neutrophils, and macrophages. Immune effector cells also include effector cell progenitor cells, which can be induced to differentiate into immune effector cells in vivo or in vitro. Thus, in certain embodiments, the immune effector cells are hematopoietic stem cells (HSCs) contained within a CD34+ population of cells derived from immune effector cell progenitor cells, such as umbilical cord blood, bone marrow, or mobilized peripheral blood. include those that differentiate into mature immune effector cells upon administration in a subject, or that can be induced to differentiate into mature immune effector cells in vitro.

[0469] As used herein, immune effector cells genetically engineered to contain BCMA-specific CARs may be referred to as "BCMA-specific redirected immune effector cells."

[0470] "CD34 + The term "cell" as used herein refers to a cell that expresses the CD34 protein on its cell surface. "CD34" as used herein refers to a cell surface glycoprotein (e.g., sialomucin protein) that often acts as a cell-cell adhesion factor and is involved in T cell entry into lymph nodes. . CD34 + The cell population contains hematopoietic stem cells (HSCs), which upon administration to the patient differentiate into all hematopoietic lineages, including T cells, NK cells, NKT cells, neutrophils, and cells of the monocyte / macrophage lineage. Contribute to

[0471] In certain embodiments, provided herein are methods for producing immune effector cells that express the CARs contemplated herein. In one embodiment, the method involves transfecting or transducing immune effector cells isolated from an individual such that the immune effector cells contain one or more CARs described herein. The method includes a step of causing the expression to be expressed. In certain embodiments, immune effector cells are isolated from an individual and genetically modified without further manipulation in vitro. Such cells can then be readministered directly to the individual. In a further embodiment, the immune effector cells are first activated and stimulated to proliferate in vitro before being genetically modified to express the CAR. In this regard, immune effector cells may be cultured before and / or after being genetically modified (ie, transduced or transfected to express a CAR as contemplated herein).

[0472] In certain embodiments, a source of cells is obtained from the subject prior to in vitro manipulation or genetic modification of immune effector cells as described herein. ...

Claims

1. 1. A method for predicting whether a cancer in a human will be responsive to chimeric antigen receptor (CAR) T cells, comprising: (i) determining the level of one or more inflammation-associated soluble factors in serum from a human; and (ii) determining to administer a therapeutically effective dose of said CAR T cells to said human if the level of one or more inflammation-associated soluble factors of (i) is similar to that in serum from another human that is responsive to the CAR T cells.

2. 1. A pharmaceutical composition comprising chimeric antigen receptor (CAR) T cells for treating cancer in a human in need thereof, characterized in that the pharmaceutical composition is adapted to be administered to the human when a level of one or more inflammation-associated soluble factors in a serum sample from the human is similar to a level of one or more inflammation-associated soluble factors in a serum sample from another human that is responsive to the CAR T cells.

3. 1. A method of determining whether a human patient diagnosed with cancer should be administered chimeric antigen receptor (CAR) T cells, comprising determining a level of one or more inflammation associated soluble factors in a serum sample from the patient, wherein if the level of one or more inflammation associated soluble factors in the serum sample from the patient is similar to the level of one or more inflammation associated soluble factors in a serum sample from a patient that is responsive to CAR T cells, then the patient is a candidate for the CAR T cells.

4. 4. The pharmaceutical composition of claim 2 or the method of claim 1 or 3, wherein the one or more inflammation-associated soluble factors are selected from the group consisting of placental growth factor (PGF), CD70, TNFRSF4, TNFRSF9 (sCD137 or s4-1BB), DCN, CD83, IL10, PDCD1, IL12, and NCR1.

5. 5. The pharmaceutical composition or method of claim 4, wherein the one or more inflammation-associated soluble factors are selected from the group consisting of PGF, CD70, TNFRSF9, and CD83.

6. The pharmaceutical composition of any one of claims 2, 4 and 5 or the method of any one of claims 1 and 3 to 5, wherein the cancer is multiple myeloma.

7. The CAR T cell is a heavy chain variable region (V H ) and a light chain variable region (V L 7. The pharmaceutical composition of claim 2 or the method of claim 1, comprising a CAR comprising an extracellular antigen-binding domain comprising the

8. 8. The pharmaceutical composition of any one of claims 2 and 4 to 7 or the method of any one of claims 1 and 3 to 7, wherein the CAR T cell comprises a CAR, said CAR comprising an amino acid sequence as set forth in SEQ ID NO: 9 or 37.

9. The pharmaceutical composition of any one of claims 2 and 4 to 8 or the method of any one of claims 1 and 3 to 8, wherein the CAR T cell is a CAR T cell directed against BCMA.

10. CAR T cells directed against BCMA include BCMA02, idecabutagen viculeucel cells (ide-cel), JCARH125, JNJ-68284528 (LCAR-B38M; a protein comprising SEQ ID NO:265 of 10,934,363 or SEQ ID NO:300 of WO2018 / 028647, with or without a signal peptide) (Janssen / Legend); 10. The pharmaceutical composition or method of claim 9, wherein the therapeutic agent is selected from the group comprising P-BCMA-101 (Poseida), PBCAR269A (Poseida), P-BCMA-Allo1 (Poseida), Allo-715 (Pfizer / Allogene), CT053 (Carsgen), Descartes-08 (Cartesian), PHE885 (Novartis), and CTX120 (CRISPR Therapeutics).

11. The pharmaceutical composition or method of claim 10, wherein the CAR T cells directed against BCMA are ideca-butagen bicelucel cells (ide-cel).

12. A pharmaceutical composition according to any one of claims 2 and 4 to 11 or a method according to any one of claims 1 and 3 to 11, wherein the level of one or more inflammation-related soluble factors is determined by O-link IO analyte assay.

13. 13. The pharmaceutical composition of any one of claims 2 and 4-12 or the method of any one of claims 1 and 3-12 containing CAR T cells for treating cancer in a human in need thereof, wherein said pharmaceutical composition is administered in combination with an antagonist of an inflammation-associated soluble factor, said antagonist being selected from the group consisting of placental growth factor (PGF), CD70, TNFRSF4, TNFRSF9, DCN, CD83, IL10, PDCD1, IL12, and NCR1.

14. 1. A pharmaceutical composition comprising CAR T cells for treating cancer in a human in need thereof, wherein said pharmaceutical composition is administered in combination with an antagonist of an inflammation-associated soluble factor, wherein said antagonist is selected from the group consisting of placental growth factor (PGF), CD70, TNFRSF4, TNFRSF9, DCN, CD83, IL10, PDCD1, IL12, and NCR1.

15. 15. The pharmaceutical composition of claim 14, wherein the inflammation-associated soluble factor is selected from the group consisting of PGF, CD70, TNFRSF9, and CD83.

16. 16. The pharmaceutical composition of claim 14 or 15, wherein the antagonist of an inflammation-associated soluble factor is administered to a human in a therapeutically effective amount to reduce the level of an inflammation-associated soluble factor in the human to the level of the inflammation-associated soluble factor in a patient responsive to CAR T cells.

17. The pharmaceutical composition according to any one of claims 14 to 16, wherein the cancer is multiple myeloma.

18. The CAR T cell is a heavy chain variable region (V H ) and a light chain variable region (V L 18. The pharmaceutical composition of claim 14, comprising a CAR comprising an extracellular antigen-binding domain comprising:

19. 19. The pharmaceutical composition of any one of claims 14 to 18, wherein the CAR T cell comprises a CAR, and the CAR comprises an amino acid sequence as set forth in SEQ ID NO: 9 or 37.

20. The pharmaceutical composition of any one of claims 14 to 19, wherein the CAR T cell is a CAR T cell directed against BCMA.

21. CAR T cells directed against BCMA include BCMA02, idecabutagen viculeucel cells (ide-cel), JCARH125, JNJ-68284528 (LCAR-B38M; a protein comprising SEQ ID NO:265 of 10,934,363 or SEQ ID NO:300 of WO2018 / 028647, with or without a signal peptide) (Janssen / Legend); 21. The pharmaceutical composition of claim 20, selected from the group comprising P-BCMA-101 (Poseida), PBCAR269A (Poseida), P-BCMA-Allo1 (Poseida), Allo-715 (Pfizer / Allogene), CT053 (Carsgen), Descartes-08 (Cartesian), PHE885 (Novartis), and CTX120 (CRISPR Therapeutics).

22. The pharmaceutical composition of claim 21, wherein the CAR T cells directed against BCMA are ideca-butagen viculeucel cells (ide-cel).

23. 23. The pharmaceutical composition of any one of claims 14 to 22, wherein an antagonist of an inflammation-associated soluble factor is administered prior to said administration of the pharmaceutical composition comprising human CAR T cells.

24. 24. The pharmaceutical composition of any one of claims 14 to 23, wherein the antagonist of an inflammation-associated soluble factor is administered 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days prior to said administration of the pharmaceutical composition comprising human CAR T cells.

25. 24. The pharmaceutical composition of any one of claims 14 to 23, wherein the antagonist of an inflammation-associated soluble factor is administered about 1 week, 2 weeks, 3 weeks, or 4 weeks prior to said administration of the pharmaceutical composition comprising human CAR T cells.

26. 24. The pharmaceutical composition of any one of claims 14-23, wherein the antagonist of an inflammation-associated soluble factor is administered about 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months prior to said administration of the pharmaceutical composition comprising human CAR T cells.